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General introduction
9General introduction and outline
Epidemiology 
Colorectal cancer (CRC) is a major global health problem with approximately 1.2 million 
cases worldwide every year.1 It ranks as the third most common malignancy in males 
(after prostate and lung cancer) and the second most common malignancy in females 
(after breast cancer). It primarily effects the elderly with about 80% of cases occurring 
in patients over 60 years of age.2, 3 The incidence of CRC is rising, partly due to aging 
of the population, as well as factors related to an increasingly unhealthy lifestyle, such 
as a rising incidence of overweight, increased red meat consumption and reduced 
physical activity. In the Netherlands there were 15565 cases of CRC diagnosed in 2015, 
and this included 4684 cases of rectal cancer (30%).4
Anatomy of the rectum
The rectum is the most distal part of the colon. It is a tubular structure which is firmly 
embedded in the bony pelvis and has an intimate relation with the organs of the 
urogenital tract and the sacrum, as well as the anal sphincter complex. The rectal wall 
is surrounded by the mesorectal fatty tissue, which contains the vascular supply, 
nerves and lymphatic drainage system. The mesorectum is surrounded by an 
avascular connective tissue layer called the mesorectal fascia (MRF), which separates 
the mesorectum from the other pelvic structures. This unique anatomy has profound 
consequences for the surgical approach of tumours in the rectum compared with 
those in the peritonealised colon. In addition, the retroperitoneal localization of the 
rectum in the pelvis and the associated distance to the small bowel ensures that the 
rectum can be readily subjected to radiation therapy, as opposed to the colon, which 
is in close proximity to the small bowel. A generally accepted anatomical definition to 
describe the extent of the rectum is lacking, however, for clinical purposes it is often 
said to extend for 12-15cm proximally of the anal verge. Alternatively, the peritoneal 
reflection is used as a landmark to indicate the transition from the rectosigmoid to the 
rectum, although this is highly variable and depends on age, sex and gynecological 
conditions. 
Pathophysiology
Molecular pathogenesis
The dominant pathway that leads to CRC is the adenoma-carcinoma sequence, 
which is responsible for development of 70-80% of sporadic CRC in general and an 
even higher proportion in the rectum. It is characterized by accumulation of mutations 
10 11
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Inflammatory bowel disease related CRC
Patients with inflammatory bowel disease (IBD), including ulcerative colitis, Crohn’s 
disease and indeterminate colitis, have an elevated risk of developing CRC which 
depends on disease duration and extent. About 1–2% of CRC cases arise in patients 
with IBD and these develop through the inflammation-dysplasia-carcinoma pathway.16, 17 
The mechanisms that drive this pathway are complex, although sustained DNA 
damage, in part through oxidative stress in inflamed mucosa, is thought to play an 
important role. The molecular pathogenesis of IBD related CRC is distinct from 
sporadic CRC. For example, APC gene mutations are less common and appear late 
in colitis associated compared with sporadic CRC, whereas chromosomal instability 
and P53 mutations often occur early and may even be present in normal mucosa.18 
Some studies report that deficiencies in the MMR system may play a role, although 
this has not been confirmed. 
The progression rate of dysplastic colonic mucosa to invasive carcinoma in IBD 
patients is believed to be higher than that of the progression of sporadic adenomas 
to carcinoma. In addition, there is thought to be a field effect with all the colonic 
mucosa in a patient with dysplasia being at risk, due to diffuse clonal molecular 
aberrations. Furthermore, dysplasia and carcinomas may be multifocal. Repetitive 
screening colonoscopies are performed in IBD patients with at least 8-10 years 
disease duration and a colectomy should be considered in case of high grade 
dysplasia or in case of flat low grade dysplasia in at least two simultaneous biopsies 
or in 2 subsequent biopsies.19, 20
TNM staging and prognosis
The TNM staging system (figure 1) is used to stratify patients with CRC according to 
the extent of tumour invasion (T-category), nodal status (N-category), and presence 
of distant metastases (M-category). Clinical stage (cTNM) is based on physical 
examination, colonoscopy and imaging, and is instrumental in treatment planning. 
Pathological stage (pTNM) is based on the histopathological examination of the 
resection specimen and plays an important role in selecting patients eligible for 
adjuvant treatment (colon cancer) as well as determining prognosis. 
The prognosis for patients with rectal cancer in the Netherlands has improved over 
the years with a 5-year survival rate of 65% for patients diagnosed between 2008 and 
2012. TNM stage specific survival is roughly 90%, 70%, 55%, and 10% for patients 
with stage I, II, III, and IV at diagnosis respectively. About 30% of rectal cancer patients 
present with a tumour limited to the bowel wall (T1 or T2), and 20% of patients have 
distant metastases at diagnosis.2 However, this is expected to change with the 
introduction of bowel screening programs, since results from the British bowel cancer 
in tumour suppressor genes and oncogenes. These mutations lead to formation of 
aberrant crypt foci, which subsequently develop into adenomas, and which may 
ultimately transform into invasive cancer.5-7
Classically, one of the first events in adenoma development is silencing of the APC 
tumour suppressor gene, with subsequent mutations in oncogenes, such as KRAS, 
which promote growth and prevent apoptosis. Mutations in P53 are a late event in 
CRC development and disrupt the ability of the cells to stop the cell cycle and activate 
apoptosis in response to DNA damage, leading to rapid accumulation of chromosomal 
aberrations which promote invasive growth.8 
The adenoma-carcinoma sequence is also the causative mechanism for CRC 
development in patients with familial adenomatous polyposis (FAP). These patients 
have a germ line inactivating mutation in APC and therefore only one more “hit” is 
necessary to knock out this tumour suppressor, which leads to the formation of 
hundreds of adenomas in the colon and elsewhere in the gastrointestinal tract.9, 10
In addition, about 10-15% of CRC are associated with microsatellite instability (MSI), 
although these are often located proximally in the colon and very rarely in the rectum. 
Presence of MSI is indicative of a defective DNA mismatch repair (MMR) system. 
Failure to repair spontaneous replication errors throughout the genome leads to a 
hypermutated state in these patients, characterized by lengthening of areas with 
repetitive DNA sequences (microsatellites), as well as rapid accumulation of mutations 
in oncogenes and tumour suppressor genes, which may subsequently result in 
cancer.10 The majority of MSI cancers occur sporadically (primarily in elderly patients), 
and are caused by methylation of the promoter of MLH-1, which disrupts the function 
of this gene by inhibiting its transcription.11 However, a quarter of patients with MSI 
tumours have Lynch syndrome (formerly known as the Hereditary Non-Polyposis Coli 
Cancer syndrome), caused by a germ line mutation in one of the MMR genes.12 This 
predisposes patients to various types of cancer including colorectal, endometrial, 
ovarian, gastric, and small bowel cancer, as well as transitional cell tumours of the 
ureter and renal pelvis, skin neoplasms (sebaceous tumours and keratoacanthomas), 
and brain gliomas. 
Furthermore, about 10-20% of CRC may develop from traditional serrated adenomas 
(TSA) and sessile serrated polyps/lesions (SSP/SSL), and this mechanism is termed 
the serrated pathway.13 The morphology of these lesions is characterized by a 
serrated architecture and they often contain mutations in KRAS or BRAF. TSAs 
predominantly occur in the sigmoid and rectum, although they are very rare (less 
than 1-2% of colonic polyps).14 SSLs are often located in the right colon. CRC 
developing through the serrated pathway are associated with a poor prognosis and 
therapy resistance.15
12 13
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resection, can lead to local recurrence after rectal cancer surgery.22, 23 During a TME 
the rectum and mesorectum are excised by precise dissection under direct vision of 
the avascular “holy” plane between the visceral and parietal pelvic fascia separating 
the mesorectal fat from the other pelvic structures (figure 2). Discontinuous tumour 
deposits in the mesorectum as well as all the lymphatics draining the rectum are 
hereby removed together with the tumour.24
The introduction of the TME has resulted in a substantial improvement of local 
recurrence rates from 20-45% after a classical blunt rectal dissection to around 10% 
after TME surgery, as well as reductions in cancer related death25-27 and is nowadays 
considered to be the standard surgical procedure for rectal cancer. 
Tumours in the upper and middle thirds of the rectum can be treated with a low 
anterior resection (LAR) in which the anal sphincter complex remains intact and an 
anastomosis is created with the sigmoid (with or without a temporary deviating stoma). 
In case of a low rectal tumour for which an oncologically safe margin cannot be 
achieved with LAR, an abdominoperineal resection (APR) is indicated. This procedure 
includes removal of the anal sphincter (may include levator muscles), as well as the 
perineum and is combined with a permanent colostomy. Both procedures can be 
performed open or with laparoscopy depending on surgeon preference and experience.
screening program showed substantially more early (stage I) colorectal cancers in 
the screen-detected population compared with patients who refused participation or 
where never invited.21 
Treatment
The treatment of patients with rectal cancer is aimed at improving survival and preventing 
local recurrences. 
Surgery
Surgery is the cornerstone of rectal cancer treatment. Heald and Ryall developed the 
total mesorectal excision (TME) technique, based on the concept that discontinuous 
tumour deposits in the mesorectal fat, which are not removed in classic anterior 
Figure 1  Tumour, Nodes, Metastases (TNM) classification
Figure 2  Total Mesorectal Excision (TME), delineation of surgical margin
(1) Rectal lumen. (2) Rectal muscular wall. (3) Mesorectal fat. (4) Lymph node. (5) Tumour.  
(6) Anal sphincter. (7) Levator muscle. (8) Peritoneal cavity. (9) Urinary bladder. (10) Prostate. (11) Spine.
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tumour response and can be used to identify histopathological risk factors for locally 
recurrent disease.
Postoperative chemotherapy
Postoperative chemotherapy, which is routinely given to colon cancer patients with 
stage III disease, does not provide a survival benefit in stage II or III rectal cancer 
patients who received optimal preoperative treatment and high quality TME surgery, 
as was shown by several randomized trials including the recent Dutch SCRIPT trial.38, 39 
Some older studies, that largely did not perform surgery according to modern TME 
principles, found postoperative chemotherapy to improve survival in rectal cancer 
patients after surgery only (no preoperative treatment), although there is insufficient 
evidence for a benefit in stage III rectal cancer patients who were treated with high 
quality TME surgery.40
Preoperative therapy
Several European trials, including the Dutch TME trial, have shown that preoperative 
short-course radiotherapy (SC-RT) with 5 x 5Gy followed by immediate TME surgery 
reduces local recurrence rates (2.6-6%) compared with TME surgery only (10%), 
although there was no improvement in overall survival.26-28 Subsequent analysis 
showed that the benefits in terms of local control in low risk rectal cancer patients 
(cT1-3, <5mm extramural invasion, cN0) do not outweigh the long term radiation 
induced toxicity. The current Dutch guideline3 recommends SC-RT for all cT3 tumours 
with at least 5mm mesorectal invasion or with 1-3 pathological lymph nodes on 
imaging (cN1). However, experts who participated in a recent European consensus 
guideline prefer to limit the indication for SC-RT to patients with cT3N0 tumours,29 
and SC-RT is not commonly given in North America.30
Neo-adjuvant chemoradiation therapy (CRT) is indicated for patients with locally 
advanced rectal cancer (LARC) or with a threatened MRF (defined as tumour ≤1mm 
from the MRF on MRI). This consists of long course radiotherapy with 45-50Gy in 
fractions of 1.8-2.0Gy and concurrent fluoropyrimidine based chemotherapy followed 
by TME after an 8-12 week interval. This treatment is intended to improve local control 
and to facilitate radical surgery by inducing tumour regression and possible 
downstaging; although a survival benefit has not been shown. Local recurrence rates 
of 6-9% have been reported for LARC patients treated with CRT. 31-33
Local excision
Local excision is an attractive option for small tumours in the rectum, since it is associated 
with considerably less surgery-related morbidity and almost no post-operative mortality 
compared with TME. Transanal endoscopic microsurgery (TEM) is the preferred 
technique, as it is safer compared with transanal excision (TE) and more often resulted 
in complete excision of a lesion with clear margins. It is primarily used to excise rectal 
adenomas, since these lesions do not develop lymph node metastases (LNM) and 
therefore do not require radical surgery. However, some adenomatous lesions, especially 
the larger ones, may be found to contain invasive foci on histopathological examination. 
LNM are present in 11-18% of unselected pT1 rectal cancers, and additional radical 
surgery may be required for curing the disease in these cases.34-36
Due to expected increase in the number of early rectal cancers associated with the 
introduction of bowel cancer screening programmes the role of local excisions in 
rectal cancer treatment will probably become more prominent. In addition, there is 
increasing emphasis on rectal preservation in patients with a clinical complete 
response after CRT. Varying results have been published after a “wait and see” policy, 
mainly depending on patient selection.37 A full thickness local excision of the scar 
area, using TEM, is an attractive alternative to “wait-and-see”, since it removes 
possible tumour remnants in the bowel wall. It also provides additional information on 
Figure 3A-F  Histopathological characteristics
(A) Mesorectal tumour deposit. (B) lymphatic invasion. (C) Venous invasion (smooth muscle lined wall). 
(D) Venous invasion (erythrocytes in the lumen; adjacent artery). (E) perineural invasion. (F) Budding.
A B C 
D E F 
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A minimum number of 10 or 12 lymph nodes are recommended depending on which 
guideline is cited.3, 48 After preoperative therapy lymph node yield may be reduced by 
7-53%.49
Mesorectal tumour deposits
Tumour foci in the mesorectum, which are separated from the main tumour bulk, are 
called tumour deposits. A tumour deposit may represent a variety of causes, such as 
an overgrown LNM, vascular invasion, perineural growth or discontinuous tumour 
spread. How pathologists interpret these tumour deposits is crucial in staging.50
Other pathological characteristics
A variety of other tumour related characteristics can be observed in histopathological 
specimens, some of which are routinely scored by pathologists. Lymphatic invasion 
is defined by some authors as “tumour cells in a space covered with endothelial cells 
in the absence of erythrocytes” and is associated with worse prognosis in patients 
with negative lymph nodes, although its relevance in patients with LNM is less clear.51-53 
Venous invasion is “tumour within a smooth muscle-lined space or in an endothelial-
lined space with additional fibrin clots, erythrocytes or both without erythrocyte 
extravasation into the surrounding tissue”.52 Extramural venous invasion is a well 
known indicator of poor prognosis and is especially associated with liver metastases.54 
Tumour budding or sprouting is the presence of de-differentiated single cells or 
clusters of up to 5 cells at the invasion front of a tumour.55 It is associated with 
presence of LNM and poor outcome,56, 57 although integration in daily reporting has 
long been delayed, due to lack of agreement on how exactly it should be scored.58
Tumour expansion along nerves is called perineural invasion (PNI) and is reported to 
occur in 20.6% of rectal cancers. By definition tumour cells should surround at least 
a third of the nerve circumference. PNI is associated with increased local recurrence 
and worse disease free, cancer specific and overall survival.59
Rectal cancers treated with chemoradiation therapy or long course radiation therapy 
show variable levels of tumour regression. In 8-24% of patients a pathological 
complete response (pCR) may be observed, which is associated with an excellent 
prognosis.31, 60, 61 Several methods, including 5-tier systems as described by 
Mandard and Dworak62, 63 and newer simplified 3-tier systems64, 65 have been 
developed to further differentiate tumour response. Some studies report these clas-
sifications of TRG to be an independent prognosticator for survival,66 although others 
do not.67 
Histopathology
Tumour types
Adenocarcinoma not otherwise specified (NOS) is the most common type of rectal 
cancer (85-90%), and is made up of invasive, irregular glandular epithelium with 
tubular or villous architecture.41 Differentiation grade is associated with prognosis 
and is determined by the proportion of solid growth of tumour epithelium (<50% solid 
= low grade, ≥50% solid = high grade).42 In addition, around 8-10% of tumours are 
mucinous carcinomas, in which the tumour volume contains at least 50% mucin 
(often up to 90%). It is more common in Lynch syndrome patients and more often 
presents with an advanced stage. This tumour type should not be graded and has 
classically been associated with a worse prognosis compared with adenocarcinoma 
NOS, although recent research showed that modern rectal cancer treatment has 
resulted in an equal survival in patients with adenocarcinoma NOS and mucinous 
carcinoma.43 Signet ring cell carcinoma is an uncommon (2%), yet highly aggressive 
variant in which at least 50% of tumour cells have signet ring cell morphology with 
intracytoplasmic mucus which pushes the nucleus to the periphery of the cell.44 
Other tumour variants including medullary carcinomas, adenosquamous carcinoma, 
squamous cell carcinoma, small cell carcinoma, undifferentiated carcinoma and 
mixed carcinoid-adenocarcinoma are rare.41
Circumferential resection margin (CRM)
TME surgery generates a pathological specimen with a circumferential resection 
margin (CRM) which involves the entire non-peritonealised surface of the specimen. 
CRM involvement, defined as a tumour distance of ≤1mm to the radial margin, is 
observed in 1-28% of patients with curatively operated rectal cancer, and is a powerful 
predictor of local recurrence (HR 2.7 [95%CI 1.72-4.35]), distant recurrence (HR 2.78 
[95%CI 1.85-4.35]), and survival (HR 1.72 [95%CI 1.27-2.27]). After preoperative therapy 
the predictive value of CRM involvement for local recurrence is even stronger HR 6.3 
[95%CI 3.7-16.7]), although an effect on distant recurrence and survival was not found. 45
Number of lymph nodes
Presence of LNM is a strong adverse prognostic factor in rectal cancer patients and 
is firmly integrated in staging. However, prognosis is also influenced by the total 
number of evaluated lymph nodes, with improved local recurrence and survival rates 
associated with a higher number of examined nodes in patients with stage II and III 
disease.46 The number of lymph nodes retrieved depends on many factors related to 
the patient (BMI, age, and gender), the tumour (size, differentiation grade, inflammatory 
reaction, localization), the surgeon (surgical technique, extent and quality of the resection), 
as well as the presence of preoperative therapy and the effort of the pathologist.47 
18 19
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Outline of the thesis
This thesis discusses clinical and pathological aspects of rectal cancer with emphasis 
on the role of pathological evaluation of surgical specimens in improving diagnostics 
and treatment of this frequently occurring disease. In chapter 1 the literature is 
systematically reviewed to determine the clinical significance of macroscopic 
evaluation of surgical quality by pathologists. The prognostic value of the plane of 
resection achieved during rectal surgery, as well as various factors that may influence 
surgical quality are discussed. Histopathology also helps determine the optimal 
treatment type for specific patient groups. For example, in patients with early 
colorectal cancer a radical resection may constitute overtreatment in the absence of 
LNM. Chapter 2 systematically reviews the literature to identify histopathological 
factors that predict nodal involvement in pT1 colorectal cancer, which helps select 
patients who may be cured with a limited local excision. Interest in organ sparing 
approaches is also increasing in patients with substantial downstaging after 
preoperative treatment. The study in chapter 3 investigates predictors of residual 
nodal disease after long course CRT, which may help identify patients for whom a 
local excision could be safe. Tumour regression is associated with improved 
outcomes, although differences in methodology make it difficult to compare study 
results. Chapter 4 evaluates the association between tumour regression grading and 
outcome in a prospective cohort of uniformly treated and strictly defined LARC 
patients with central revision of histopathology. In chapter 5 the results of a population 
based study are described which compares TNM stage specific overall survival in 
rectal cancer patients treated either with preoperative CRT, SC-RT, or surgery only. 
Although the benefits of preoperative therapy have been demonstrated extensively in 
rectal cancer patients, clinicians are reluctant to offer this treatment to patients with 
IBD, due to fear of excessive side-effects. Therefore, the retrospective clinical study 
described in chapter 6 was conducted, which investigates preoperative therapy 
induced toxicity and postoperative complications in rectal cancer patients with IBD. 
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Abstract
Total mesorectal excision (TME) is considered standard of care for rectal cancer 
treatment. Failure to remove the mesorectal fat envelope entirely may explain part of 
observed local and distant recurrences. Several studies suggest quality of the 
mesorectum after TME surgery as determined by pathological evaluation may 
influence prognosis. We aimed to determine the prognostic value of the plane of 
surgery as well as factors influencing the likelihood of a high quality specimen by 
reviewing the literature. A pooled meta-analysis of relevant outcome data was 
performed where appropriate. A muscularis propria resection plane was found to 
increase the risk of local recurrence (RR 2.72 [95% CI 1.36 to 5.44]) and overall 
recurrence (RR 2.00 [95% CI 1.17 to 3.42]) compared to an (intra)mesorectal plane. 
Plane of surgery is an important factor in rectal cancer treatment and the 
documentation by pathologists is essential for the improvement of TME quality and 
patient outcome. 
Introduction
The development of total mesorectal excision (TME), introduced by Heald and Ryall 
in the early 1980s, is based on the notion that lateral mesorectal spread of small 
tumour foci, which are not removed in classic anterior resection, can lead to local 
recurrence after rectal cancer surgery.1, 2
In a TME procedure the rectum and mesorectum are excised by precise dissection 
under direct vision of the avascular “holy” plane between the visceral and parietal 
pelvic fascia separating the mesorectal fat from the other pelvic structures.3 
Discontinuous tumour deposits and possibly involved lymph nodes present in the 
mesorectum are hereby removed together with the tumour. 
The introduction of TME lead to the reduction of local recurrence rates from 20-45%,3 
to around 10% with TME surgery alone, and to 2.4-6% after short-term neo-adjuvant 
radiotherapy.4-6 Predicting local recurrence by acknowledging the importance of 
lateral tumour spread led to the introduction of the circumferential resection margin 
(CRM). This margin, which comprises the entire non-peritonealised circumference of 
the resection specimen, has a relatively short, distally located anterior aspect, 
whereas posteriorly it has a triangular shape and runs up to the start of the sigmoid 
mesocolon.7 Currently, CRM involvement is considered to be one of the key factors in 
rectal cancer treatment. A large number of studies, pooled in a meta-analysis by 
Nagtegaal and Quirke and including over 17,500 patients, showed a CRM of ≤1 mm 
to be a strong predictor of local recurrence (HR 2.7 [95% CI 1.72 to 4.35]), distant 
recurrence (HR 2.78 [95% CI 1.85 to 4.35]) and survival (HR 1.72 [95% CI 1.27 to 
2.27]). Moreover, after neo-adjuvant therapy, CRM involvement was found to be an 
even stronger predictor of local recurrence (HR 6.3 [95% CI 3.7 to 16.7]), but not 
distant recurrence and survival.8 However, local and distant recurrences may also 
develop in patients with an uninvolved CRM. 
The plane of resection created by the surgeon is another predictor of outcome that 
has been under investigation by pathologists for almost a decade, and which may 
explain part of the local recurrences in CRM negative patients. Several authors to 
date have included an evaluation of the plane of surgery in their protocol. However, 
these studies show considerable variation in population size, study design, and 
results, making it difficult to appreciate the relevance of studied variables. It is the 
purpose of this article to critically review the current literature on the prognostic value 
of plane of surgery and the factors associated with achieving a satisfactory surgical 
specimen. A pooled meta-analysis of relevant outcome data will be performed where 
appropriate. 
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Methods
In this review the factors influencing the plane of surgery of a resection specimen after 
TME for rectal cancer and the prognostic value of this plane are evaluated. A pubmed 
search was performed using the keywords: “TME or total mesorectal excision” combined 
with “macroscopic evaluation, plane of surgery, quality of surgery or quality of meso- 
rectum”. In addition cross referencing of relevant articles was performed. Only full text 
articles available in English and including an assessment of the surgical quality of 
the mesorectum were considered. In case of obvious overlap between studies the 
study with the highest number of patients was included. There was still some possible 
overlap of patients in some of the remaining studies, therefore the total number of 
patients cannot be determined exactly, however, 18 studies containing published data 
of between 4399 and 4469 individual patients were used. Information on outcome 
was given in 9 of these studies (n=2495). 
Data was extracted and analyzed by a single investigator. For all studies in the pooled 
analysis the frequencies of mesorectal quality and number of events were available 
from the published text or tables. Relevant outcome measures are expressed as 
relative risks (RR) with 95% confidence intervals, and total effect sizes are calculated 
using Review Manager (RevMan) [Computer program]. Version 5.1. Copenhagen: 
The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.
A summary of the articles, their methodology, and primary results is given in table 1. 
Quality of surgery: definitions 
In the CR07 trial protocol from January 1998 three grades of mesorectal surgical 
quality were introduced by Quirke et al. [P. Quirke, personal communication] (table 2). 
We 9 were the first to systematically describe the macroscopic quality of the meso- 
rectum in rectal resection specimens from a large randomised clinical trial, and 
to correlate quality to outcome. We used the definitions as formulated in the CR07 
protocol, but a specimen was called complete, nearly complete or incomplete, rather 
than good, moderate, or poor.
In more recent publications we and others prefer an even more descriptive evaluation 
of mesorectal quality based on surgical plane of resection.10, 11 The circumferential 
resection margin is therefore said to be in the mesorectal plane (previously good/
complete), the intramesorectal plane (previously moderate/nearly complete) or the 
muscularis propria plane (previously poor/incomplete) (Figure 1A + 1B). 
An underlying reason for using descriptive rather than subjective qualifications is 
that this method does more right to the surgeon, since there is evidence, discussed 
later in this review, that other factors beside surgeon competence may explain an 
inadequate resection plane. Furthermore, in light of increasing demands for auditing 
of colorectal cancer treatment it is preferable to use objective terminology that is less 
likely to be misinterpreted by non-medical professionals and the public. 
The studies described in this review generally use the definitions as mentioned in 
table 2. One study 12 uses modified definitions: an intact mesorectum is called 
complete, a mesorectum with injuries < 2 cm is incomplete, and a mesorectum with 
injuries >2cm is inadequate. Baik et al. 13 misquotes Quirke’s definitions: “25 patients 
with partial injury in the fascia propria of the rectum (less than 5 mm), thus of nearly 
complete grade”. Differences in the use of definitions may partly explain variable 
results between studies. 
Analogous to the plane of surgery of the mesorectal fat envelope, a comment can be 
made on the plane of surgery around the sphincter complex after an abdominoper-
ineal resection (APR). To date, we published the only study 14 to critically assess 
sphincter complex quality using the definitions in table 2. 
According to these definitions a specimen containing the levator ani muscle entirely is 
considered to be optimal, whereas the conventional APR specimen with the plane of 
resection on the sphincter complex is less than optimal, and defects in the muscularis 
propria of the sphincter or perforation into the lumen signify the worst grade. 
As stated for the assessment of the mesorectum, the terminology for evaluating the 
sphincter area should be descriptive and objective.
Incidence
Twelve studies 9, 10, 15-24 report frequencies of the different resection planes after 
open TME surgery on 3209 patients. The total percentage of mesorectal, intrameso-
rectal and muscularis propria planes was 56.4%, 29.0% and 14.6% respectively.
There is substantial variation in achieved plane of resection between studies. The five 
studies reporting over 70% mesorectal plane of resection are all published after 2006. 
These studies are either performed in tertiary centres or specialised units 15, 19, 23, 24 or 
report results of an audited teaching programme.22   
Differences between studies may be related to the wide variation in methodology 
regarding patient selection, interpretation of definitions, study design, and surgeon or 
centre expertise. The time period in which the included patients were operated may 
influence the results because of growing awareness amongst surgeons of the importance 
of achieving a high quality TME. This is pointed out by Quirke et al. (2009) by reporting 
an improvement in plane of surgery achieved over the course of the trial.10
Three studies stand out as having a high percentage of intramesorectal and muscularis 
propria planes. In our study on low rectal cancer we reported the surgical quality of 
APR specimens only, and this may explain the high percentage of muscularis propria 
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resection planes.14 The results reported by Leite et al. (2009) 18 may be explained as 
a reflection of the individual performance of a single centre, whereas Leonard 
et al. (2010) 20 describe an audit of the performance of 33 potential expert surgeons 
from multiple centres in Belgium. Surgeons in the latter study are candidate-TME- 
trainers, who agreed to an external audit of their consecutive TME cases to judge 
whether they could serve as an alternative to foreign TME experts in a national 
teaching programme. The fact that these are not recognized expert TME surgeons 
may explain a large part of the difference in achieved plane of resection with other 
studies. Interestingly, this study may actually give a more realistic view of average 
clinical practice than reports from trials by expert surgeons.
Table 1  Studies included in the review
Study Year Patients 
(N)
Median  
follow up
Study design Neoadjuvant 
therapy (%)
Laparoscopic 
procedure (%)
Muscularis propria  
plane of resection (%)
Involved 
CRM (%)
pT4 (%) APR (%)
Nagtegaal et al. 2002 180 25.8 mo RCT 0 0 23.9 22.7 6.1 38.8
Bretagnol et al. 2005 144 18 mo Single centre prospective study 83.3 (50 Gy) 100 7 6 0 0
Breukink et al. 2005 25 N/A Single centre prospective study 100 (5x5 Gy) 100 16 12 0 0
Nagtegaal et al. 2005 205 60 mo RCT 0 0 36.1 (mesorectum) 
33.1 (sphincter)
28.7 32.4 100
Jeyarajah et al. 2006 287 Complete 
2 yrs
Single centre prospective study 20.6 (5x5 Gy)
6.6 (CRT)
N/A 13.2 11.4 N/A 25.1
Maslekar et al. 2006 130 26 mo Single centre prospective study 31.5 (5x5 Gy)
22.3 (Chemo)
N/A 13 6.9 7.7 20
Baik et al. 2008 100 N/A Single centre prospective study 0 N/A 0 12 0 21
Biondo et al. 2008 604 N/A Multicentre prospective study with audit. 61.1 (CRT) 34.6 8.1 11.6 8.8 21.5 (open)
27.7 (lapsc)
Leite et al. 2009 127 34 mo Single centre prospective study 48 (CRT) N/A 26.8 30.7 6.6 20.5
Quirke et al. 2009 1156 3 yrs RCT 48.8 (5x5 Gy) N/A 13 11 N/A 32
Garcia-Grenaro et al. 2009 294 N/A Single centre prospective study 35.7 (CRT) N/A 5.4 13.9 12.2 20.7
Gouvas et al. 2009 72 N/A Single surgeon non-randomized 
comparative study
43.1 (CRT) 45.8 4.2 25 11.1 (cT4) 13.9
Youssef et al. 2009 158 N/A Single centre prospective study N/A N/A 8.3 10.1 N/A 17.7
Baik et al. 2009 113 14.3 mo Prospective single surgeon non-
randomized comparative study
10.6 (CRT) 50.4 (lapsc)
49.6 (robot)
1.8 8.0 0 (cT4) 0
Chambers et al. 2009 204 N/A Single centre prospective study 54,4 (CRT) N/A 9.8 9.8 10.3 15.7
Leonard et al. 2010 266 N/A multicentre audit 9 (5x5 Gy)
65 (CRT)
17.3 32 14.7 13.5 (cT4) 16.5
Kang et al. 2010 340 N/A Multicentre RCT 100 (CRT) 50 5.6 3.5 1.5 12.6
Baek et al. 2010 64 20.2  mo Single centre prospective study 85.9 (CRT) 100 (robot) 0 0 N/A 18.8
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Surgeon experience
Variability between surgeons and centres regarding CRM involvement rates has been 
demonstrated repeatedly,25, 26 and can also be expected regarding the achieved 
plane of surgery. In the previously mentioned national audit significant heterogeneity 
was demonstrated when comparing 33 surgeons.20 However, no difference was 
present in 2 smaller studies comparing consultants with supervised registrars.16, 17  
Laparoscopic TME
Evidence that laparoscopic resection for rectal cancer is safe and has similar short- 
term and long-term oncological outcome as open surgery is accumulating.24, 27-29 
The effects of this procedure on mesorectal grade is described in 8 studies 12, 15, 20-24, 30 
including 879 patients. The percentage of mesorectal, intramesorectal and muscularis 
propria planes was 61.8%, 23.7% and 14.6% respectively.
From the 8 mentioned studies, 6 report mesorectal plane of resection in over 70% of 
cases.12, 15, 22-24, 30 
These studies are performed by experienced laparoscopy surgeons from specialised 
units, and include 4 single centre trials,12, 15, 23, 30 1 RCT,24 and one multicentre 
observational study.22 
As was observed for open surgery, the study by Leonard et al. (2010) 20 shows a high 
percentage of intramesorectal (35.7%) and muscularis propria (48.2%) resection 
planes. 
A direct comparison between laparoscopic or open TME regarding achieved plane 
of surgery is made in 5 of the 8 articles, in three of those studies no difference was 
observed.21, 22, 24 One study found a better quality of surgery (as judged by the 
operating surgeon) in the laparoscopy arm,23 whereas in the national audit 20 better 
results are reported for the open surgery arm. 
A meta-analysis showed no significant difference in plane of surgery for laparoscopic 
versus open TME (RR 1.31 [95% CI 0.93 to 1.84]). 
Table 2   Evaluating plane of surgery; mesorectum and sphincter complex; 
(Nagtegaal 2005 [14])
Mesorectal fat envelope: possible planes of surgery
Mesorectal plane: 
Intact mesorectum with only minor irregularities of a smooth mesorectal surface. No defect 
deeper than 5mm. No coning toward the distal margin of the specimen. Smooth circumferential 
resection margin on slicing
Intramesorectal plane: 
Moderate bulk to the mesorectum, but irregularity of the mesorectal surface. Moderate 
coning of the specimen is allowed. At no site is the muscularis propria visible, with the 
exception of the insertion of the levator muscles
Muscularis propria plane: 
Little bulk to the mesorectum with defects down onto the muscularis propria and/or a very 
irregular circumferential resection margin
Sphincter complex: possible planes of surgery
Outside levator plane: 
This plane has a cylindrical specimen with levators removed en bloc
Sphincteric plane: 
This plane has CRM on the surface of the sphincteric muscular tube, but this is intact
Intramuscular/submucosal plane: 
This plane has perforation or missing areas of muscularis propria indicating entry into the 
muscular tube at this level
Figure 1  Planes of surgery. (A) whole specimen, (B) on slicing
Mesorectal  
plane 
Intramesorectal 
plane 
Muscularis propria  
plane 
Mesorectal 
plane 
Intra-
mesorectal
plane 
Muscularis
 propria plane 
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Robot-assisted TME
Robot-assisted TME is an alternative for laparoscopy and the results of achieved 
planes have been studied in two study populations. Baek et al. (2010) 31 (n = 64) 
report 84,2% mesorectal plane of surgery whereas Baik et al. (2009) 15 compare 
laparoscopic and robot-assisted TME in 113 consecutive cases reporting mesorectal 
plane in 75,4% and 92,9% respectively (p=0.033). These results need to be substantiated 
but seem to indicate that robot-assisted TME can produce a good quality specimen. 
Anterior resection versus abdominoperineal resection
Depending on the location of the tumour and the skills of the surgeon an anterior 
resection (AR) or abdominoperineal resection (APR) is performed. APRs tend to have 
higher local recurrence rates and worse survival than ARs. This can partly be explained 
by higher rates of CRM involvement and intraoperative perforation (IOP), which are 
related to the removal of less tissue at the level of the tumour in an APR.32, 33 
As mentioned earlier the surgical quality of an APR can be evaluated at both the 
mesorectal as well as the sphincter level (tables 2A and 2B). In our study  on quality 
of surgery in APRs 14 we demonstrated a significant correlation between the surgical 
grades of the mesorectum and the sphincter (Pearson’s R=0.144, p=0.039). 
Eight other studies 9, 10, 13, 16-20 (n=2540) compared mesorectal grades from AR 
and APR specimens after open TME. All studies except for Baik et al. (2008) 13 report 
significantly less mesorectal and more muscularis propria planes in APR compared 
to AR specimens. The combined effect analysis showed RR 2.53 [95% CI 1.94 to 
3.31] for achieving a muscularis propria plane after an APR compared to an AR. 
However, in a multifactorial analysis of 170 patients type of surgery was not an 
independent predictor of quality of surgery when compared to pathologic BMI, 
downstaging after chemoradiotherapy, and laparoscopic or open surgery.20
Tumour distance to the anal verge is an important aspect in the decision to perform 
an APR. Five studies (n=997) described a significantly lower percentage of 
mesorectal 9 and a higher percentage of muscularis propria resection planes  17-20 
in patients with tumours at <5cm from the anal verge compared to >5cm. 
Neoadjuvant therapy
A number of clinical trials over the last 20 years have demonstrated the benefits of 
neoadjuvant therapy in rectal carcinoma.4, 6, 34, 35
The effect of radiotherapy and chemoradiotherapy on mesorectal quality was compared 
to no neoadjuvant therapy in six studies (n=2260).10, 16-20 None of the studies showed a 
significant difference in plane of surgery achieved between the two groups. However, 
in one study a small subgroup of patients that did not show downstaging after long 
course CRT, had a higher incidence of muscularis propria plane of resection compared 
to patients who did show downstaging (p=0.0005 on multivariate analysis).20
Other factors
Seven authors (n=2440) make a remark on the influence of tumour extent and presence 
of lymph node metastases on quality of surgery. No significant relation was found with 
T-stage, N-stage, TNM-stage or Dukes-stage.9, 10, 16-20 
Data about the correlation of plane of surgery and gender are confusing. In three 
studies with 437 patients no correlation was found.9, 17, 18  The plane was worse in 
male patients in one study 13 (n = 100) and in female patients in two studies 16, 20 
(n = 287 and n = 266). Based on MRI pelvimetry data it would be expected that good 
planes of surgery would be more difficult to achieve in patients with a relatively short 
interspinous distance or a short distance between sacral promontory and the top of 
the symphysis pubis (obstetric conjugate), as is the case in males.36 
One study 20 found body mass index (BMI) to show a nonlinear association with the 
probability of a muscularis propria plane of resection (p=0.003), indicating that both 
patients with a relatively high as well as those with a relatively low BMI are at risk. The 
authors state that on the one hand this indicates TME surgery is difficult in obese 
patients, and on the other hand little protective mesorectal fat increases the chance 
of accidental defects onto the muscularis propria. In contrast, Baik et al. (2008) 13 
found no significant influence of BMI, but points out that the lower range of BMI 
values found in an Asian compared to a Western population may explain the lack of 
significance in this study.
Age did not influence mesorectal quality in any of the studies.
Circumferential resection margin
Circumferential resection margin involvement is an important prognostic factor for 
the development of local recurrence, distant recurrence and survival in rectal cancer 
patients. It has been associated with advanced TNM-stage, large tumour size, low 
tumour position, abdominoperineal resection, an ulcerative or stenosing growth 
pattern, surgeon experience, and on histological examination an infiltrating margin, 
poor differentiation, and vascular invasion.8 
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The association of plane of surgery with CRM involvement has been investigated 
in 9 studies (n=2744).9, 10, 13, 16-20, 37 All except one 19 of these show a significant 
association between achieving a muscularis propria plane of resection (combined with 
an intramesorectal plane in one study 37) and CRM involvement. The percentage of 
positive margins after a muscularis propria plane of resection ranges from 19% to 
29% in the reviewed articles whereas after a mesorectal plane these percentages 
range from 1.6% to 14.6%. 
Three studies showed a significant difference in the percentage of muscularis propria 
resection planes between CRM positive and CRM negative patients: respectively 
44% versus  11%  (p<0.001),9  30.3% versus 7.9% (P=0,0001) 16 and  43,6% versus 
19,3% (P=0.006).18 
Furthermore, 11.1% to 56.4% of patients with CRM involvement were found to have a 
mesorectal plane of excision 9, 10, 13, 16-20, 37, 38 indicating that a substantial part of 
CRM positivity can be explained by advanced tumour growth rather than suboptimal 
surgery.
Prognosis
Local recurrence
The prognostic value of plane of surgery after open TME was described in 6 studies 
(n=2174).9, 10, 16-19 Four of these report a significant effect of achieved plane of 
surgery on local recurrence rates in a multivariate analysis.10, 17-19 Two studies 9, 18 
combine the number of local recurrences in patients with a mesorectal and intra-
meso rectal plane of resection and one study 19 combines patients with an intra-
mesorectal or muscularis propria plane. Therefore, two different graphs (figures 2A 
and 2B) are depicted showing prognostic significance of either a mesorectal or a 
muscularis propria plane versus the combination of the other two planes. In the combined 
effect analysis patients with either a muscularis propria plane of resection have a 
significantly higher risk of local recurrence compared to patients with a mesorectal or 
intramesorectal plane (RR 2.72 [95% CI 1.36 to 5.44]).
The combination of an intramesorectal and a muscularis propria plane of resection 
also significantly increases the risk of local recurrence compared to a mesorectal 
plane (RR 2.12 [95% CI 1.05 to 4.28]). Furthermore, subanalyses performed by Quirke 
et al. (2009) 10 showed that patients who received neoadjuvant radiotherapy and 
had a mesorectal resection plane only developed local recurrence in 1% of cases 
compared to 10% of cases with a muscularis propria plane (HR 0.09 [95% CI 0.02 to 
0.49]. Moreover, CRM negative patients showed a  4% versus 12% local recurrence 
rate for mesorectal and muscularis propria plane respectively (HR 0.33 [95% CI 0.15 
to 0.74]), indicating clinical significance of quality of surgery in this group of patients. 
Overall recurrence
Five studies 9, 10, 17-19 (n=1887) report the effect of plane of resection after open TME 
on overall recurrence of which 3 show a significant difference.9, 17, 18 In 2 studies 17, 18 
the difference remains significant on multivariate analysis. In the meta-analysis the 
patients with a muscularis propria plane of resection had a significantly increased 
risk of overall recurrence compared to patients with a mesorectal or intramesorectal 
plane (RR 2.00 [95% CI 1.17 to 3.42]) (figure 3A).
The comparison between the combined group of patients with an intramesorectal 
and a muscularis propria plane of resection and the patients with a mesorectal plane 
showed a trend towards significance (RR 1.84 [95% CI 0.94 to 3.61] Z=1.79 p=0.07) 
(figure 3B).
In one study 9 CRM negative patients were found to have overall recurrence rates of 
14.9% versus 28.6% (p=0.03) for mesorectal and intramesorectal versus muscularis 
propria plane respectively, indicating the relevance of an adequate resection plane in 
this subgroup as well.
Overall survival
Overall survival rates were only addressed in 2 studies (n=310). In our study (Nagtegaal 
et al. 2002) 9 we found survival rates of 86% versus 76% (p<0.05) for mesorectal and 
intramesorectal planes versus a muscularis propria plane respectively, whereas 
Maslekar et al. (2006) 17 did not find a significant difference. 
Figure 2  Relative risk for local recurrence after a muscularis propria vs. a(n) (intra)
mesorectal plane (A) and for local recurrence after a mesorectal plane vs. both 
other planes (B)
A
B
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Conclusion
We performed a meta-analysis of published data relating plane of surgery achieved 
after TME to patient outcome. The data consistently show that avoiding a muscularis 
propria plane of resection significantly reduces the risk of local recurrence and overall 
recurrence after TME surgery. Achieving an optimal (=mesorectal) plane of surgery 
also significantly improves local recurrence rates compared to a suboptimal (=intra-
mesorectal or muscularis propria) plane, but for overall recurrence there is only a 
trend towards significance.
Worse local and overall recurrence rates after an intramesorectal or muscularis 
propria resection plane can partly be explained by CRM involvement. However, in 
most studies plane of surgery was a significant predictor of local recurrence in a 
multivariate analysis, and in CRM negative patients it is related to local recurrence as 
well, indicating an independent role for plane of surgery in rectal cancer treatment.
Many factors influence the plane of resection. Heterogeneity between surgeons 
indicates that the skill of the surgeon is an important factor. 
Type of surgery has a significant effect with APR surgery showing an inferior plane of 
resection more often than AR, as well as surgery on tumours at a short distance from 
the anal verge. In patients with either a high or low BMI it is more difficult to achieve a 
mesorectal resection plane.
Results from studies comparing laparoscopic to open TME suggest that laparoscopy 
gives at least similar quality of mesorectum as open surgery when performed by 
experienced surgeons, whereas less experienced surgeons may generate inferior 
results. Results from robot-assisted TME studies are comparable to those for laparo- 
scopy. It seems reasonable to suggest that laparoscopic and robot-assisted TME 
surgery should only be performed or supervised by surgeons well beyond the 
learning curve. Neoadjuvant therapy does not influence achieved plane of resection.
Plane of surgery is an important factor in the treatment of rectal cancer. Pathologists 
have the primary responsibility to comment on resection plane in pathology reports, 
however, surgeons need to be aware of its importance and have to ask their patho- 
logists for the information if it is missing. A shared responsibility for the evaluation of 
the mesorectum is the best way to ensure accurate feedback on surgeon performance 
and improvement of TME quality as well as patient outcome. Furthermore, achieved 
plane of surgery should be an integral part of all rectal cancer studies and audits, and 
should preferably be reported according to the definitions cited in this article to 
enable adequate comparisons.
Figure 3  Overall recurrence after a muscularis propria plane vs. both other planes 
(A) and after a mesorectal plane vs. both other planes (B)
A
B
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Abstract 
Background and objective: Population screening for colorectal cancer is expected 
to increase the number of pT1 colorectal cancers. Local excision is an attractive treatment 
option, but is only oncologically safe in the absence of lymph node metastasis (LNM). 
A systematic review of the predictive value of pathological risk factors for LNM in pT1 
colorectal cancer was conducted to provide data for an evidence-based decision 
regarding follow-up or radical surgery after local excision.
Methods: PubMed was searched for reports on predictors of LNM in pT1 colorectal 
cancer. Published papers written in English containing at least 50 patients were 
included. Meta-analyses were performed using Review Manager 5.1. 
Results: 17 studies were included totalling 3621 patients with available nodal status. 
The strongest independent predictors of LNM were lymphatic invasion (RR 5.2 [95% 
CI 4.0-6.8]), submucosal invasion ≥1mm (RR 5.2 [95% CI 1.8-15.4]), budding (RR 5.1 
[95% CI 3.6-7.3]), and poor differentiation (RR 4.8 [95% CI 3.3-6.9]). 
Limitations: Results could not be stratified according to location in colon or rectum. 
Very early tumours removed by polypectomy without surgical resection are not included 
in this meta-analysis. Included studies are primarily from Asian countries and results 
therefore need to be verified in Western populations.
Conclusion: The absence of lymphatic invasion, budding and poor differentiation is 
associated with low risk of lymph node metastases. Risk stratification models integrating 
these factors need to be investigated further.
Introduction
With the widespread introduction of population screening for colorectal cancer, 
the number of early colorectal cancers is expected to increase.1-6 In the past, 
approximately 25% of colorectal cancer cases presented with early disease (stage I) 
in which the primary tumour is limited to the submucosa (T1 tumours) or the bowel 
wall (T2 tumours). Local excision is an attractive option for early disease in both colon 
and rectal cancer, since it is associated with considerably less surgery-related morbidity 
and almost no post-operative mortality compared to colectomy and total mesorectal 
excision (TME),7-13 for which mortality rates of 1.9-6.5% (rectum) and 3.2-9.8% (colon) 
have been reported.14,15
Clinically, local treatment is especially relevant for rectal cancer, since the consequences 
of TME surgery, which often results in a colostomy, sexual and urinary dysfunction 
and complaints of soiling and faecal incontinence, are greater than for colectomy.16-20 
Moreover, the removal of tumours in the rectum, using transanal endoscopic 
microsurgery (TEM) and endoscopic submucosal dissection (ESD), is more effective 
than in the colon, where ESD is technically difficult and mainly polypectomy and endo- 
scopic mucosal resection (EMR) are used.13,21 However, there is a considerable 
move towards organ preserving surgery for colon cancer as well, since techniques 
for local treatment in the colon are improving.22
Local excision is generally reserved for T1 disease, since adequate removal of T2 
tumours using ESD or EMR in the colon is not feasible 23 and for rectal cancer local 
treatment of T2 lesions is reported to result in unacceptably high local recurrence 
rates and a lower survival compared to radical resection.10,24
Currently, patient related factors such as age and comorbidity are of primary importance 
when deciding whether or not to perform a radical resection for early colorectal cancer. 
For fit patients with T1 colorectal cancer the curative intent is absolute and a local 
excision can only be oncologically safe in the absence of lymph node metastasis (LNM). 
The overall incidence of LNM in T1 tumours is between 8-16% 25-28 and several 
pathologic features of the primary tumour, such as poor differentiation, lymphatic or 
vascular invasion, and submucosal invasion depth, have been associated with its 
presence.29-32
Patient selection through careful histological analysis of local excision specimens 
can therefore be very useful to avoid over- and under-treatment. For rectal cancer, 
some of the mentioned characteristics are already included in national guidelines as 
indicators of high risk lesions necessitating additional radical surgery (e.g. American 
(National Cancer Institute), British, Japanese and Dutch national guidelines).33-36 
However, despite the importance of high quality discrimination between low and high 
risk T1 cases, an adequate overview of the literature, quantifying the influence of 
the individual risk factors, is lacking. Although the described differences regarding 
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treatment options and associated morbidity suggest the clinical relevance is currently 
greatest for rectal cancer, risk stratification is valuable for pT1 colon cancer as well. 
Unfortunately, a separate analysis is not feasible, since studies describing nodal 
involvement exclusively for pT1 rectal cancer are very scarce. Therefore, the current 
study provides a systematic review of the risk factors for the presence of LNM in pT1 
colorectal cancer including meta-analyses where appropriate. 
Methods
Search strategy and selection criteria
A comprehensive literature search for published studies was performed using the 
PubMed database from inception to May 25, 2011. The keywords used were “lymph 
nodes”, “lymph node metastasis”, “TEM” and “T1” combined with “colorectal cancer”. 
Additional searches were performed using manual cross-referencing. Only published 
studies written in English with at least 50 patients were included. Reports describing 
use of neo-adjuvant therapy (ypT) were not included. Radical resection was required 
to obtain a reliable lymph node status. The percentage or number of patients with 
nodal involvement, specified for presence and absence of a specific risk factor was 
required. Data from pT1 patients had to be reported separately. In case of possible 
overlap of data due to duplicate publications, only the article with the largest sample 
size was included. 
Measuring submucosal invasion depth
Various methods to divide patients in a low or high risk group based on submucosal 
invasion depth are described in the literature. For sessile lesions a qualitative 
assessment according to Kudo et al. (1993) 37 is commonly used (sm1, sm2, 
and sm3: invasion into the most superficial, intermediate and deepest 1/3 of the 
submucosa respectively). This has been modified slightly into a semi-quantitative 
system by Kikuchi et al. (1995) 32 (sm1: invasion up to 0.2-0.3mm, sm2: intermediate 
invasion, sm3: invasion near the muscularis propria). A third method quantifies invasion 
depth (sm1: up to 0.5 mm, sm2: 0.5 to 1.0mm, sm3: beyond 1.0mm).38 Alternatively, 
the invasion depth is measured and a cut-off value is defined distinguishing between 
superficial and deep submucosal invasion.
For the purpose of performing our meta-analysis the studies were divided into two 
groups: one group includes studies using a quantitative invasion depth and the other 
includes studies using qualitative or semi-quantitative invasion depth. 
Statistical analysis
Data was extracted and analyzed by a single investigator (SLB). For all studies in the 
meta-analysis the frequencies of LNM per factor were available either from the text or 
from tables. Risk factors, incidence and events from the individual studies were 
entered into Review Manager 5.1 (RevMan, Copenhagen: The Nordic Cochrane Centre, 
The Cochrane Collaboration, 2011). If a factor was reported in at least 3 studies with 
comparable methodology, a meta-analysis was performed to summarize its prognostic 
effect in terms of a relative risk with 95%-confidence interval. A random effects model 
with Mantel-Haenszel weighting was used. Heterogeneity was assessed using a χ2 
test for heterogeneity with a P-value of <0.10 taken to reflect the presence of significant 
heterogeneity. The I2 statistic was calculated to quantify the degree of heterogeneity. 
Publication bias was assessed by inspection of the funnel plot by an experienced 
statistician (ST). Data presented as pooled estimates do not account for heterogeneity 
between studies and are reported for explorative purposes only. 
Results
Study selection and inclusion
The initial search returned a total of 43 studies (figure 1). Following review, 32 potentially 
relevant studies were identified as eligible of which 12 were excluded for duplicate 
series of patients, and 2 32,42 were excluded since they did not report separate data 
for patients with a radical resection and patients with local excision only.
In 3 studies 39-41 patients who underwent local excision only were reported separately 
and only the patients who received radical resection were included in our analyses. 
Another study was excluded, because of  a major discrepancy between data reported 
in text and tables.43 Repeated attempts to contact the authors by email to clarify this 
issue were unsuccessful. Therefore, we assumed the data from this study were 
unreliable. 
The 17 studies selected for this review 28,38-41,44-55 included a total of 3621 patients 
with pT1 tumours and available nodal status after radical resection. The median number 
of patients per study was 140 (range: 65-865). Table 1 outlines the characteristics 
of these studies. A number of 1544 were rectal carcinomas (41.3%), 2056 were colon 
carcinomas (54.9%) and in 141 cases no distinction was made between colon and 
rectal carcinomas (3.8%). The incidence of LNM was 11.4% (414/3621). Of the included 
studies 2 were performed prospectively and 15 retrospectively. 
Publication bias and heterogeneity
Inspection of the funnel plots (Supplemental content 1) did not reveal asymmetry, 
therefore there was no indication for publication bias. However, the funnel plot 
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analysis was limited in many cases by the low number of studies. Forest plots 
(Supplemental content 2 to 7) were checked for consistency of the effects. There was 
only quantitative heterogeneity. 
Factors predicting LNM 
Factors that were investigated in at least 3 studies with comparable methodology 
were included in our meta-analyses. These factors are depicted in figure 2 and include 
tumour location, lymphatic, vascular and lymphovascular invasion, submucosal invasion 
depth (based on sm-levels, cut-off value 1mm and cut-off value 2mm), width of sub- 
mucosal invasion (cut-off 5mm), histological differentiation grade (high grade vs. low 
grade), budding, and poor differentiation at the invasion front. Forest plots generated 
for the analysis of each individual risk factor are included in supplemental content 
2 to 7.
Table 2 provides the data for the dichotomous risk factors with total number of 
patients available for each analysis, the calculated relative risks (RR) for presence of 
LNM, and the level of heterogeneity. The data for submucosal invasion depth based 
on the three-tiered sm-levels (see method section) are shown in table 3. For all relevant 
factors the corresponding sensitivity, specificity, positive predictive value and negative 
predictive value are included in table 4. The table in Supplemental content 8 shows 
the results of the multivariable analyses in the different studies. For submucosal invasion 
depth the methodology differs considerably between the studies.
Figure 1  Flow chart illustrating study selection process
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Lymphatic, vascular and lymphovascular invasion
Most studies included lymphatic or vascular (sometimes called venous) invasion 
either as separate variables or gathered under the heading of lymphovascular invasion. 
Definitions were not often provided, with the exception of Tsuruta et al. (2000) and 
Wang et al. (2005)  who define lymphatic invasion as tumour cells in a space covered 
with endothelial cells in the absence of erythrocytes. Blood vessel invasion was defined 
as tumour within a smooth muscle-lined space or in an endothelial-lined space with 
additional fibrin clots, erythrocytes or both without erythrocyte extra -vasation into the 
surrounding tissue (Wang, 2005). Lymphovascular invasion has been defined by 
Okabe et al. (2004) as the presence of tumour cells within an epithelium- lined channel 
thought to represent either a lymphatic vessel or a blood vessel. 
Additional staining techniques such as Victoria blue 46,53 and Elastica von Gieson 
(EVG) 44,45,54 or immunohistochemical stains like D2-40,45 LYVE1,46 vWF,46 and 
CD34 41 have been used by some authors.Figure 2  Forest plot summarizing effect sizes of analyzed risk factors
Table 2   Dichotomous variables: results of the meta-analyses
Factor Studies 
(N)
references Patients 
(N)
Low risk  
group
LNM+ / total LNM 
(%)
High risk 
group
LNM+ / total LNM+ 
(%)
RR 
(95% CI)
Heterogeneity
Tumour location 10 [28, 38, 45-47, 49-51, 53, 55] 2722 Colon 169/1699 9.9 Rectum 141/1023 13.8 1.4  (1.1-1.7) χ 2 : 8.12, p = 0.52, I2: 0%
Lymphatic invasion 10 [28, 44-48, 50, 53-55] 1931 neg 71/1324 5.4 pos 162/607 26.7 5.2 (4.0-6.8) χ 2 = 8.74, p = 0.46, I2 = 0%
Vascular invasion 10 [28, 44-48, 50, 53-55] 1931 neg 154/1552 9.9 pos 79/379 20.8 2.2 (1.4-3.2) χ 2 = 17.32, p = 0.04, I2 = 48%
Lymphovascular invasion 5 [38, 41, 49, 51, 52] 1332 neg 75/1053 7.1 pos 73/332 22.0 3.9 (2.7-5.6) χ 2 = 4.30, p = 0.37, I2 = 7%
Submucosal invasion depth 
(cut-off 1mm)
5 [38, 41, 47, 48, 51] 1835 <1mm 6/405 1.5 ≥1mm 176/1430 12.3 5.2 (1.8-15.4) χ 2 : 6.26, p=0.18, I2: 36%
Submucosal invasion  
depth (cut-off 2mm)*
3 [41, 47, 51] 1463 <2mm 25/464 5.4 ≥2mm 133/999 13.3 2.4 (1.6-3.7) χ 2 : 1.55, p=0.46, I2: 0%
Submucosal invasion width  
(cut-off 5mm)
3 [41, 51, 53] 620 <5mm 12/213 5.6 ≥5mm 69/407 16.9 2.7 (1.4-5.4) χ 2 : 2.40, p = 0.30, I2: 7%
High vs. low grade 
histology
13 [28, 38, 39, 41, 44, 45, 47, 
48, 51-55]
2847 Low grade 229/2578 8.9 High grade 66/269 24.5 4.8 (3.3-6.9) χ 2 = 16.04, p = 0.19, I2 = 25%
Budding 7 [41, 44, 46, 47, 51, 54, 55] 1991 neg 59/1173 5.0 pos 174/818 21.3 5.1 (3.6-7.3) χ 2 = 7.54, p = 0.27, I2 = 20%
Poor differentiation at 
invasive front
4 [45-47, 51] 1307 neg 111/1083 10.2 pos 48/250 19.2 2.5 (1.8-3.5) χ 2 = 0.04, p = 1.00, I2 = 0%
*This result is mainly based on one large study [47], which contributes 69.6% of the weight in this analysis.
LNM: lymph node metastasis, neg: negative, pos: positive
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Lymphatic invasion was the most powerful predictor of LNM emerging from the 
meta-analyses (RR 5.2 [95% CI 3.7-7.3]). Multivariable analyses also provide solid 
evidence for an independent effect. It is important to report lymphatic invasion and 
vascular/venous invasion separately, since vascular invasion is a much weaker predictor 
of LNM (RR 2.2 [95% CI 1.4-3.2]). Combining the two factors as lymphovascular 
invasion (LVI) logically generates an intermediate relative risk (RR 3.9 [95% CI 2.7-5.6]), 
which is less informative. Additional staining techniques increase inter-observer 
agreement for lymphatic invasion from fair in HE stained slides (κ=0.30) to moderate 
(κ=0.56) in D2-40 stained slides, and for vascular invasion from considerable for HE 
slides (κ= 0.10) with marked improvement after EVG staining (κ=0.48).58 
Tumour budding 
Budding, which is also called “sprouting” or “single cell infiltration”, is reported in 7 studies 
41,44,46,47,51,54,55 totalling 1991 patients. The various authors do not use a uniform definition, 
however budding is usually described as foci of isolated cancer cells or clusters of 
less than 5 cancer cells at the invasive front of the lesion. Ueno et al. (2004) regard 5 
or more of these foci in a microscopic field at 200x magnification as positive, whereas 
Ishikawa et al. (2008) require more than 4 foci at a magnification of 400x. Other T
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Table 4   Sensitivity, specificity, positive predictive value and negative predictive 
value for the identified histological risk factors
Factor Sensitivity 
(%)
Specificity 
(%)
PPV 
(%)
NPV 
(%)
Tumour location in rectum 45.5 63.4 13.8 90.1
Lymphatic invasion + 69.5 73.8 26.7 94.6
Vascular invasion + 33.9 82.3 20.8 90.1
Lymphovascular invasion + 49.3 79.1 22.0 92.8
Submucosal invasion depth  ≥1mm 96.7 24.1 12.3 98.5
Submucosal invasion  depth ≥2mm 84.2 33.6 13.3 94.6
Submucosal width of invasion ≥5mm 85.2 37.3 17.0 94.4
High grade histology 22.4 92.0 24.5 91.1
Budding 74.7 63.4 21.3 95.0
Poor differentiation at invasive front 30.2 82.8 19.2 89.8
sm2/3 (vs. sm1) 92.7 30.4 16.8 96.6
sm3 (vs. sm1/2) 72.0 63.5 22.6 93.9
PPV: positive predictive value, NPV: negative predictive value
52 53
Chapter 2 Predicting LNM in pT1 colorectal cancer
2
authors do not provide a cut-off value. Interestingly, the use of various definitions and 
cut-off values did not result in significant heterogeneity in the meta- analysis (χ2= 
7.54, p = 0.27, I2 = 20%, table 2). The relative risk is strongly increased (RR 5.1 [95% 
CI 3.6-7.3]), and 5 of 6 studies show an independent predictive value.
Submucosal invasion depth: qualitative or quantitative measurement
In this meta-analyses, studies evaluating submucosal invasion depth for sessile 
lesions were divided into two groups consisting of the ones applying a qualitative or 
semi-quantitative definition 49,52,54,55 and those applying a strictly quantitative 
definition for submucosal invasion.38,41,47,48,50,51 Although the studies by Masaki et 
al. (2006) and Yamamoto et al. (2004) use the designations sm1, sm2 and sm3 we 
included them in the quantitative group, since they define sm-levels according to a 
specific invasion depth in mm. In both groups, submucosal invasion depth is strongly 
associated with risk of LNM. Increasing semi-quantitatively determined invasion 
depth is associated with increased risk of lymph node metastases (table 3, sm1/2 
versus sm3 (RR 3.3 [95%CI 1.8-6.2]) and for sm1 vs. sm2/3 (RR 3.6 [95%CI 1.3-9.8]). 
However, an independent value was only shown in 1 of 3 multivariable tests (sm1 vs. 
sm3, Nascimbeni et al. 2002). In our meta-analysis there was a significant difference 
between sm2 and sm3 (RR 2.7 [95% CI 1.6-4.4]), but only a trend for sm1 versus sm2 
(RR 2.4 [95% CI 0.9-6.1], p=0.08). 
For specimens lacking a muscularis propria layer, quantitative measurement of the 
invasion depth from the muscularis mucosa to the deepest part of invasion is an 
alternative. An invasion depth of more than 1mm in the submucosa shows a strong 
increase in relative risk for LNM (RR 5.2 [95% CI 1.8-15.4]), and is an independent 
predictive factor in 2 out of 3 multivariable analyses. 
Additional histological factors
Several additional histological factors have been evaluated, however, a meta-analysis 
was not justified in these cases because of a small number of studies, use of varying 
definitions and classifications or lack of relevant data. These factors include sub- 
mucosal invasion depth according to Haggitt levels for polypoid lesions, tumour size, 
histological tumour type, presence of inflammatory infiltrate, growth pattern, a cribriform 
subtype, microvessel density, and macroscopic tumour type.
Discussion
Published data of 3621 patients with pT1 colorectal carcinoma and available nodal 
status following radical resection were included in this systematic review. The tumour 
related factors that showed the strongest independent predictive value for LNM are 
lymphatic invasion, budding, poor histological differentiation, and a submucosal 
invasion depth ≥1mm. Since a curative intent for all fit patients with a pT1 colorectal 
cancer is the most important principle, focus should be on selecting patients, who 
have a very low risk and can safely be spared radical surgery. 
Several issues need to be solved before such selection procedure can safely be 
performed. Standards should be set for histological characteristics in order to 
improve reproducibility. Appropriate cut-off levels for several factors should be 
established and risk stratification models applying a combination of risk factors 
should be evaluated to establish the optimal combination of predictive factors. Stand-
ardization starts with the use of specific definitions. The results for the predictive 
value of lymphatic invasion illustrate this. While lymphatic invasion is a strong and 
reproducible predictive factor for LNM, especially when determined by specific 
antibody staining,58 the combination with vascular invasion results in an intermediate 
relative risk, which is not informative enough for clinical treatment decisions. Similarly, 
histological differentiation is well known for its inter-observer variation,59,60 although 
the current classification in which low grade and high grade tumours are distinguished, 
has improved reproducibility.61 In the current study, poorly differentiated or high 
grade carcinoma is indeed a strong predictor of LNM, with confirmation in four out of 
ten multivariable analyses. 
Budding is a relatively new and not routinely reported risk factor that consistently 
shows a strong association with the presence of LNM. However, many different 
definitions are used throughout the literature and there is limited evidence for repro-
ducibility.62 However, the strong result from the meta-analysis, which lacked 
significant heterogeneity, indicates that budding, evaluated by any method, is still a 
powerful marker for LNM.
Determination of cut-off levels is especially important in the determination of 
submucosal invasion depth. While semi-quantitative methods have proven to be 
useful in subsets of tumours in the literature, their value in daily practice might be 
more limited. Especially in endoscopically resected specimens the muscularis 
propria is often missing and the involved proportion of the submucosal layer is 
therefore hard to estimate. Quantitative measurement of the invasion depth from the 
muscularis mucosa to the deepest part of invasion is a more feasible method, 
although the muscularis mucosa may not always be identifiable due to tumour 
overgrowth.41 On the other hand, an invasion depth of more than 1mm in the 
submucosa shows a strong increase in relative risk for LNM (RR 5.2 [95% CI 1.8-15.4]), 
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and is an independent predictive factor in 2 out of 3 multivariable analyses, suggesting 
it could be a helpful tool for risk stratification. Indeed, assuming the pooled data are 
representative for clinical practice, a 1mm cut-off point would assign LNM positive 
patients to the high risk group with a sensitivity of 96.7%. However, this would be at 
the expense of a low specificity (24.1%) resulting in a high number of patients 
undergoing unnecessary surgery (false positives). A 1mm cut-off may therefore not 
be the optimal method for risk stratification. 
As becomes clear from table 4 no single predictor discussed in this review allows 
an optimal selection of low-risk patients by itself, since they are either not sensitive 
or not specific enough. It therefore seems sensible to investigate the potential of 
combining risk factors in algorithms to identify low risk patients. 
Ueno et al. (2004) investigated several combinations of risk factors and distilled a low 
risk group, defined by absence of unfavourable grade, lymphovascular invasion, and 
budding, that contained 55% of patients and is associated with only 0.7% nodal 
involvement. The addition of submucosal depth of invasion ≥2mm as a high risk 
factor eliminated nodal involvement in the low risk group, but also decreased the 
percentage of low risk patients to 32.3%. 
In a paper by Nakadoi et al. (2011) 63 the authors employed the high risk factors 
described in the 2010 guidelines of the Japanese Society for Cancer of the Colon and 
Rectum (JSCCR),36 which are very similar to the ones used by Ueno et al. (2004) and 
found that when a tumour was low risk (well/moderately differentiated, no vascular 
invasion or tumour budding) the incidence of LNM was only 1.2% with 49.9% of 
patients assigned to the low risk group. 
A limitation of the current study is that we were not able to investigate those 
combinations of factors. Another inevitable source of bias is that this systematic 
review only includes tumours of patients who underwent radical surgery. There is a 
population of early T1 cancers removed by polypectomy without radical surgery, 
which are not considered in our analysis as the definitive lymph node status is not 
available. We realise that this is especially relevant for pedunculated lesions, which 
undergo local excision more frequently (Ueno et al), and are known to have a low risk 
of LNM.47 Future studies should take this into account. 
Furthermore, the majority of papers included in this study originated from Asian 
countries in which pathological workup may be more extensive, which might influence 
results. Validation of the currently identified risk factors in Western populations is 
necessary.  
In conclusion, several factors can be identified in pT1 tumours that predict the 
presence of LNM. Lymphatic invasion, budding, and poor histological differentiation 
are the strongest predictors of LNM that also show a consistent independent 
predictive value in multivariable analyses. Their absence indicates a low risk of LNM 
and may justify a conservative policy. Future studies should investigate all of the 
above mentioned factors, including invasion depth in mm, and aim to standardize the 
detection of these powerful markers, preferably using immunohistochemical staining 
techniques. These recommendations may lead to the development of a validated 
model incorporating various risk factors for the prediction of LNM, which may help to 
select patients who can be spared radical resection, and such a model may thereby 
prevent unnecessary surgery without compromising oncological safety.
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Supplemental Content 8 Multivariable analyses (review of the literature)
Studies that reported results of a multivariable analysis are included here. Factors 
with independent prognostic value are marked with an X. Included factors that were 
non-significant are marked with an O. 1 sm-levels; 2 cut-off 1mm; 3 cut-off 2mm; 
4 cut-off 3mm; 5 cut-off 0.4mm; 6 cut-off unknown; * distal 1/3 of rectum vs. rest of 
rectum and colon.
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Submucosal invasion depth O3 O2 O6 X2 X1 O5 X4 O1 O1 X2
Differentiation grade O O O O X O X X X O
Lymphatic invasion X X X X O O X
Lymphovascular invasion X X O X X
Vascular invasion (intramural) O O O O
Budding X X X O X X
Invasive front differentiation grade O X O O O
Colon vs. rectum O O X* O O
Macroscopic type O X O
Tumour size O O O
Initial treatment O
Microvessel density X
Cribiform subtype O X
Age O O O
Gender O O O
Inflammation at the invasive front X X
Muscularis mucosae identifiable O
Adenoma present or absent O
Tumour type O O O
Clinicopathological characteristics  
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Abstract
Background: Changes in rectal cancer treatment include increasing emphasis on 
organ preservation. Local excision after chemoradiotherapy (CRT) for rectal cancer 
with excellent clinical response reduces morbidity and mortality compared to total 
mesorectal excision, although residual lymph node metastases (LNM) may cause 
local recurrence. Our aim is to identify clinicopathological factors predicting the 
presence of residual LNM in rectal cancer patients with ypT0-2 tumours after 
neo-adjuvant CRT. These risk factors may help select patients who can be spared 
radical surgery without compromising oncological outcomes.
Methods: Rectal cancer patients with ypT0-2 tumours after CRT and radical resection 
from five centres treated between June 1999 and February 2012 were included. 
Histopathology was extensively reviewed. Clinicopathological characteristics and 
their association with residual LNM were investigated. 
Results: Out of 657 consecutive CRT treated rectal cancer patients 210 with ypT0-2 
disease were included. Residual nodal disease was found in 44 cases (21.0%). 
Independent predictors of LNM were clinical nodal involvement (cN+) (OR 2.79 [95% 
CI 1.04-7.48], p=0.042), “high grade” histopathology assessed in the post-CRT 
resection specimen (OR 6.46 [95% CI 1.23-34.02], p=0.028), and residual tumour 
diameter ≥10mm (OR 2.54 [95% CI 1.06-6.09], p=0.036). An algorithm combining 
these factors adequately stratified patients according to LNM risk, independently of 
ypT category.
Conclusions: Clinical nodal involvement, “high grade” histopathology, and residual 
tumour diameter ≥10mm are strong and independent predictors of residual nodal 
disease in rectal cancer patients with ypT0-2 tumours after CRT. Risk stratification 
based on these factors may help identify patients suitable for organ preserving 
therapy and should be validated in appropriately selected populations. 
Introduction
For locally advanced rectal cancer patients, neo-adjuvant chemoradiotherapy (CRT) 
consisting of long course radiotherapy and concurrent chemotherapy followed by 
total mesorectal excision (TME) is the standard of care. In 8-24% of patients, 
neo-adjuvant CRT results in a pathological complete response (pCR). These patients 
have been reported to have an excellent prognosis with a five-year local recurrence 
rate of 0-2.8% and 83.3-96.9% five-year disease free survival.1-3 
Radical resection may therefore be superfluous in selected patients with a good 
clinical response and postoperative morbidity and mortality associated with TME4, 5 
could be avoided. Indeed, local recurrence rates as low as 2.8% and 4.7% have been 
reported after a “wait-and-see” policy for selected patients with a clinical complete 
response after CRT.6, 7 Nevertheless, several other studies showed worse outcomes 
(local failure rates of 23-60%).8-10 Critics of “wait-and-see” point out that criteria for 
clinical complete response cited in the literature are not consistent and the evidence 
is based on highly selected patient groups.11 
A full thickness local excision of the residual tumour or scar area is an attractive 
alternative to “wait-and-see”, since it removes possible tumour remnants in the bowel 
wall. It also provides additional information on tumour response and can be used to 
identify histopathological risk factors for locally recurrent disease. Especially for early 
tumours in the distal part of the rectum, this strategy has been successfully used in 
several small international studies.12 However, identification of patients who are most 
likely to benefit from an organ preserving procedure remains difficult. A validated set 
of histopathological risk factors could help to stratify patients according to local 
recurrence risk. Unfortunately, studies on local excision after CRT are relatively scarce 
and often lack sufficient numbers of patients to perform a risk stratification based on 
histopathological factors. 
An alternative approach is to investigate tumour characteristics associated with 
residual lymph node metastases (LNM) in the mesorectal fat of CRT treated radical 
TME specimens. Residual LNM are a potential source of recurrent disease after local 
excision and predictors of LNM in radical resection specimens are therefore likely to 
overlap with predictors of local recurrence after local excision.13, 14 In addition, 
patients with ypT0-2 rectal cancers after CRT may be cured with a full thickness local 
excision in the absence of LNM. We therefore investigated possible predictors of 
LNM in this group of patients in a multicenter study with central review of histopathology. 
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Materials and methods
Patients and study design
This report describes a pooled analysis of consecutive rectal cancer patients from 
five independent centres with ypT0-2 tumours who received neo-adjuvant CRT 
followed by TME surgery between June 1999 and February 2012. Patients considered 
for CRT either had evidence of locally advanced disease on pre-operative MRI 
(defined as a cT4 tumour, a cT3 tumour with threatened mesorectal fascia, a cT3 
tumour less than 5cm from the anal verge, and/or clinical N2 disease), or were 
otherwise expected to benefit from CRT during a multidisciplinary team meeting (e.g. 
attempt to preserve the sphincter in case of a very low T2 tumour). Patients received 
external beam long course radiotherapy consisting of 45-50Gy in 25-28 fractions of 
1.8-2.0Gy and concomitant fluoropyrimidine based chemotherapy (with or without 
oxaliplatin). The clinical target volume included the primary tumour and the meso- 
rectum with vascular supply, containing the perirectal, presacral and internal iliac 
nodes. For this purely restrospective study ethics approval and informed consent 
were not required.
Histopathology
Routine histopathological evaluation of the resection specimens was performed in 
the laboratories of the participating hospitals according to international guidelines. 
For the study, haematoxylin and eosin (H&E) stained glass slides or high resolution 
digitally scanned slides as well as histopathology reports were retrieved and centrally 
reviewed by a single investigator (SLB). Difficulties and discrepancies with the original 
histopathology report were resolved by consulting an expert gastro-intestinal pathologist 
(IDN).
Cases were excluded if a tumour was determined to be >ypT2 at review or the histo-
pathological slides (glass or digital) were unavailable. 
The pathological tumour category (ypT) and pathological nodal category (ypN) were 
evaluated according to the 5th edition of TNM15 classifying mesorectal tumour 
deposits of ≥3mm without evidence of residual lymph node tissue, as positive lymph 
nodes regardless of their contour. Lymph nodes with fibrosis or acellular mucin lakes, 
but without viable tumour cells were considered to be negative for tumour. 
In addition to ypT category the evaluated tumour related characteristics included 
residual tumour diameter (RTD), histopathological type and differentiation grade, 
tumour regression grade (TRG), extent of tumour necrosis, and presence of intramural 
venous and lymphatic invasion, perineural growth, budding, intramural acellular 
mucinous lakes, calcifications, and peritumoural inflammatory infiltrate.
RTD was defined to be the largest distance between viable tumour cells in the 
mucosa, submucosa or muscularis propria. In case of tumour regression with fibrosis 
and scattered residual tumour cells and glands, this was the largest distance between 
individual tumour cells in the slide. In case tumour cells were present in two slides, 
RTD was estimated to be at least 4mm, since a block of paraffin embedded tissue 
was estimated to be 4mm thick. This was at least 8mm in case of tumour in three 
slides etc. However, due to the retrospective nature of the study it was not possible in 
every case to reliably reproduce the position of the various tissue blocks and 
associated slides relative to each other. 
Histopathological type and differentiation grade of the tumour were assessed in the 
post-CRT resection specimen and defined according to WHO 2010 criteria.16 For 
analytical purposes the cases were subsequently categorized as having “high grade” 
histopathology (including poorly differentiated adenocarcinoma, undifferentiated 
carcinoma and signet ring cell carcinoma) vs. “other” histopathology (including low 
grade adenocarcinoma, mucinous carcinoma, and pathological complete response).
For TRG, a four-tier grading scale adjusted from Dworak’s system17 was used. Grades 
are defined as follows: grade 1 (no significant response) “no fibrosis or significant 
fibrosis outgrown by cancer”; grade 2 (partial response) “residual cancer outgrown 
by fibrosis”; grade 3 (near complete response) “scattered single tumour cells or small 
groups of tumour cells”; grade 4 (pathological complete response) “no viable tumour 
cells”. 
Lymphatic invasion was defined as tumour cells in a space covered with endothelial 
cells in the absence of erythrocytes.18 Venous invasion was diagnosed in case of 
tumour within a smooth muscle-lined space or in an endothelial-lined space with 
additional fibrin clots, erythrocytes or both, without erythrocyte extravasation into the 
surrounding tissue.18, 19 Budding was defined as “presence of at least five foci of up 
to five tumour cells in a microscopic field using a 20x objective and evaluated in the 
area where such foci are most dense” as described by Ueno et al.20 Grade of tumour 
necrosis was evaluated according to Pollheimer et al.21 Acellular mucinous lakes 
were determined to be present or absent in the specimen regardless of tumour cells 
in the surrounding tissue. Peritumoural inflammatory infiltrate was determined to be 
conspicuous or non-conspicuous as originally described in the Jass classification.22 
Statistical analysis
SPSS version 20 was used to perform the analyses. For RTD a receiver operating 
characteristic curve (ROC) was created to estimate the cut-off value with optimal 
sensitivity and specificity for predicting presence of LNM. Mann-Whitney U test or 
independent samples Kruskal-Wallis test was used for non-parametrical continuous 
variables. Categorical variables were analyzed using the χ2 test, Mann-Whitney U test 
or independent samples Kruskal-Wallis test where appropriate. Factors with a 
statistically significant association with LNM or a statistical trend were subsequently 
included in a multivariate analysis using binary logistic regression. A p-value of <0.05 
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was considered statistically significant whereas a p-value of <0.1 was taken to reflect 
a trend towards significance.  
Results
Patient selection
Out of 657 consecutive rectal cancer patients from five centres, who received long 
course CRT and TME, 211 (32.1%) were found to have ypT0-2 disease. One patient 
was excluded for lack of the histopathological slides, resulting in 210 patients who 
were included in the analysis. 
Lymph nodes
Median number of examined lymph nodes per patient was 7 (range 0-39). Residual 
nodal disease was found in 44 patients (21.0%). Presence of LNM was not related to 
number of lymph nodes sampled in the current population (median number of 
examined lymph nodes: 6.5 vs. 7.0 respectively in patients with vs. without residual 
LNM (p=0.439). Of the patients without LNM there were 34 who showed signs of 
tumour regression in lymph nodes including acellular mucin in 7 cases. 
Clinical characteristics
Table 1 shows clinical characteristics and their association with presence of LNM. 
Centre of origin, gender, clinical nodal status (cN), and type of chemotherapy (fluoro-
pyrimidine only vs. capecitabine + oxaliplatin) were significantly associated with 
presence of LNM. 
Histopathological tumour characteristics
Changes in classification of histopathological characteristics compared with the original 
pathology reports were made in 18 cases after slide review (8.6%). This included either 
a T-category downgrade (n=8), T-category upgrade (n=6), N-category downgrade 
(n=1), or N-category upgrade (n=3). Tumour type was not changed. Other factors 
investigated in this study (e.g. tumour differentiation grade, lymphatic invasion, 
tumour regression grade, budding etc.) were not consistently described in the original 
reports and were therefore primarily scored at the time of slide review. 
Table 2 shows the investigated histopathological characteristics and the associated 
LNM rate. The ypT category did not significantly predict residual nodal disease (LNM 
rate 17.4%, 14.8% and 25.8% for ypT0, ypT1, and ypT2 respectively; p=0.159; and 
LNM rate 16.8% vs. 25.8% for ypT0-1 vs. ypT2 respectively; p=0.112). RTD had 
a strong association with presence of LNM. Initial analysis of histopathological 
 characteristics revealed that mean RTD was significantly higher in the ypN+ 
Table 1   Association of clinical characteristics with residual lymph node  
metastases
Clinical characteristics Univariate analysis
Total N=210 ypN0 ypN+
P-value *
N % N %
Total no. of patients 166 79.0 44 21.0
Age (years) # 62 (55-68) 59.5 (54.25-69.75) 0.665 ^
Total number of examined 
lymph nodes #
7 (4-11) 6.5 (5-12.75) 0.439 ^
Centre of origin
Centre 1 64 86.5 10 13.5 0.004
Centre 2 27 61.4 17 38.6
Centre 3 21 70.0 9 30.0
Centre 4 6 75.0 2 25.0
Centre 5 48 88.9 6 11.1
Gender
Male 125 83.9 24 16.1 0.007
Female 41 67.2 20 32.8
cT
cT2 7 87.5 1 12.5 0.184^
cT3 99 75.6 32 24.4
cT4 60 85.7 10 14.3
Missing - - 1 -
cN
cN0 60 89.6 7 10.4 0.018
cN+ 98 75.4 32 24.6
Missing 8 - 5 -
Type of chemotherapy
 FP only ‡ 121 75.6 39 24.4 0.033
CAPOX 44 89.8 5 10.2
Missing 1 - - -
Distance to anal verge
<5cm 92 82.9 19 17.1 0.148
≥5cm 74 74.7 25 25.3
FP: fluoropyrimidine; CAPOX: capecitabine + oxaliplatin; cT: clinical primary tumour category;  
cN: clinical nodal category; ypT: pathological primary tumour category after multimodality therapy;  
ypN: pathological nodal category after multimodality therapy. 
* Chi-square test is used unless stated otherwise, ^ Mann-Whitney U test, # Median and interquartile 
range, ‡ Capecitabine (n=139) or bolus 5FU + leucovorin (n=21; centre 1 and 4).
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compared to the ypN0 group (11.2mm and 6.0mm respectively, p=0.022). A ROC 
curve showed a RTD of ≥10mm to be the optimal cut-off value to predict LNM 
(sensitivity 43.2%; specificity 81.9%; AUC 0.598). Therefore, this value was used in 
the subsequent analyses which showed LNM in 16.0% vs. 38.3% for RTD <10mm 
and ≥10mm respectively (p=0.001). 
Out of 24 patients with a near complete response (TRG 3) there were 3 with a RTD of 
≥10mm and 1 of those showed residual nodal disease.
“High grade” histopathology (assessed after neo-adjuvant therapy) was found in 
8 patients including 6 with poorly differentiated adenocarcinoma and 2 with undiffer-
entiated carcinoma. There were no cases with signet ring cell carcinoma. The majority 
Table 2   Association of pathological characteristics with residual lymph node 
metastases
Histopathological 
characteristics
Univariate analysis
Total N=210 ypN0 ypN+
P-value *N % N %
Total no. of patients 166 79.0 44 21.0
ypT
ypT0 71 82.6 15 17.4 0.159^
ypT1 23 85.2 4 14.8 0.112 ‡
ypT2 72 74.2 25 25.8
RTD
 <10mm 137 84.0 26 16.0 0.001
 ≥10mm 29 61.7 18 38.3
Histopathological  
type/grade #
“Other” 163 80.7 39 19.3 0.003
“High grade” 3 37.5 5 62.5
TRG
pCR 71 82.6 15 17.4 0.769^
Near complete response 16 66.7 8 33.3
Partial response 76 80.9 18 19.1
No significant response 3 50.0 3 50.0
Intramural venous invasion
Present 0 - 0 - N/A
Absent 166 79.0 44 21.0
Intramural lymphatic 
channel invasion
Present 11 68.8 5 31.2 0.292
Absent 155 79.9 39 20.1
Intramural perineural 
growth
Present 0 - 0 - N/A
Absent 166 79.0 44 21.0
Budding
Positive 8 61.5 5 38.5 0.117
Negative 155 79.9 39 20.1
Missing 3 - - -
Table 2   Continued
Histopathological 
characteristics
Univariate analysis
Total N=210 ypN0 ypN+
P-value *N % N %
Necrosis
Absent 136 81.0 32 19.0 0.117^
Focal (<10%) 17 81.0 4 19.0
Moderate (10-30%) 4 44.4 5 55.6
Extensive (>30%) 8 72.7 3 27.3
Peritumoural inflammatory 
infiltrate
Conspicuous 27 73.0 10 27.0 0.317
Other  139 80.3 34 19.7
Acellular mucinous lakes
Present 40 75.5 13 24.5 0.459
Absent 126 80.3 31 19.7
Calcification
Present 42 85.7 7 14.3 0.190
Absent 124 77.0 37 23.0
ypT: pathological primary tumour category after multimodality therapy; ypN: pathological nodal 
category after multimodality therapy; RTD: residual tumour diameter; TRG: tumour regression grade; 
pCR: pathological complete response
* Chi-square test is used unless stated otherwise, ^ Mann-Whitney U test, ‡ ypT0-1 vs. ypT2,  
# “Other” histopathology includes low grade adenocarcinoma (n=103), mucinous carcinoma (n=13) 
and pathological complete response (n=86). “High grade” histopathology includes poorly differentiated 
carcinoma (n=6), and undifferentiated carcinoma (n=2).
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of patients had “other” histopathology (n=202) including low grade adenocarcinoma 
(n=103), mucinous carcinoma (n=13) and pathological complete response (n=86). 
“High grade” histopathology was a statistically significant predictor for the presence of 
LNM (LNM rate 62.5% vs. 19.3% for “high grade” vs. “other” histopathology respectively 
(p=0.003)). 
Routine histopathology details
The median number of tissue blocks available for re-evaluation per case was 15 
(range 5-52) and the median number of blocks from the tumour area was 6 (range 
2-43). The proportion of cases in which the entire tumour area was embedded could 
not be reliably determined retrospectively, since this was not consistently described in 
the original reports. Additional tumour area blocks were embedded in 23 cases (11.0%) 
that lacked residual viable tumour in the initial slides, and this included 14 patients 
with ypT0 (16.3%). Three additional levels from the tumour blocks were cut in 5 cases 
(2.4%), including 2 cases with ypT0 (2.3%). Immunohistochemistry with cytokeratins 
was performed in 12 cases (5.7%) including 5 patients (5.8%) with ypT0.
Multivariate analysis
Factors with a statistically significant association with residual nodal disease or a 
statistical trend were included in a multivariate analysis (table 3). Independent predictive 
value was shown for clinical nodal involvement (OR 2.79, 95%CI 1.04-7.48 for cN+ vs. 
cN0; p=0.042), residual tumour diameter ≥10mm (OR 2.54, 95%CI 1.06-6.09 for RTD 
≥10mm vs. <10mm; p=0.036), and “high grade” histopathology (OR 6.46, 95% CI 
1.23-34.02 for “high grade” vs. “other” histopathology; p=0.028). Centre of origin, 
gender, and type of chemotherapy did not show an independent association with 
ypN category.
Combining independent risk factors
The independent risk factors identified in the multivariate analysis were subsequently 
combined to investigate their potential for risk stratification in the current study 
population (table 4). Patients without clinically detectable LNM (cN0) and with “other” 
histopathology had the lowest LNM risk (7.7%), whereas patients with “high grade” 
histopathology had a high risk regardless of clinical nodal status and RTD. RTD was 
of additional value for stratification of patients who had both clinical nodal involvement 
(cN+) and “other” histopathology (17.8% vs. 47.8% for RTD <10mm and ≥10mm 
respectively; p=0.002). 
Based on these data we devised an algorithm which stratifies patients in three 
subgroups (low, intermediate, and high risk) according to risk of residual LNM (figure 1). 
LNM risk was 7.7%, 17.8%, and 51.6% for the low, intermediate, and high risk categories 
respectively (p<0.001; figure 2). 
Table 3   Multivariate analysis
Odds ratio (95% CI) P-value
Centre of origin 0.426
Centre 1 1.00
Centre 2 1.42 (0.37-5.42)
Centre 3 1.32 (0.32-5.46)
Centre 4 0.0 (0.0-∞)
Centre 5 0.48 (0.11-2.07)
Gender 0.110
Male 1.00
Female 1.98 (0.86-4.59)
cN 0.042*
cN0 1.00
cN+ 2.79 (1.04-7.48)
Type of chemotherapy 0.298
FP only 1.00
CAPOX 0.45 (0.10-2.01)
RTD 0.036*
<10mm 1.00
≥10mm 2.54 (1.06-6.09)
Histopathology 0.028*
“Other” 1.00
“High grade” 6.46 (1.23-34.02)
cN: clinical nodal category; RTD: residual tumour diameter; FP: fluoropyrimidine; CAPOX: capecitabine 
+ oxaliplatin.
*statistically significant (p<0.05)
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Role of ypT category 
The ypT category did not reach statistical significance or a statistical trend in this 
study. In a subgroup analysis of patients with a ypT2 tumour (n=88), the algorithm 
described in the previous paragraph was able to adequately stratify patients 
according to LNM risk (7.7%, 14.7%, and 50.0% for patients in the low, intermediate 
and high risk categories respectively; p<0.001). For patients with a ypT0-1 tumour 
this was 7.7%, 19.4%, and 66.7% (p=0.024). Patients with a pathological complete 
response of the primary tumour (ypT0) had residual nodal disease in 10.3% and 
20.8% of cases depending on clinical nodal status (cN0 and cN+ respectively; 
p=0.231).
Table 4   Independent risk factors and lymph node metastases rate (N=197^ )
cN0 cN+
“Other” 
histopathology
“High grade” 
histopathology
“Other” 
histopathology
“High grade” 
histopathology
RTD 
<10mm
8.0% (4/50) 100.0% (1/1) RTD 
<10mm
17.8% (18/101) * 25.0% (1/4) #
RTD 
≥10mm
6.7% (1/15) 100.0% (1/1) RTD 
≥10mm
47.8% (11/23) 100.0% (2/2)
Total 7.7% (5/65) 100.0% (2/2) Total 23.4% (29/124) 50.0% (3/6)
Figures represent patients with LNM in each subgroup: % (N/Ntotal). 
cN: clinical nodal category; RTD: residual tumour diameter.
^ Cases with at least one missing value (n=13) were excluded, * p=0.002 for RTD <10mm vs. RTD 
≥10mm, # p=0.083 for RTD <10mm vs. RTD ≥10mm
Figure 1  Flow chart depicting algorithm for risk stratification
LNM: lymph node metastases; cN: clinical nodal category
Figure 2  Risk of residual LNM based on the flow chart algorithm* (n=197^ )
* Risk factors are: clinical nodal involvement (cN+), residual tumour diameter ≥10mm, and “high grade” 
histopathology (including poorly differentiated and undifferentiated carcinoma).
^ Cases with at least one missing value (n=13) were excluded.
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the primary tumour and LNM have been reported to undergo similar levels of regression 
with loss of the most susceptible tumour components27 it may be hypothesized that 
the post-CRT morphology is likely to reflect the risk of residual LNM most adequately.
The relatively low number of examined lymph nodes is a limitation to this study, since 
a minimum of 12 nodes is generally recommended for adequate nodal staging.31 
However, lymph node yield is known to decrease after chemoradiation and the 
median number of 7 nodes found in this study is comparable with results described 
in several previous reports after neo-adjuvant therapy.32-35 Lymph node yield was not 
associated with nodal positivity in the current population. However, this may be 
related to a lack of statistical power to detect a correlation, since previous studies 
found LNM rate to increase with number of examined lymph nodes.33, 34
Furthermore, the multicenter design of this study implies some inherent variations 
between centres in distribution of patient and treatment characteristics, such as 
gender, clinical stage, and type of chemotherapy. However, the included rectal 
cancer patients constitute an adequate reflection of the case-mix encountered in 
clinical practice, and results may therefore be widely applicable. Moreover, the 
multivariate analysis showed the identified risk factors to be independent of centre. 
However, the current results cannot be extrapolated directly to a local excision setting. 
For example, pathological tumour category may be underestimated in local excision 
specimens due to the often discontinuous nature of residual tumour foci after 
neo-adjuvant CRT, since some residual tumour cells may remain undetected in the 
mesorectal fibrosis. Furthermore, our study is based on a relatively unfavourable 
population including many patients with unfavourable clinical characteristics such as 
T4 tumours or clinical N2 disease, and many of them would in practice never be 
considered for rectal preservation. Therefore, our results are hypothesis generating, 
and the identified risk factors, as well as their association with local recurrence risk, 
should be investigated and validated in appropriately selected populations.  
In summary, this study shows that clinical nodal involvement, “high grade” histo- 
pathology, and residual tumour diameter are strong and independent predictors for 
the presence of residual nodal disease in rectal cancer patients with ypT0-2 tumours 
after neo-adjuvant CRT. An algorithm combining these risk factors to stratify patients 
according to low, intermediate, or high LNM risk was shown to be accurate, regardless 
of ypT category. If validated in appropriately selected populations these factors may 
contribute to an effective stratification of patients according to risk of LNM and local 
recurrence. This may improve decision making regarding local or radical surgery, 
and may help save selected patients from undergoing an unnecessary, yet potentially 
harmful TME, while ensuring oncological safety.
Discussion
In this study including 210 TME specimens of consecutive rectal cancer patients with 
ypT0-2 tumours after CRT, we showed that clinical nodal involvement (cN+), “high 
grade” histopathology (i.e. poorly differentiated or undifferentiated carcinoma), and 
residual tumour diameter (RTD) of ≥10mm are strong independent risk factors for 
residual LNM. We devised an algorithm based on these risk factors, which adequately 
stratifies patients according to risk of residual nodal disease in the current population. 
Moreover, we showed that the predictive value of this algorithm was independent of 
pathological tumour category after neo-adjuvant treatment (ypT). 
Clinically suspected nodal disease was the strongest independent risk factor for 
residual LNM at histopathological examination. Residual LNM risk in cN+ patients 
was 24.6%, which explains why clinical trials investigating feasibility of local excision 
after CRT generally exclude patients with clinical evidence of nodal involvement.23, 24 
However, LNM rate was 10.4% in the cN0 group showing that clinical imaging is 
relatively inaccurate for the prediction of nodal disease.25 26
RTD was useful only in cN+ patients. RTD can be regarded as a footprint of the original 
tumour which reflects its level of therapy resistance, similar to tumour regression 
grade. TRG correlates with the therapy resistance of associated LNM, with similar 
levels of regression in both the primary tumour and the lymph nodes.27 The predictive 
value of RTD is most likely based on the same principle. In case of a local excision 
the advantage of RTD over TRG is that it is based on the amount of microscopically 
detectable residual tumour in the specimen, whereas for TRG, an estimate of the 
amount of “tumour mass turned fibrosis” is essential.17 Estimates of TRG are therefore 
not feasible after local excision, since an important part of the fibrotic areas are 
located in the mesorectal fat and therefore missing in the specimen. 
“High grade” histopathology was a strong and independent risk factor associated 
with a 62.5% risk of LNM, although it was found in relatively few cases in the current 
population. This result is in accordance with previous series on early colorectal 
cancer.20, 28 Differentiation grade was determined in the CRT treated resection 
specimens, since pre-therapy biopsies are notoriously unreliable for grading purposes 
with substantial variation between grade of differentiation determined on biopsy and 
after definitive surgery,29 probably due to sampling error. Indeed, WHO criteria define 
type and grade according to the relative dominance of specific tumour components 
(e.g. more or less than 50% gland formation; more or less than 50% mucin 
production),16 and a superficial biopsy may miss a relevant component entirely. 
On the other hand, CRT may induce significant morphological changes including 
disappearance of tumour tissue with fibrosis and mucinous degeneration.30 This may 
change the proportion of various tumour components and may yield a different grade 
than would have been the case without neo-adjuvant treatment. However, since both 
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Abstract
Background: After preoperative chemoradiotherapy (CRT) for rectal cancer, clinically 
undetectable residual tumour deposits or pathologic lymph nodes may remain in the 
mesorectum. 
Aim: The aim of this study was to report histopathological effects of CRT and factors 
affecting outcome in a uniformly treated series of locally advanced rectal cancer 
(LARC) patients.
Methods: Between 2004-2008, 107 patients with cT3 (threatening the mesorectal 
fascia or <5 cm from the anal verge), cT4 or cN2 rectal cancer were treated with pre- 
operative CRT (25x2 Gy with capecitabine) and TME 6-8 weeks later. Central histo-
pathological review followed. Tumour regression grade (TRG) was scored in pCR, 
near-pCR, response and no response. Cox regression was performed to identify 
prognosticators. 
Results: The 3-year distant metastasis-free interval, disease-free rate and overall survival 
rate were 82%, 73% and 87% (median 44 months follow-up). TRG consisted of 
20% pCR, 11% near-pCR, 55% response and 14% no response. 6/21 pCR patients 
harboured nodal metastases. 5/12 near-pCR had ypT3 disease, while 6 harboured 
node metastases. 5/12 near-PCR patients developed distant metastases. ypN and 
TRG were powerful outcome discriminators. 
Conclusion: The high number of near-pCR with ypT3 or ypN1/2 and their poor outcome 
demonstrates that “watch-and-wait” in LARC patients should be applied with care.
Introduction
The increasing use of neoadjuvant chemoradiotherapy in rectal cancer provides new 
challenges for pathologists. Tumours appear to respond heterogeneously to neo- 
adjuvant therapy; mechanisms governing response or resistance remain unclear. 
The histopathological regression of tumour to the CRT is assessed by a semi- 
quantitative scoring of the relative proportion of residual tumour to stromal fibrosis, 
the tumour regression grade (TRG)1. It is conceivable that after CRT a highly 
responsive tumour is associated with superior treatment outcome. Published series2 
demonstrate excellent outcome in those 8-24% of the cases in which no viable primary 
tumour cells are found in the resection specimen after CRT (pathologic complete 
response or pCR). The results after more intensive combination-regimens, however, 
have been disappointing, with more adverse effects3;4. Therefore, radiotherapy to a 
dose of 45-50 Gy with concurrent daily capecitabine, an oral prodrug of 5-FU, seems 
to have become the standard of care.
The concept of a pCR after CRT questions the need for additional resection. The group 
of Habr- Gama et al5;6 have published multiple series on a non-operative “watch and 
wait” policy in those patients in whom no residual tumour is detected at clinical 
assessment after CRT. Meticulous clinical, endoscopic and radiological follow up 
was implemented to guarantee a sustained clinical complete response (cCR). Using 
this policy, a locoregional failure rate of only 3% was reported in a series5 of distal 
rectal cancer patients (20% cT2, 70% cT3, 11% cT4 and 23% cN+), which is comparable 
to those with a pCR after resection. These excellent results have been confirmed in 
another series7. Other groups have observed significant clinical complete response 
rates in T2-T3 tumours treated with high dose rate endorectal brachytherapy followed 
by external beam radiotherapy indicating a possible role of radiotherapy alone in a 
subset of patients in the future8-10. However, data are scarce regarding those in which 
the cCR is not sustained, and in which salvage resection is required due to loco- 
regional failure. The risks of a non-operative (or local) treatment include under-treatment 
or treatment delay in those with residual lymph node metastases and those with 
undetectable tumour deposits in the mesorectum. 
Differences in patient selection, indications for the treatment, definition of locally 
advanced rectal cancer (LARC), preoperative regimens, but also lack of standardized 
TME and pathology make comparisons between different series difficult. The aim of 
this study was to report histopathological effects of CRT and factors affecting 
outcome in a uniformly treated series of MRI-defined LARC patients. 
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Patients and Methods
Patients
In the period between June 2004 to February 2008 a total of 147 consecutive patients 
with LARC, defined as a cT4 tumour, a cT3 tumour <5 cm from the anal verge or 
threatening the mesorectal fascia (MRF) on magnetic resonance imaging (MRI) or 
cN2 disease, underwent preoperative CRT in the Netherlands Cancer Institute. MRI 
was used to evaluate tumour infiltration and the presence of lymph nodes larger than 
1 cm or with clinical characteristics suspicious of metastases. A CT-scan of the 
abdomen and X-ray or CT-scan of the thorax were used to evaluate dissemination.
Preoperative chemoradiotherapy
Preoperative radiotherapy consisted of 50 Gy in 25 fractions on week days. The 
clinical target volume included the primary tumour and the mesorectum with vascular 
supply, containing the perirectal, presacral and internal iliac nodes. The recommended 
upper field border was at the level of the promontory. The perineum was included if 
an abdominoperineal resection (APR) was planned, whereas the lower border was 
3 cm above the anal verge if the planned operation was low anterior resection (LAR). 
From April 2006 onwards, intensity-modulated radiotherapy (IMRT) substituted the 
three-field, three-dimensional conformal technique. Capecitabine was administered 
orally and twice daily at a dose of 825 mg/m2, starting on the first day and ending 
on the last day of radiotherapy, including weekends. The mean cumulative dose of 
capecitabine was 95 % (range 32–100) of the prescribed dose, while 98% of patients 
received at least 45 Gy. 
Surgery
Surgical resection according to the principles of TME followed 6-8 weeks later in the 
Netherlands Cancer Institute or in one of ten regional hospitals. Exenterative surgery 
was performed for infiltration into surrounding organs or structures. Preoperative 
clinical assessment of response with endoscopy or imaging was not standard 
treatment. Of 147 patients receiving neo-adjuvant CRT, 138 were considered fit for 
surgery and underwent laparotomy after completion of neo-adjuvant therapy. Of these, 
131 were considered resectable intra-operatively. A further 19 patients were excluded 
because of synchronous distant metastases while in 5 patients pathology slides were 
not available prohibiting pathological review. Thus, 107 patients were included for 
the analysis. Adjuvant chemotherapy is not standard of care in the Netherlands; four 
patients received adjuvant chemotherapy as part of a prospective trial.
Histopathological analysis
Routine macroscopic and microscopic examination of the resection specimens was 
performed in the pathology laboratories of the participating hospitals according to 
the principles proposed by Quirke11. Overall, a median of 14 blocks per patient were 
examined, while for pCR patients the median was 16 blocks. In 13 patients deeper 
levels were evaluated to facilitate accurate scoring. All H&E-stained slides of the resection 
specimens together with the original pathology reports were revised. The specimen 
was staged according to the 5th TNM staging system12, as is common practice in the 
Netherlands. Tumour deposits (TD) were defined as tumour nests demonstrating 
discontinuous growth from the primary tumour, with mesorectal fat or fibrosis separating 
the TD from the growth front of primary tumour. Furthermore, tumour nests sectioned 
as possible lymph nodes but with no signs of a lymph node or with a recognizable 
capsule but without a bordering layer of lymphocytes were considered a tumour 
deposit. A tumour was considered mucinous when the mucinous proportion was 
≥ 50%, and was not graded to further extent. Due to limited numbers venous invasion, 
lymphangio-invasion and perineural growth were grouped together into one factor, 
“neuro-vascular invasion”. Since no photos were available for review/scoring of the 
completeness of the specimen, this information was not explored. 
Tumour regression was scored using a simple and practical 4 tier system as illustrated 
in supplementary figure 1: a) pCR, pathological complete response without residual 
primary tumour; b) near pCR, only isolated residual tumour cells or small groups of 
residual tumour cells; c) response: stromal fibrosis outgrowing tumour and; d) no 
response: no regression or those with stromal fibrosis outgrown by tumour.
Local recurrence, distant metastases and overall survival
Distant metastases were defined as systemic metastases of rectal cancer to another 
organ, to distant lymph nodes stations or by dissemination to the peritoneal surface. 
Local recurrence was defined as a radiological or histopathological determination of 
rectal cancer recurrence in the pelvis. Follow-up information for local recurrence or 
distant metastasis and overall and disease-free survival was gathered by a comprehensive 
review of all patients files and contacting the patient’s general practitioner. Distant 
metastasis-free interval (DMFI) was defined as the time between surgery and distant 
metastasis or last assessment. Disease-free survival (DFS) was defined as the time 
between surgery and the first event (local recurrence, distant metastasis, second 
primary or death) or last assessment. OS was defined as time between surgery and 
death or last assessment. 
Statistical analysis
Associations between pre- or post-treatment factors and tumour regression was 
assessed using linear by linear or Fisher exact tests, as appropriate. The associations 
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between these factors and DMFI, DFS and OS was performed using Cox proportional 
hazard regression. Survival curves were constructed using the Kaplan-Meier technique. 
In the multivariable regressions, missing data on pre- or post-treatment factors were 
imputed using the largest subgroup. The level of significance was set at 0.05 in all 
analyses. 
Results
Patient demographics 
The study involved 107 patients, 64 male and 43 female with a median age of 64 
years (range 38-82). Baseline characteristics are listed in Table 1. Forty (37%) patients 
underwent a LAR, 15 (14%) patients underwent a Hartmann procedure, while in 52 
(49%) patients an APR was required due to close relation to the sphincter complex. 
Total exenteration was required in 6 patients, while partial exenterative surgery was 
performed in 25 patients.
Response to chemoradiotherapy
Table 2 presents associations between tumour regression and other histopathological 
factors. Downstaging to ypT0-2 occurred in 43 (40%) patients, while lymph node 
metastases were still present in 40 (37%) patients. Tumour deposits were identified 
in 28 (26%) patients (median = 1, range = 1-12), with a median size of 7 mm (range 
0.5-30 mm). 
Twenty-one (20%) patients achieved a pathologic complete response (pCR) of the 
primary tumour and in 12 (11%) patients a near pCR was observed. Seven of the pCR 
patients and 6 of the near pCR patients initially had a cT4 tumour. Response was seen 
in an additional 59 (55%) patients, while in 15 (14%) patients the tumour showed no 
response to CRT. Of note, 6 of 21 (29%) pCR patients had mesorectal lymph nodes 
metastases.
In the univariate analysis no pre-treatment factors (age, cT, cN, and distance from the 
anal verge) were significantly associated with tumour regression, while no association 
was demonstrated between interval (between CRT and surgery) and tumour regression 
(p=0.82). Regression grade was associated with decreasing invasion depth (ypT, 
p<0.001) and the absence of neurovascular invasion (p=0.03). A positive CRM occurred 
more frequently in those showing no regression (p=0.01). Neither TRG nor ypT were 
associated with pathological node status (p=0.47 and p=0.24, respectively). 
Table 1   Baseline patient demographics
Demographics (n=107) n %
Age
Median 64 (38 - 82)
Sex
Male 64 60
Female 43 40
WHO performance status*
0 69 64
1 24 22
2 8 7
Missing 6 6
Distance from anal verge
0-5 cm 62 58
5-10 cm 30 28
>10 cm 15 14
Clinical tumour stage (cT)
0 - -
1 - -
2 1 1
3 64 60
4 42 39
Clinical node stage (cN)
0 31 29
1 46 43
2 29 27
Missing 1 1
Interval CRT and TME**
3-5 weeks 16 15
5-7 weeks 65 61
>7 weeks 26 24
*WHO Performance status: 0 – Asymptomatic, 1 – Symptomatic but completely ambulatory 2 – 
Symptomatic, <50% in bed during the day.
** Median = 44 days (IQR = 39 – 49 days).
96 97
Chapter 4 Tumour regression grading after CRT for locally advanced rectal cancer
4
Ta
b
le
 2
   U
ni
va
ria
bl
e 
as
so
ci
at
io
ns
 b
et
w
ee
n 
hi
st
op
at
ho
lo
gi
ca
l f
ac
to
rs
 a
nd
 th
e 
4-
tie
r t
um
ou
r r
eg
re
ss
io
n 
gr
ad
e 
(T
R
G
)
To
ta
l
n=
10
7
p
C
R
n=
21
ne
ar
 p
C
R
n=
12
R
es
p
on
se
n=
59
N
o 
R
es
p
on
se
n=
15
p
-v
al
ue
n
%
n
%
n
%
n
%
n
%
yp
T 
<
0.
00
1
T0
21
20
21
10
0
-
-
-
- 
-
-
T1
3
3
-
-
2
17
1
 2
-
-
T2
19
18
-
-
5
42
13
22
1
7
T3
59
55
-
-
5
42
42
71
12
80
T4
5
5
-
-
-
- 
3
5
2
13
yp
N
0.
47
N
0
67
63
15
71
6
50
37
63
9
60
0.
26
*
N
1
28
26
5
24
4
33
15
25
4
27
N
2
12
11
1
5 
2
17
7
12
2
13
Tu
m
ou
r 
D
ep
os
its
0.
15
N
o
79
74
17
81
10
83
43
73
9
60
Ye
s
28
26
4#
#
19
2
17
16
27
6
40
C
irc
um
fe
re
nt
ia
l
re
se
ct
io
n 
m
ar
g
in
0.
19
>
 1
m
m
90
85
21
10
0
10
83
50
85
9
64
≤ 
1m
m
16
15
-
- 
2
17
9
15
5
 3
6
M
is
si
ng
1
-
-
-
-
-
-
-
1
-
H
is
to
lo
g
ic
al
 ty
p
e
0.
42
A
de
no
ca
rc
in
om
a
76
88
-
-
9
75
54
92
13
87
M
uc
in
ou
s
10
12
-
-
3
25
5
8
2
13
N
ot
 a
pp
lic
ab
le
 
21
-
21
-
-
-
-
-
-
-
G
ra
d
e 
of
 
D
iff
er
en
tia
tio
n
0.
11
W
el
l/m
od
er
at
e
59
78
-
-
8
89
43
80
8
62
Po
or
/u
nd
iff
17
22
-
-
1
11
11
20
5
39
N
ot
 a
pp
lic
ab
le
**
31
-
21
-
3
-
5
-
2
-
N
eu
ro
-v
as
cu
la
r
In
va
si
on
#
0.
03
N
o
69
80
-
-
11
92
49
83
9
60
Ye
s
17
20
-
- 
1
8
10
17
6
40
N
ot
 a
pp
lic
ab
le
21
-
21
-
-
-
-
-
-
-
A
ce
llu
la
r 
M
uc
in
 
La
ke
s
0.
38
N
o
71
66
15
71
8
67
40
68
8
53
Ye
s
36
34
6
29
4
 3
3
19
32
7
47
* 
p 
va
lu
e 
fo
r p
C
R
 v
er
su
s 
“t
he
 re
st
” 
  *
*a
ll 
m
uc
in
ou
s 
tu
m
ou
rs
 a
nd
 p
C
R
. #
ly
m
p
ha
ng
io
-in
va
si
on
, p
er
in
eu
ra
l g
ro
w
th
, i
nt
ra
- a
nd
 e
xt
ra
m
ur
al
 v
en
ou
s 
in
va
si
on
. #
#
 T
D
 >
 3
 
m
m
98 99
Chapter 4 Tumour regression grading after CRT for locally advanced rectal cancer
4
Ta
b
le
 3
   U
ni
va
ria
bl
e 
as
so
ci
at
io
ns
 b
et
w
ee
n 
tim
e-
to
-e
ve
nt
 o
ut
co
m
es
 a
nd
 h
is
to
pa
th
ol
og
ic
al
 fa
ct
or
s.
 T
he
 s
ec
on
d 
p
-v
al
ue
 d
en
ot
es
 
te
st
s 
ad
ju
st
in
g 
fo
r y
pN
3-
ye
ar
 D
M
FI
3-
ye
ar
 D
FS
3-
ye
ar
 O
S
n
%
95
%
 C
I
p
-v
al
ue
%
95
%
C
I
p
-v
al
ue
%
95
%
 C
I
p
-v
al
ue
TR
G
0.
00
2
0.
00
1
<
0.
00
1
pC
R
21
95
87
-1
00
0.
02
84
69
-1
00
0.
02
95
86
-1
00
0.
00
2
N
ea
r p
C
R
12
65
42
-1
00
50
28
-8
8
67
45
-9
9
R
es
po
ns
e
59
86
 
77
-9
5
76
65
-8
9
91
83
-9
9
N
o 
re
sp
on
se
15
64
44
-9
5
60
40
-9
1
79
61
-1
00
yp
T
0.
00
2
0.
02
0.
16
0-
2
43
93
85
-1
00
0.
00
4
80
68
-9
3
0.
04
90
82
-1
00
0.
23
3-
4
64
75
65
-8
7
68
57
-8
1
85
77
-9
5
yp
N
<
0.
00
1
<
0.
00
1
0.
00
4
N
0
67
91
84
-9
8
83
73
-9
3
95
90
-1
00
N
1
28
73
58
-9
2
60
44
-8
2
75
60
-9
3
N
2
12
58
36
-9
4
44
21
-9
2
75
54
-1
00
Tu
m
ou
r 
d
ep
os
its
<
0.
00
1
0.
00
4
0.
01
N
o
79
90
84
-9
7
0.
17
80
71
-9
0
0.
47
92
86
-9
8
0.
57
Ye
s
28
61
45
-8
2
53
37
-7
5
75
61
-9
3
C
R
M
0.
11
0.
02
0.
04
>
 1
m
m
90
84
76
-9
2
0.
85
76
67
-8
6
0.
35
89
83
-9
6
0.
54
≤ 
1m
m
16
73
54
-1
00
51
30
-8
7
75
57
-1
00
H
is
to
lo
g
ic
al
 ty
p
e
0.
01
0.
03
0.
03
A
de
no
ca
rc
in
om
a
76
83
75
-9
2
0.
26
74
64
-8
5
0.
29
87
80
-9
6
0.
24
M
uc
in
ou
s
10
50
27
-9
3
38
16
-8
7
70
47
-1
00
G
ra
d
e 
of
d
iff
er
en
tia
tio
n
0.
02
0.
03
0.
11
W
el
l/m
od
er
at
e
59
88
80
-9
7
0.
33
79
69
-9
1
0.
33
91
83
-9
9
0.
46
Po
or
/u
nd
iff
er
en
tia
te
d
17
64
43
-9
6
57
37
-8
8
76
58
-1
00
N
eu
ro
-v
as
cu
la
r
in
va
si
on
0.
54
0.
81
0.
54
N
o
69
80
71
-9
0
1
71
60
-8
3
0.
76
87
79
-9
5
0.
84
Ye
s
17
76
59
-1
00
66
44
-9
8
78
59
-1
00
A
ce
llu
la
r
M
uc
in
 la
ke
s
0.
00
7
0.
02
0.
67
N
o
71
88
80
-9
6
0.
1
78
68
-8
9
0.
16
89
82
-9
0.
91
Ye
s
36
72
59
-8
8
62
48
-8
1
83
72
-9
6
100 101
Chapter 4 Tumour regression grading after CRT for locally advanced rectal cancer
4
Association between response and outcome
After a median follow-up period of 3.7 years (95%CI 3.3-4.2), 87 (81%) patients were 
alive (follow-up ranging from 1.6-5.8 years), of whom 75 (70%) were free of cancer, 
5 (5%) developed a local recurrence only, 19 (18%) developed a distant metastasis 
only and 4 developed both (2 synchronously, 1 local recurrence first and 1 distant 
metastasis first). Four patients died due to other causes. The overall 3-year distant 
metastasis-free interval (DMFI) was 82%, the disease free survival (DFS) rate was 
73% and overall survival (OS) rate was 87%. Neither preoperative tumour nor nodal 
stage influenced outcome (DMFI, DFS or OS). Table 3 displays the associations 
between histopathological features and outcomes. Due to small numbers (n=9) of 
local recurrence, no further analysis regarding prognosticators was performed. 
The tumour regression grade (TRG) was a significant prognosticator of the DMFI 
(p=0.002). In addition, ypN (p<0.0001), presence of tumour deposits (p<0.001), ypT 
(p=0.002), acellular mucin lakes (p=0.007), histological type (p=0.01) and grade of 
differentiation (p=0.02) were all significantly associated with DMFI. TRG (p=0.02) 
and ypT (p=0.004) both retained their prognostic value for DMFI after adjusting for 
ypN. Due to the limited number of patients with distant metastases (n=23), no further 
multivariable analysis towards independent prognostic factors for DMFI could be 
performed. 
The TRG was a significant prognosticator of the DFS (p=0.001). Post-treatment pT 
(p=0.02) and ypN (p<0.001), presence of tumour deposits (p=0.004), histological 
type (p=0.03), grade of differentiation (p=0.03), acellular mucin lakes (p=0.03), and 
CRM (p=0.02) were also significantly associated with DFS. After adjusting for ypN, 
TRG (p=0.02) and ypT (p=0.04) retained prognostic value. 
Regarding overall survival, TRG was a powerful prognosticator (p<0.001). Histo-
pathological factors predicting OS included ypN (p=0.004), CRM (p=0.04), TD 
(p=0.01) and histological type (p=0.03), but only TRG retained significance after 
adjusting for ypN. 
When patients with residual disease (near pCR versus response versus no response) 
were analysed separately from the pCR group, TRG retained its prognostic value for 
DMFI (p=0.02), DFS (p=0.005) and OS (p<0.001). After adjusting for ypN, TRG held 
a trend in significance (p=0.06) for DMFI, while for DFS (p=0.02) and OS (p=0.003) 
it retained significance. 
Hazard ratios and confidence intervals for Cox analyses are depicted in supplementary 
tables 1-3.
Excellent outcome in the pCR group
In Figure 1, time to recurrence, second primary or death has been displayed for the 
separate TRG groups, illustrating that the 21 patients with a pCR have an excellent 
outcome, with no local recurrences and only one patient developing distant 
metastases. This patient was one of six patients with a pCR still harbouring lymph 
node metastases. 
Poor prognosis in the near pCR group 
A summary of all near pCR patients is presented in Table 4. Three-year DMFI, DFS 
and OS rates for near pCR patients were 65%, 50% and 67% respectively, which are 
comparable to those with no response (64%, 60%, 79%). Of the 12 patients with a 
near pCR, 7 died, of whom 6 with disease progression. Five near pCR patients 
developed distant metastases. One near pCR patient developed a local recurrence. 
In 6 (50%) of the 12 near pCR patients, nodal metastases were still present (of which 
2 ypN2). In 5 patients isolated tumour cells were found invading the fat (ypT3), while 
in 2 patients the CRM was positive. 
Figure 1  Survival durations and event types for the four different TRG groups
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Discussion
In this series of 107 patients with LARC, we confirm the excellent outcome in those with 
a pathological complete response after CRT and resection. However, the subgroup 
with a near complete response unexpectedly fared poorly. Furthermore, we identified 
prognosticators for the development of distant metastases. 
In our series, 20% of patients achieved a pCR after CRT. One third of these were 
clinical T4 tumours. In the literature different definitions for a pathologic complete 
response have been reported: when reporting a complete response in the context of 
a TRG, strictly speaking, only the primary tumour is included while others define a 
pCR as those with no residual disease at all (ypT0N0). In our study looking at the 
TRG, patients with a pCR (ypT0Nx) have an excellent outcome with no local recurrence 
while one patient developed a distant metastasis. This is in line with the literature2;13 
and raises the question whether more aggressive neoadjuvant strategies should be 
implemented to increase the pCR rate. Some studies have shown an increase in pCR 
rate with a longer interval between radiotherapy and surgery. So far, however, it remains 
unclear whether this translates into an outcome similar to patients with pCR after 
shorter intervals. 
Provided that clinical assessment after CRT is accurate and robust the concept of a 
pCR has introduced opportunities for less radical surgery, such as local excision of 
the tumour and even for omission of surgery all together (the “watch and wait” policy). 
Avoiding surgical morbidity and subsequent decrease in quality of life as a result of 
organ resection are obvious advantages of this approach. However, the “watch and 
wait” policy has only been analysed in a few single centre series5;7, is questioned by 
Table 4   Patients with a pathological near complete response
Pt cTNM Distance 
from  
anal verge
Type of resection ypTNM CRM status TD  
present
Neuro- 
vascular 
invasion
Type Diff Acellular 
mucin 
lakes
Progression Location distant metastasis  
or 2nd primary
Status
1 cT4N0 <5 cm LAR ypT3N0 > 1 mm - No Adenoca Well No LR anastomosis 2nd primary: non-small cell lung  
carcinoma
Dead
2 cT4N2 <5 cm APR ypT3N2 0 mm (node) 1 No Mucinous Yes M+, LR- Inguinal, iliac, retroperitoneal nodes Dead
3 cT4N0 <5 cm APR total exent. ypT3N0 > 1 mm - No Adenoca Well No M+ ,LR- Glandula parotis with mandibular 
destruction
Dead
4 cT4N1 <5 cm APR ypT2N1 > 1 mm - No Adenoca Well No No progression Alive
5 cT3N2 6-10 cm LAR ypT3N1 > 1 mm 1 No Mucinous Yes M+, LR- Peritoneal and lung Dead
6 cT3N0 <5 cm APR ypT2N0 > 1 mm - No Adenoca Well Yes No progression Alive
7 cT4N2 <5 cm APR post exent. ypT3N0 > 1 mm - No Mucinous Yes M+, LR- Bone and Inguinal nodes. 2nd prim: 
facial melanoma
Dead
8 cT3N1 6-10 cm Hartmann ypT2N2 0.5 mm (node) - No Adenoca Well No No progression 2nd primary: colon transversum 
pT3N1
Alive
9 cT4N1 <5 cm APR post exent. ypT2N0 > 1 mm - No Adenoca Well No No progression Alive
10 cT3N2 <5 cm APR ypT1N1 > 1 mm - No Undiffer - No No progression Dead
11 cT3N1 <5 cm APR ypT1N0 > 1 mm - No Adenoca Well No No progression Alive
12 cT3N2 >10 cm LAR ypT2N1 > 1 mm - Yes Adenoca Well No M+, LR- Liver and lung Dead
Pt: patient number, cTNM/pTNM: clinical/pathological Tumour Node Metastases stage according to TNM 5th edition. 
LAR: Low anterior resection. APR: abdominoperineal resection. CRM: Circumferential resection margin. TD: tumour 
deposit. Diff: differentiation of tumour (well versus poorly). M+: distant metastasis. LR: local recurrence. – : absent. 
+ : present.
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the primary tumour with only isolated tumour cells or islands of cells spread throughout 
the bowel wall and mesorectal fat (Table 4). In contrast to others, these near pCR 
patients were associated with an unexpectedly poor outcome (DMFI, DFS and OS), 
which was comparable to those not responding to CRT at all. No single prognosticator 
could be identified, but half of the near pCR patients harboured nodal metastases 
while in 5 patients isolated tumour cells were found in the mesorectal fat (ypT3). 
In recent series poor outcome is also reported in near pCR: Gosens et al17 reported 
an overall survival of 66% after a near complete response which was comparable to 
the poor responders, while Rödel19 described a similar trend of decreased disease- 
and distant metastasis-free survival for their group of good responders (73%) as 
compared to their moderate responders (83%). Another study demonstrated that 
patients with a pCR are different to those with a near pCR with regard to non-negligible 
rates of distant metastases25. The prognosis of those with a near pCR is probably 
multi-factorial and this, once again, underlines the potential risk involved using a 
“watch and wait” policy. 
Few studies focus on distant metastases after CRT, which develop in up to 39%34 of 
LARC patients and have become the event governing outcome. In our series, distant 
metastases developed in 21% of patients indicating the need of a more thorough 
understanding of factors predicting DMFI. Four studies have investigated the correlation 
between TRG and distant metastases. Rödel et al19 and Gavioli et al25 reported a 
significant univariate association between their TRG and distant metastases, while 
Bujko et al35 found no correlation when excluding the pCR group. Vecchio et al18 
reported a series of 144 patients with mainly cT3 tumours receiving neoadjuvant 
therapy (84% CRT) and observed that the four TRG groups, as used in the present 
series, significantly predict those at risk for distant metastases. TRG, together with 
ypT and ypN stage, retained prognostic power in their multivariable analysis. This is 
in line with our observations: when adjusting for ypN, we observed that both ypT and 
TRG were still significantly associated with a decreased DMFI, suggesting independent 
prognostic value of TRG next to nodal status. We also found that TRG is prognostic 
for those with residual disease (near pCR, response and no response) with regards 
to DMFI, DFS and OS, which has only been reported for LR in one other series26, but 
contradicted by others25;36. 
Central histopathological review of the resection specimens assured quality of 
histopathology thereby minimizing inter-observer variability. Apart from shortcomings 
inherent to retrospective analyses, other shortcomings include the absence of a full 
model multivariable analysis due to low number of events and that no correction for 
multiple-testing was performed, thereby categorizing our data as hypothesis generating 
and in need of further validation. 
In conclusion, CRT followed by TME for LARC patients is effective and leads to an 
acceptable outcome. Histopathological assessment of tumour regression after CRT 
others14-16 and therefore requires further validation. Since the clinical imaging modalities 
at hand still lack diagnostic accuracy, omitting surgery in patients with undetected 
(nodal) disease may worsen prognosis. This study confirms these concerns and 
demonstrates potential risks involved in LARC patients treated with CRT in particular. 
In line with Gosens et al17 studying a similar population of LARC patients, but in 
contrast to others18;19 nodal response after CRT was not related to primary tumour 
regression in our series, suggesting independent modes of response to CRT. Even in 
patients with a ypT0, nodal metastases were still present in 6/21 (29%) patients in our 
series of strictly defined locally advanced cases and in 5-19% of patients in the 
literature2;14;16;17;20;21. In a recently published series of ypT0-2 patients after CRT, Park 
et al16 demonstrated that 17% of ypT1 and 21% of ypT2 patients still harboured nodal 
disease after TME. The impact on prognosis of not removing these lymph nodes, as 
is the case with both the “watch and wait” policy and local excision procedures, is as 
yet unknown.
Another major concern is the effect of microscopic tumour deposits in the mesorectal 
fat, since those cannot be assessed by re-staging endoscopy and are difficult to 
discriminate from fibrosis on MRI. A recent publication by Duldulao et al demonstrated 
that 17 of 53 ypT3-4 patients after CRT revealed tumour cells in deeper layers but not 
in the mucosa or submucosa14. In a review15, of 208 patients with a cCR approximately 
30% were actually confirmed to be a pCR after resection, indicating the need of more 
accurate re-staging. Of note, the prognostic importance of these tumour deposits 
after neoadjuvant therapy is unclear22;23 and a topic of on-going discussion. Tumour 
deposits form part of the pathological T or N stage in the TNM 5th edition, depending 
on their size, and have been correlated with poor outcome22. Their presence showed 
to be a firm predictor of distant metastases in our series, possibly indicative of more 
aggressive tumour biology. 
Tumour regression grading has been implemented to predict outcome in many series 
with conflicting results, possibly because no standard pathologic work up for 
response evaluation or definitions of TRG subgroups has been established. Univariate 
associations with LR24-27, DFS19;24;28;29 and OS24;29 have been reported. Vecchio et 
al18 reported a significant multivariate correlation between TRG and LR, DMFI, DFS 
and OS, while Guillem et al30 reported this for OS and recurrence-free survival and 
Bouzourene et al24 for LR. On the other hand, these results have been contradicted 
by others for LR17, DFS31, recurrence-free survival32 and OS17;31;33, indicating the 
need for uniform pathological evaluation and definitions for TRG subgroups.
The relatively poor outcome of the near pCR cases in comparison to those responding 
well in our study seems contradictory to the fact that TRG has prognostic value and 
is not a universal finding. Others have reported excellent outcomes in near pCR 
patients18;28 or in those with >95% regression30 and even reported outcome comparable 
to those with a pCR. In our series, 12 patients exhibited a near complete response of 
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Supplementary table 1   Hazard Ratios and 95% confidence intervals for 
univariable Cox regression
DMFI DFS OS
HR L-CI U-CI HR L-CI U-CI HR L-CI U-CI
TRG
Ref=pCR near pCR 13.8 1.6 118.5 7.3 1.9 27.5 18.4 2.2 152.4
response 4.3 0.6 33.4 2.2 0.6 7.4 2.3 0.3 19.2
no response 14.0 1.7 118 5.7 1.4 22.3 7.6 0.9 65.7
ypT
Ref=T0-1 T2 2.4 0.2 26.4 1.4 0.4 5.3 1.7 0.3 9.9
T3 8.6 1.1 64.6 2.8 1.0 8 2.5 0.6 11.0
T4 12.8 1.2 141.4 4.7 1.1 21.2 5.4 0.8 38.4
yN
Ref=N0 N1 2.4 0.9 6.4 2.1 1 4.6 3.5 1.3 9.6
N2 7.1 2.6 19.4 5.0 2.1 11.9 5.1 1.6 16.2
CRM
Ref= >1 mm ≤ 1mm 2.2 0.8 6.1 2.5 1.1 5.7 2.8 1.0 7.8
Tumour deposits
Ref=no yes 4.0 1.8 9.1 2.6 1.3 5.1 3 1.3 7.3
Histological type
Ref=adenocarcinoma mucineus 3.3 1.2 9.1 2.6 1.1 6.5 3.4 1.1 10.6
Grade of differentiation
Ref=well/moderate poor/undiff 3.1 1.2 8.1 2.4 1.1 5.4 2.3 0.8 6.4
Neuro-vascular invasion
Ref=no yes 1.4 0.5 3.7 1.1 0.5 2.7 1.4 0.5 3.9
Acellular mucin lakes
Ref=yes no 0.3 0.1 0.8 0.5 0.2 0.9 0.8 0.3 2.1
Interval CRT and TME
Ref= 3-5 wks
5-7 weeks 0.9 0.3 2.6 0.6 0.3 1.3 0.4 0.1 0.9
>7 weeks 0.6 0.2 2.4 0.5 0.2 1.3 0.3 0.1 1.2
Ref = reference factor level, HR = Hazard ratio (as compared to reference level), L-CI = lower 95% CI,  
U-CI = upper 95% CI
Supplemental content
Supplementary table 2   Hazard Ratios and 95% confidence intervals for 
univariable Cox regression. Excluding pCR individuals
DRFI DFS OS
HR L-CI U-CI HR L-CI U-CI HR L-CI U-CI
TRG
Ref=near pCR response 0.3 0.1 0.9 0.3 0.1 0.7 0.1 0 0.4
no response 1 0.3 3.4 0.8 0.3 2.2 0.4 0.1 1.4
ypT
Ref=T0-2 T3 3.9 0.9 16.9 1.8 0.7 4.3 1.2 0.4 3.7
T4 5.8 0.8 41.6 3 0.8 12.2 2.6 0.5 14.3
ypN
Ref=N0 N1 1.8 0.7 5.1 1.6 0.7 3.8 2.9 1 8.2
N2 5.8 2.1 16.1 4.4 1.8 10.5 4.2 1.3 13.3
CRM
Ref= > 1 mm ≤ 1mm 1.8 0.6 4.9 2.2 1 5 2.3 0.8 6.6
Tumour deposits
Ref= no yes 3.1 1.4 7.3 2 1 4 2.3 0.9 5.7
Histological type
Ref=adenocarcinoma mucinous 3.3 1.2 9.1 2.6 1.1 6.5 3.4 1.1 10.6
Grade of differentiation
Ref=well/moderate poor/undiff 3.1 1.2 8.1 2.4 1.1 5.4 2.3 0.8 6.4
Neuro-vascular invasion
Ref=no yes 1.4 0.5 3.7 1.1 0.5 2.7 1.4 0.5 3.9
Acelullar mucin lakes
Ref=yes no 0.4 0.2 1 0.6 0.3 1.3 1.1 0.4 2.9
Interval CRT and TME
Ref= 3-5 wks
5-7 weeks 0.6 0.2 1.8 0.4 0.2 1 0.4 0.1 1
>7 weeks 0.5 0.1 1.9 0.4 0.1 1.2 0.3 0.1 1.3
REF = reference factor level, HR = Hazard ratio (as compared to reference level), L-CI = lower 95% CI, 
U-CI = upper 95% CI
112 113
Chapter 4 Tumour regression grading after CRT for locally advanced rectal cancer
4
Supplementary table 3   Hazard Ratios and 95% confidence intervals for Cox 
regressions adjusting for pN
DMFI DFS OS
HR L-CI U-CI HR L-CI U-CI HR L-CI U-CI
ypT
Ref=T0-1 T2 2.0 0.2 21.8 1.2 0.3 4.4 1.3 0.2 7.8
T3 6.4 0.8 49.0 2.1 0.7 6.3 1.9 0.4 8.6
T4 14.3 1.3 159.5 5.2 1.2 23.6 5.5 0.8 39.4
TRG
Ref=pCR near pCR 10.3 1.2 89.5 5.8 1.5 22.3 14.2 1.7 118.8
response 3.6 0.5 28.1 1.9 0.5 6.5 2.0 0.2 16.7
no response 10.5 1.2 89.4 4.4 1.1 17.7 6.0 0.7 53.8
Ref = reference factor level, HR = Hazard ratio (as compared to reference level), L-CI = lower 95% CI,
U-CI = upper 95% CI
Supplementary figure 1A-D  Microscopic illustration of different grades of  
tumour regression
(A) Pathological complete response (pCR): only fibrosis. (B) near-pCR: only isolated tumour cells or 
islands of tumour cells. (C) Response: tumour < fibrosis. (D) No response: tumour > fibrosis
A B 
C D 
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Abstract 
Aim: Preoperative chemoradiation therapy (CRT) may induce downstaging in rectal 
cancer (RC). Short-course radiation therapy (SC-RT) with immediate surgery does 
not cause substantial downstaging. However, the TNM classification adds the “y” prefix 
in both groups to indicate possible treatment effects. We aim to compare stage- 
specific survival in these patients.
Methods: RC patients treated with surgery only, preoperative SC-RT followed by 
surgery within 10 days, or preoperative CRT, and diagnosed between 2008 and 2014, 
were included in this population-based study. Clinicopathological and outcome 
 characteristics were analyzed.
Results: The study included 11925 patients. Large discrepancies existed between 
clinical and pathological stage after surgery only. Surgery only patients were older 
with more comorbidities compared with SC-RT and CRT, and had worse 5-year 
survival (64%, 76%, and 74% respectively; p<0.001). Five-year survival for stage I was 
similar after CRT and SC-RT (85% vs. 85%; p=0.167), and comparable between CRT 
treated patients with stage I and those reaching a pathological complete response 
(pCR; 85% vs. 89%; p=0.113). CRT was independently associated with worse overall 
survival compared with SC-RT for stage II (HR 1.57 [95%CI 1.27-1.95]; p<0.001) and 
stage III (HR 1.43 [95%CI 1.23-1.70]; p<0.001). 
Conclusion: Stage I disease after CRT has an excellent prognosis, comparable with 
pCR and with same-stage SC-RT treated patients without regression. Stage II or III 
after CRT has worse prognosis than after SC-RT with immediate surgery. TNM should 
take the impact of preoperative therapy type on stage-specific survival into account. 
In addition, clinical stage was a poor predictor of pathological stage. 
Introduction
The standard of care for rectal cancer (RC) patients is total mesorectal excision 
(TME) with or without preoperative therapy depending on clinical stage. For patients 
with locally advanced RC, preoperative treatment consists of chemoradiation therapy 
(CRT) intended to reduce local recurrence rates and to facilitate radical surgery by 
inducing tumour regression and possible downstaging.1,2 Significant tumour and 
nodal downstaging is reported in patients treated with CRT and depends on factors 
such as tumour type, clinical stage and interval between radiation therapy and 
surgery.3-7 Downstaging is associated with an improved prognosis, especially in the 
8-24% of patients with a pathological complete response (pCR).1,6,8,9 The TNM staging 
system 10,11 recommends adding the prefix “y” to the TNM stage after pre- operative 
therapy to indicate that a tumour may have undergone treatment induced response 
or regression. 
Especially in Western European countries, patients may also undergo preoperative 
short-course radiation therapy (SC-RT) followed by immediate surgery.12-15 
Randomized trials show a small downstaging effect in these patients 13,14 and 
according to the definitions of the TNM classification, the “y” prefix should be added. 
However, downstaging does not occur after SC-RT if the overall treatment time 
(i.e. interval between start of radiation therapy and rectal resection) does not exceed 
10 days.16 The prognostic significance of ypTNM stage for patients in these groups 
(with vs. without possible downstaging) is still unclear. Due to the differences in levels 
of downstaging between groups of patients treated either with preoperative SC-RT 
followed by immediate surgery or with CRT 17 it may be hypothesized that the 
prognostic implications of the “y” prefix depend on the type of preoperative therapy 
received, which limits the prognostic value of staging.
The purpose of this study is therefore to investigate on a population level whether 
stage-specific overall survival is different between patients treated with either SC-RT 
followed by surgery within 10 days after start of treatment (no tumour regression 
expected; ypTNM by definition, but may reflect pTNM), or preoperative long course 
CRT (intended to induce tumour regression; ypTNM), and to compare results with 
patients who underwent surgery only (pTNM). 
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Patients and Methods
Study design and patient selection
A population-based approach was employed using data from the nationwide 
Netherlands Cancer Registry (NCR). This institute collects data on all newly diagnosed 
cancer patients in the Netherlands since 1989. The registration is primarily based on 
notification by the Dutch national digital pathology registry (PALGA). Patient and 
 clinicopathological data are routinely collected from medical records by specially 
trained data managers. Tumour location and histology is registered according to the 
ICD-O3 classification. Follow-up data and vital status are retrieved by linkage to the 
nationwide population registries network. 
Patients with RC diagnosed between January 2008 and December 2014 who under- 
went a surgical resection were selected from the NCR. Clinicopathological characteristics 
and overall survival (including TNM stage-specific survival) were compared between 
patients treated with surgery only, preoperative SC-RT with an overall treatment time 
that did not exceed 10 days, and preoperative long course CRT. The maximum interval 
of 10 days between start of SC-RT and surgery was chosen, since tumour regression 
is not likely to occur within this timeframe.16 For patients in the CRT group an interval of 
at least 63 days (duration of CRT + 4 weeks to provide the opportunity for tumour 
regression) and no longer than 182 days (6 months; arbitrary) was required.
Cases were excluded if the date of surgery was not available, or if there was presence 
of distant metastases at time of surgery or missing data regarding distant metastases. 
The same was true for cases with histopathological tumour type other than adeno-
carcinoma, mucinous carcinoma, or signet ring cell carcinoma. Other exclusion criteria 
were missing values for pathological T or N categories and surgical procedures other 
than a low anterior resection (LAR), Hartmann’s procedure, abdominoperineal excision 
(APE) or intersphincteric resection. 
Comorbidity was only registered in the NCR for one specific region in the Netherlands, 
covering 12% of the population. A subgroup analysis of this data was performed. 
Preoperative therapy
The prevailing RC clinical guideline 18 during the inclusion period recommended 
preoperative SC-RT for primarily resectable RC (with the exception of cT1N0 tumours) 
consisting of 5x5Gy followed by surgery within one week. Long course CRT consisting 
of 45-50Gy given in 25 fractions of 1.8-2.0Gy per day with concurrent oral chemo - 
therapy (capecitabine 825-1000mg/m2 twice daily) and followed by surgery within 
4-6 weeks was indicated for locally advanced RC (i.e. patients with clinical N2 
disease, cT4 tumours or tumours with suspected involvement of the mesorectal 
fascia on imaging). Patients treated with surgery only either had cT1N0 disease or 
were unfit or not consenting to undergo preoperative treatment.
Statistical analysis
All data was entered in a database and analyzed using IBM SPSS Statistics for 
Windows, Version 22.0. Armonk, NY: IBM Corp. Categorical variables were analyzed 
using the χ2 test. Cumulative overall survival was analyzed using the Kaplan-Meier 
method with log rank test. Multivariable analyses were performed by entering all 
applicable clinical and pathological factors in a Cox regression model. A p-value of 
<0.05 was considered statistically significant whereas a p-value of <0.1 was taken to 
reflect a trend towards significance. 
Results
Patient selection
The initial search of the NCR database identified 19737 patients. Figure 1 depicts the 
selection process, resulting in the inclusion of a total of 11925 patients (2590 with 
surgery only, 4534 with SC-RT, and 4801 with CRT).
Clinicopathological factors
Table 1 provides the clinical and pathological characteristics. Median interval between 
start of SC-RT and surgery was 8 days (range 0-10) and in the CRT group the median 
interval was 100 days (range 63-182). Patients in the surgery only group were older 
than those in the SC-RT group, who in turn were older than the CRT treated patients 
(age >75 years: 40%, 28% and 13% in the surgery only, SC-RT and CRT groups 
respectively; p<0.001). Other factors that were significantly associated with type of 
preoperative treatment were cT category, cN category, cTNM stage, type of resection, 
pT category, pN category, pTNM stage, CRM involvement, histological type, and 
presence of postoperative chemotherapy. Patients in the CRT group showed ypT0 in 
20% of cases and had a reduced rate of (y)pT2 and (y)pT3 tumours compared to the 
surgery only and SC-RT groups (p<0.001). A pCR (ypT0N0) occurred in 18% of cases 
after CRT.
A subgroup analysis of cases with available comorbidity data (n=1270) showed a 
higher rate of comorbidities in the surgery only group compared with both the SC-RT 
and CRT groups with ≥2 comorbidities in 45%, 35%, and 25% of cases for surgery 
only, SC-RT, and CRT respectively (p<0.001 for surgery only vs. CRT; p=0.006 for 
surgery only vs. SC-RT; p=0.003 for SC-RT vs. CRT). 
Correlation between cTNM and (y)pTNM
The data showed substantial discrepancies between clinical and pathological TNM 
stage (table 2). Patients with suspected LN on clinical imaging had histopathology 
showing nodal disease in 57%, 49% and 35% of cases that were treated with surgery 
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only, SC-RT, and CRT respectively (p<0.001). Patients with clinical stage I disease 
had histopathological nodal involvement in 19%, 24%, 13% after surgery only, SC-RT, 
and CRT respectively (p=0.004). For patients with clinical stage II this was 26%, 30%, 
and 15% respectively (p<0.001). In the CRT group there was complete tumour 
regression in 30%, 19%, and 17% of cases for patients with clinical stage I, II, and III 
disease, respectively (p<0.001).
Survival analysis
Median follow up was 28 months (range 0-84 months) and 1949 deaths were 
recorded (16.3%). Cumulative 5-year overall survival was 73% (table 3). The surgery 
only group showed worse overall survival than the SC-RT and CRT groups (64%, 
76%, and 74% for surgery only, SC-RT, and CRT respectively; p<0.001). However, 
there was no significant difference between patients treated with SC-RT vs. CRT 
(p=0.147). 
Figure 2a-c shows stage-specific overall survival for patients with surgery only, 
SC-RT and CRT. Survival was worst in the surgery only group (cumulative 5-year 
survival: 77%, 63%, and 52% for pathological stages I, II and III respectively; p≤0.003 
compared with SC-RT and CRT). SC-RT treated patients with pathological stage I 
disease had similar overall survival as same-stage patients in the CRT group 
(cumulative 5-year survival 85% vs. 85% respectively; p=0.167). After CRT overall 
survival was comparable in patients with pathological stage I and those who reached 
a pCR (cumulative 5-year survival 85% vs. 89% respectively; p=0.113). The SC-RT 
group showed better survival than the CRT group for patients with pathological stage 
II (cumulative 5-year survival 77% vs. 68% for SC-RT vs. CRT respectively; p=0.002) 
and stage III (cumulative 5-year survival 67% vs. 58% for SC-RT vs. CRT respectively; 
p<0.001).
The multivariable analysis (table 4) showed that CRT was independently associated 
with a higher mortality compared with SC-RT in patients with pathological stage II 
(HR 1.57 [95%CI 1.27-1.95]; p<0.001) and stage III (HR 1.43 [95%CI 1.23-1.70]; 
p<0.001), but not in those with stage I (HR 0.99 [95%CI 0.77-1.27]; p=0.146). The 
hazard ratio for patients with surgery only was also increased compared with SC-RT 
for patients with pathological stage II (HR 1.67 [95%CI 1.35-2.08]; p<0.001) and 
stage III (HR 1.60 [95%CI 1.36-1.87]; p<0.001), but not stage I (HR 1.25 [95%CI 
0.99-1.59]; p=0.137). 
Figure 1  Flow diagram showing the selection process
SC-RT: short-course radiation therapy; CRT: chemoradiation therapy; NOS: not otherwise specified; pT: 
pathological tumour category; pN: pathological nodal category 
Initial database search
n=19737 
n=19718 
 
n=17787 
 
n=13466 
 
n=13434 
 
n=12405 
 
SC-RT: 
N= 4534 
Study population:
n=11925 
 Excluded:
- Date of surgery unknown: n=19 
- pT and/or pN category missing: n=1027 
- Local excision: n=225 
- Hemicolectomy NOS: n=22 
- Partial resection NOS: n=5 
- Sigmoid resection: n=15 
- Subtotal colectomy: n=37 
- Total (procto)colectomy: n=74 
- Multisegment resection: n=9 
- Total resection NOS: n=3 
- Multiorgan surgery: n=90 
Surgery only
N= 2590 
CRT: 
N= 4801 
 Excluded:
- Distant metastases present: n=1552 
- Distant metastases unknown: n=379 
- Neoplasm NOS: n=1 
- Carcinoma NOS: n=4 
- Neuro-endocrine tumor: n= 14 
- Metaplastic carcinoma: n=5 
- Squamous cell carcinoma: n=4 
- Medullary carcinoma: n=1  
- Carcinosarcoma NOS: n=1 
- Papillary thyroid carcinoma: n=2 
- Chemotherapy only: n=25  
- Long course radiotherapy: n=185 
- SC-RT + chemotherapy: n=21 
- SC-RT with interval >10 days: n=1348 
- Radiotherapy NOS: n=1833 
- Radiotherapy NOS + chemo: n=830 
- CRT with interval <63 or >182 days: 79 
Excluded:
Excluded:
Excluded:
Excluded:
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Table 2   Correlation between clinical and pathological stage
N= 9323 a Clinical stage
Stage I Stage II Stage III
n % n % n %
Surgery only Pathological stage
   Stage 0
   Stage I
   Stage II
   Stage III
2
481
154
152
0.3
61.0
19.5
19.3
1
146
237
135
0.2
28.1
45.7
26.0
0
81
108
247
0.0
18.6
24.8
56.7
Total 789 100.0 519 100.0 436 100.0
SC-RT Pathological stage
   Stage 0
   Stage I
   Stage II
   Stage III
15
535
199
240
1.5
54.1
20.1
24.3
1
286
368
275
0.1
30.8
39.6
29.6
4
359
320
658
0.3
26.8
23.9
49.1
Total 989 100.0 930 100.0 1341 100.0
CRT Pathological stage
   Stage 0
   Stage I
   Stage II
   Stage III
30
40
18
13
29.7
39.6
17.8
12.9
129
205
235
99
19.3
30.7
35.2
14.8
601
898
821
1230
16.9
25.3
23.1
34.6
Total 101 100.0 668 100.0 3550 100.0
SC-RT: short-course radiation therapy; CRT: chemoradiation therapy. a cases with missing values for  
clinical TNM stage were excluded (n=2602).
Table 3   Cumulative 5-year overall survival of included patients
Cumulative 5-year 
overall survival (%)
p-value a
Overall 73.1
Preoperative therapy 
   None (surgery only)   
   SC-RT
   CRT
64.1
76.3
73.5
<0.001
0.147 †
Gender 
   Male 
   Female 
71.3
76.0
<0.001
Age at diagnosis
   0-44
   45-59
   60-74
   75+ 
85.2
82.0
76.9
56.1
<0.001
Clinical T category
   cT1
   cT2
   cT3
   cT4
   Missing
75.0
78.7
73.1
61.0
71.2
<0.001
Clinical N category
   cN0
   cN1
   cN2
   Missing
74.2
71.9
73.6
70.6
0.007
Clinical TNM stage
   Stage I
   Stage II
   Stage III
   Missing
78.9
72.0
72.4
71.5
<0.001
Type of resection
   Sphincter saving
   Non-sphincter saving
74.0
71.1
0.004
Pathological T category
   pT0
   pT1
   pT2
   pT3
   pT4
87.2
82.0
81.0
65.2
45.9
<0.001
Pathological N category
   pN0
   pN1
   pN2
79.2
67.2
47.6
<0.001
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Table 3   Continued
Cumulative 5-year 
overall survival (%)
p-value a
Pathological stage
   Stage 0
   Stage I
   Stage II
   Stage III
89.2
83.3
71.5
60.9
<0.001
Histological type
    Adenocarcinoma 
    Mucinous carcinoma 
    Signet ring cell carcinoma 
73.9
66.2
21.9
<0.001
CRM involvement
   Absent
   Present
   Missing 
75.0
53.5
73.1
<0.001
Postoperative CTx
   No 
   Yes
72.7
77.4
0.007
SC-RT: short-course radiation therapy; CRT: chemoradiation therapy; CRM: circumferential resection 
margin; CTx: chemotherapy. a log rank test. † SC-RT vs. CRT.
Figure 2A-C  Overall survival for patients treated with surgery only, SC-RT or CRT
(A) pathological stage I. (B) pathological stage II. (C) pathological stage III. SC-RT: short-course radiation 
therapy; CRT: chemoradiation therapy 
Number at risk
Surgery only         1057             569              413               300               215              174                62 
SC-RT         1704           1464            1199               920               625              349              145 
CRT         1306           1019              758               504               313              168                58 
P=0.163 
P=0.003 
P=0.001 
Number at risk 
Surgery only         814               509               355              255               159                95                52
SC-RT        1575             1298            1035              745               513              306              144
CRT        1435             1051              729              451               228              116                36
Number at risk 
Surgery only         712              431               320               211              140                93                50
SC-RT       1227            1034               848              620               434              247              111
CRT       1191              873               646              432               240              113                36
A
 
B
 
C
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showed that comorbidity levels were higher in the SC-RT than in the CRT group. As a 
consequence the SC-RT group as a whole may be expected to show a bias towards 
a worse prognosis compared with the CRT group. However, the multivariable analysis 
showed the direct opposite with a better prognosis in the SC-RT group for patients 
with stage II and III disease. The observed survival differences may therefore be 
expected to be even larger if the results could be adjusted for comorbidity. 
The introduction of preoperative CRT for RC which has resulted in tumour downstaging 
in substantial proportion of patients has not resulted in improved survival.20 The 
stage-specific outcome differences between the groups in this study are therefore 
not based on a therapeutic effect of the preoperative treatment, but are probably best 
explained by pathological stage migration. Patients with nodal disease may undergo 
sterilization of involved LN after CRT resulting in classification as pathological stage I 
or II disease instead of stage III. These patients may contribute to an increased 
observed mortality in the stage I or II groups, as they may be expected to have a 
higher risk of harbouring concurrent occult residual disease or distant metastases 
than patients who had no LN involvement at presentation. In addition, survival may 
decrease in pathological stage III as well, since remaining stage III patients have 
tumours that are resistant to preoperative therapy. This effect, called “the reverse of 
the Will Rogers phenomenon”, has been described before with data from the German 
CAO/ARO/AIO-94 trial, showing that patients with pathological stage II disease after 
preoperative CRT had worse overall survival than same-stage patients from the 
control arm treated with selective postoperative CRT.21 
A limitation to the current study is that it is not possible to determine the exact rate of 
stage migration in CRT treated patients, since clinical staging (especially cN category) 
is notoriously unreliable.22-25 Indeed, data from this study showed large discrepancies 
between clinical and pathological stage in the surgery only group (no downstaging 
by definition) with pathologically confirmed LN metastases in only 57% of patients 
with clinical stage III disease. The differences between clinical and pathological 
stage in the surgery only and SC-RT groups and at least a part of the variation 
observed in the CRT group are therefore probably related to the imprecision of clinical 
staging and not to actual stage migration. Another important restriction is the lack of 
an adequate pTNM control group, due to the high level of selection bias in patients 
treated with surgery only.
In conclusion, this population-based study provides evidence that pathological stage I 
after preoperative CRT for RC is associated with an excellent prognosis, which is 
comparable with reaching a pCR and similar to same-stage SC-RT treated patients 
without tumour regression. In patients with pathological stage II and III disease after 
CRT the prognosis is worse than after SC-RT with immediate surgery. These results 
contain important prognostic information for individual patients and physicians, and 
may have consequences for predictive models. Staging systems, such as TNM, 
Discussion
In this population-based study, using data from the Netherlands Cancer Registry, 
long-term stage-specific survival data was analyzed from 11925 RC patients who 
underwent TME surgery with or without preoperative treatment consisting of either 
SC-RT or CRT. Patients with pathological stage I had an excellent 5-year overall 
survival after both SC-RT (85%) and CRT (85%). For patients with pathological stages 
II and III, survival was significantly worse after CRT (68% and 58%) compared with 
SC-RT (77% and 67%). In addition, clinical staging was a poor predictor of pathological 
stage based on the large discrepancies between clinical and pathological stage in 
the surgery only group.
In the study period, the national clinical guideline 18 recommended preoperative 
SC-RT for primarily resectable RC (with the exception of cT1N0 tumours), and long 
course CRT for locally advanced RC. Patients treated with surgery only in this period 
either had cT1N0 disease or were unfit or did not give consent to undergo the 
indicated preoperative therapy. Indeed, patients in the surgery only group were found 
to be substantially older and had more comorbidity compared with both the SC-RT 
and CRT groups. These patients were therefore considered to be unsuitable as a 
control population in the current study. 
On the other hand, the comparison of the SC-RT and CRT treated patients in this 
study yields some interesting results. Although some small downstaging effect on 
T-stage as well as nodal downstaging have been reported in randomized trials after 
SC-RT with immediate surgery,13,14 the SC-RT treated patients in the current study all 
had an overall treatment time not exceeding 10 days, and evidence from a large 
randomized controlled trial showed that both tumour and nodal downstaging do not 
occur in this short time-frame.16 Furthermore, stage-specific 10-year overall survival 
was shown to be similar in randomized patients with preoperative SC-RT and those 
with surgery only or surgery with selective postoperative CRT.12-14 This lack of 
downstaging and absence of a survival difference suggest that the SC-RT treated 
patients in the current study may be regarded best as pTNM rather than ypTNM.19 
The observed difference in stage-specific survival between patients treated with CRT 
(substantial downstaging) and SC-RT (no downstaging) was substantial and highly 
significant, and the effect was independent of several known possible confounders. 
However, selection bias may be a concern when interpreting these results. The 
inherently higher levels of treatment induced toxicity caused by CRT may motivate 
clinicians to withhold this treatment in elderly patients with comorbidity, whereas the 
same comorbidity level would not preclude a treatment with much less toxic SC-RT. 
Unfortunately, comorbidity data was not available in the majority of patients and the 
results of the multivariable analysis could therefore not be corrected for this 
confounder. However, the subset analysis of patients with available comorbidity data 
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Abstract
Purpose: Preoperative therapy reduces local recurrences and may facilitate surgery 
in rectal cancer patients. However, in patients with inflammatory bowel disease (IBD) 
this treatment is often withheld due to the perceived risk of excessive side-effects, 
even though evidence is limited. The purpose of this study is to investigate the effects 
of preoperative therapy on acute toxicity and post-operative complications in IBD 
patients with rectal cancer.
Methods: The Dutch pathology registry (PALGA) was searched for patients with IBD 
and rectal cancer treated between January 1991 and May 2010. Histopathology and 
clinical charts were reviewed to confirm IBD diagnosis and evaluate clinical and 
pathological characteristics. 
Results: Out of 161 patients, 66 received preoperative therapy (41%), including 
short-course radiation therapy (SC-RT), long course radiation therapy (LC-RT), and 
chemoradiation therapy (CRT) in 32, 13, and 21 patients respectively. Grade≥3 acute 
toxicity occurred in 0 patients (0.0%), 1 patient (7.7%), and 6 patients (28.6%) 
respectively (p=0.004). Systemic corticosteroids were used by 10.5% of patients at 
time of treatment. Grade≥3 post-operative 30-day complication rate (28.1% overall) 
was not associated with type of preoperative therapy. 
Conclusion: Results did not show excessive rates of toxicity or post-operative 
complications and support the use of standard preoperative therapies for rectal 
cancer (especially SC-RT) in IBD patients with relatively indolent disease. Caution is 
warranted in patients with active IBD, since the exact impact of active bowel 
inflammation could not be determined retrospectively. Prospective studies should 
investigate the influence of active IBD on acute and late toxicity in patients receiving 
pelvic irradiation.
Introduction
Inflammatory bowel disease (IBD), including ulcerative colitis (UC), Crohn’s disease 
(CD) and indeterminate colitis (IC), is a chronic, idiopathic and immunologically 
mediated inflammatory disorder of the gastrointestinal (GI) tract characterized by 
episodes of exacerbations and remissions.1 Patients with IBD have an elevated risk 
of developing colorectal cancer through the inflammation-dysplasia-carcinoma 
pathway. The risk increases markedly with disease duration and extent, although 
modern management has been effective in decreasing the colorectal cancer 
incidence to levels not much higher than in the general population.2-8 However, 
colorectal cancer remains a significant problem in IBD patients, with worse stage- 
specific survival rates compared with colorectal cancer in patients without IBD.9 
For IBD patients who develop cancer in the rectum, optimal treatment strategies 
remain unclear. Standard preoperative therapy regimes, such as chemoradiation 
therapy (CRT) for locally advanced rectal cancer or short course radiation therapy 
(SC-RT), sometimes used for non-advanced tumours or in frail patients, are often 
withheld in patients with IBD, due to the perceived risk of excessive levels of side- 
effects.10-12 A review on radiotherapy for cancer in IBD patients concluded that 
external beam radiotherapy (EBRT) produced a moderate increase in acute and late 
toxicity in IBD compared with non-IBD patients, whereas toxicity levels after brachy -
therapy for prostate cancer were similar.13 However, this review included tumours in 
various locations treated with either pelvic or abdominal irradiation. Previous studies 
specifically investigating the effects of radiation therapy in IBD related rectal cancer 
showed conflicting results, and are restricted by limited patient numbers treated over 
an extended period of time in which imaging and radiation techniques, as well as 
(peri-)operative management have evolved substantially.14,15 
The current study therefore aims to investigate the risk of both acute RT induced 
toxicity and 30-day post-operative complications in IBD patients with rectal cancer 
undergoing preoperative (chemo)radiation therapy. Results may guide and optimize 
current rectal cancer treatment strategies for patients with IBD.
Methods
Patient selection
We searched PALGA, the nationwide network and registry of histopathology and 
cytopathology in the Netherlands, to identify patients with a history of IBD who were 
diagnosed with rectal cancer between January 1991 and May 2010. PALGA collects 
histopathological and cytopathological diagnoses generated in the Netherlands 
since 1971 and has complete national coverage since 1991.16 Approval of the PALGA 
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Privacy Commission and Scientific Council as well as the Radboudumc institutional 
ethics committee was obtained (registration number 2012/030). A search was 
performed using the search terms: “rectal cancer” and/or “rectosigmoid cancer” 
combined with “ulcerative colitis”, “Crohn’s disease”, and/or “indeterminate colitis” as 
well as several related terms including “ileitis”, “ulceration”, “ulcer”, “inflammation”. 
The search yielded records of all patients with a history of rectal/rectosigmoid cancer 
combined with at least one pathology report of IBD or non-specific bowel inflammation. 
Records were manually scrutinized by two investigators (SB and IN) to select patients 
who were suspected to have a genuine IBD diagnosis. Of the selected patients, his-
topathological slides of diagnostic IBD biopsies and rectal resection specimens 
containing the primary tumour (or tumour biopsy if a resection was unavailable) were 
obtained and reviewed to confirm both the IBD and rectal cancer diagnoses and 
document tumour characteristics. In addition, medical charts were searched to extract 
clinical data. 
Inclusion and exclusion criteria
Only patients with available clinical data after medical chart review were included in 
the analysis. Patients were excluded if the IBD diagnosis could not be confirmed after 
review of pathology data and clinical charts, or when IBD was diagnosed after 
treatment for rectal cancer. Likewise, patients who did not have a rectal tumour (distal 
edge >15 cm from the anal verge) were excluded. In addition, cases were excluded 
in case of an administrative mismatch, incorrectly linking records from a patient with 
IBD to another patient with rectal cancer who had a similar last name and birth date. 
Clinicopathological characteristics
All clinical and treatment characteristics were retrieved retrospectively from the medical 
charts. Pathological characteristics were determined retrospectively by centrally reviewing 
the original histopathological slides and pathology reports. Extracted clinical data 
included sex, date of birth, presence of comorbidities, type of IBD, date of IBD diagnosis, 
disease duration, date of rectal cancer diagnosis, presence of distant metastases, 
type of preoperative treatment (if any), use of corticosteroids at time of treatment, 
therapy-induced acute toxicity/adverse events, type of surgery, and 30-day post- 
operative complications. 
IBD diagnosis was specified as UC, CD or IC based on clinical, histopathological and 
endoscopic characteristics. Preoperative radiation therapy consisted of EBRT using 
a three-dimensional conformal technique or intensity-modulated radiotherapy (IMRT). 
From 2001 onwards the prevailing guidelines recommended that the clinical target 
volume should include the primary tumour and the mesorectum with vascular 
supply, containing the perirectal, presacral and internal iliac nodes. The recommended 
upper border was at the level of the promontory. The perineum was included if an 
abdominoperineal excision (APE) was planned, whereas the lower border was 3 cm 
above the anal verge if the planned operation was a low anterior resection (LAR.17 
SC-RT was defined as 5 x 5 Gy given over a 5-7 day period.18 LC-RT treated patients 
received preoperative radiation with 45-50 Gy given in 25-28 fractions of 1.8-2.0 Gy. 
In the CRT group concurrent fluoropyrimidine based chemotherapy was added to 
the long-course radiation schedule.11,19,20 
Acute toxicity (occurring during preoperative therapy) was graded according to the 
National Cancer Institute Common Terminology Criteria (version 4.0).21 In patients 
who underwent radical surgery, 30-day post-operative complications were graded 
using the modified Clavien-Dindo classification.22 Comorbidities were scored 
according to the Charlson comorbidity index (CCI).23 Tumour related histopathological 
characteristics were scored in patients who underwent a resection of the rectum. 
This included TNM-stage,24 circumferential margin (CRM) involvement (tumour cells 
at a distance of ≤ 1mm from the CRM), and histopathological type/ differentiation 
grade.25 
Statistical analysis
All data were entered in a database and analyzed using IBM SPSS Statistics for 
Windows, Version 20.0. Armonk, NY: IBM Corp. Categorical variables were analyzed 
using the χ2 test. For non-parametrical continuous variables the Mann-Whitney U test 
or independent samples Kruskal-Wallis test was used were appropriate. A p-value of 
<0.05 was considered statistically significant whereas a p-value of <0.1 was interpreted 
as a trend towards significance. 
Results
Patient selection
The initial PALGA search yielded 2035 potential cases with rectal or rectosigmoid 
cancer and possible IBD (figure 1). The manual search identified 364 patients, treated 
in 75 hospitals, who were considered likely to be genuine IBD patients with rectal 
cancer. For reasons of feasibility clinical chart review was limited to 196 patients who 
underwent surgery in 41 centres, including all centres with at least 4 eligible patients. 
For the remaining 168 patients either the medical charts were not available in the 
visited treatment centre or the patients were treated in one of the centres with no more 
than 3 eligible patients. Thirty-five cases were excluded after review of clinical and 
histopathological data resulting in 161 IBD patients with rectal cancer who were 
included in the analysis. Reasons for exclusion were: no rectal cancer (tumour >15cm 
from the anal verge; n=17 and tumour in a perineal fistula after proctectomy; n=1), 
unconfirmed IBD diagnosis (n=6), both absence of rectal cancer and unconfirmed 
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IBD diagnosis (n=2), IBD diagnosis following rectal cancer treatment (n=3), and 
administrative mismatch (n=6). 
Clinicopathological characteristics 
Table 1 provides clinical and pathological characteristics per treatment group. Out of 
161 IBD patients, 83 patients had UC, 69 had CD, and 9 had IC. A total of 34 IBD 
patients (21.1%) were diagnosed with rectal cancer within 8 years disease duration 
(the recommended start of endoscopic surveillance). Sixty-six patients received 
preoperative therapy (41.0%), including SC-RT in 32, LC-RT in 13, and CRT in 21 
patients. These 66 patients underwent surgery in 29 different hospitals, but preoperative 
therapy was given in a total of 10 different regional radiation oncology centres. Patients 
with SC-RT were treated between 1996 and 2010, patients with LC-RT were treated 
between 1991 and 2006, and patients with CRT were treated between 2002 and 2009. 
At time of rectal cancer diagnosis the patients in the LC-RT and CRT groups were 
younger than patients in the SC-RT and no preoperative therapy groups (no preoperative 
therapy: median age 59, range 28-91; SC-RT: median age 61 years, range 32-88; 
LC-RT: median age 48 years, range 35-84; CRT: median age 51 years, range 34-72; 
p<0.006). The rate of metastatic disease at baseline was higher in the CRT group 
(28.6%) compared with the LC-RT (6.3%) and SC-RT (6.6%) group (p=0.048). Systemic 
corticosteroids were used by 10.5% of patients at time of treatment. 
There were 145 patients who underwent a radical rectal resection. Two patients under- 
went local excision, 1 patient refused surgery, and 13 patients were considered to be 
palliative because of patient condition, a non-resectable tumour and/or metastatic 
disease. 
Acute preoperative therapy-induced toxicity 
Severe acute toxicity (grade≥3) occurred in 0.0% (0/32), 7.7% (1/13), and 28.6% (6/21) 
of patients in the SC-RT, LC-RT, and CRT group respectively (p=0.004). One patient 
with LC-RT showed perianal abscess formation grade 3. In the CRT group 1 patient 
developed severe oral mucositis resulting in systemic inflammatory response syndrome 
(SIRS) and respiratory insufficiency requiring admission to the intensive care unit 
(grade 4). One patient was diagnosed with radiation cystitis causing severe hematuria 
which required blood transfusion (grade 4). Four patients developed grade 3 lower GI 
toxicity requiring hospital admission including diarrhea (n=3) and anorectal infection 
(n=1). One patient with diarrhea also developed grade 3 skin toxicity. In the CRT 
group (n=21) there was no significant difference in the development of severe acute 
toxicity for patients with vs. without use of corticosteroids at time of treatment (grade≥3 
toxicity rate: 50% (1/2) vs. 27.8% (5/18) respectively; 1 missing value; p=0.515). There 
was no significant association between type of IBD and grade≥3 acute toxicity.
Clavien-Dindo graded 30-day post-operative complications
The overall complication rate in patients with rectal resection (n=145) was 46.8% and 
was comparable after SC-RT, LC-RT, CRT and surgery only (table 2). Grade≥3 
adverse events occurred in 28.1% and surgical reinterventions in 18.0% of patients, 
and were comparable in each treatment group. There were no significant differences 
in rates of multiple complications, specific types of complications, or mortality. 
Charlson comorbidity index was associated with development of severe adverse 
events with grade≥3 complication rates of 20.2%, 36.4%, and 48.0% for CCI 0, CCI 1, 
and CCI ≥2 respectively (p=0.015). 
Figure 1  Patient selection flowchart
*clinical chart review included all hospitals with at least 4 eligible cases. RC: rectal cancer, IBD: 
inflammatory bowel disease, SC-RT:  short course radiation therapy, LC-RT: long course radiation therapy, 
CRT: chemoradiation therapy 
Possibly relevant cases yielded by initial
Palga search: 2035  
Eligible cases selected after manual
review of pathology records: 364 
Clinical data collected: 196*
Excluded: 
No RC: 18
IBD not confirmed: 6
Both of the above: 2
Administrative missmatch: 6
IBD diagnosis after RC: 3    
 
Included: 161
 
No pre-
operative
therapy: 95 
SCRT: 32 LC-RT: 13 CRT: 21
144 145
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Discussion
The current study evaluated the effects of standard preoperative therapies on acute 
toxicity and 30-day post-operative complications in 161 patients with IBD related rectal 
cancer identified by a nationwide search of the Dutch pathology registry (PALGA). 
Type of preoperative therapy showed a strong association with the development of 
acute toxicity, with severe (grade ≥3) toxicity occurring almost exclusively in patients 
treated with CRT. There was no difference in post-operative complication rate for 
patients treated with preoperative therapy or surgery only. 
The mechanisms of radiation toxicity are multifactorial and highly complex and 
include direct damage to DNA which may result in cell cycle arrest with repair or 
apoptosis through activation of P53, or necrosis. Crypt epithelial cell death ensues 
and results in insufficient replacement of the bowel epithelium leading to breakdown 
of the mucosal barrier with inflammation. Further tissue damage may be caused 
by many factors including radical oxygen species produces by attracted leuko- 
cytes.26-28 In patients with IBD, on the other hand, it is widely accepted that the bowel 
inflammation is caused by a defective mucosal immune system which reacts in-
appropriately to commensal bacteria and other luminal antigens.29 It is therefore 
conceivable that the inflammation which follows radiation induced mucosal damage 
may be aggravated in IBD patients by an inappropriate activation of the immune 
system in response to the exposure to luminal contents.  
However, our data showed that SC-RT with 5x5 Gy was well tolerated with no grade≥3 
acute toxicity, which is in line with the literature on sporadic rectal cancer reporting 
severe side effects to be exceedingly rare after SC-RT.17,20,30,31 The rate of grade≥3 
acute toxicity was 28.6% in IBD patients after CRT, which is at the high end of the 
range reported for sporadic rectal cancer in several prospective series (8-29%) .31-37 
The most frequently observed severe side effect was diarrhea, whereas the life 
threatening events (grade 4 oral mucositis resulting in SIRS in a UC patient requiring 
admission to the intensive care unit and a grade 4 radiation cystitis necessitating 
blood transfusion due to hematuria), were not related to the bowel. 
The exact role of active IBD in radiation induced toxicity remains uncertain, since IBD 
activity was not consistently documented in the retrospectively searched medical 
charts. Instead, corticosteroid use at time of preoperative treatment was considered 
to be an indication of possibly active IBD, even though this may also include patients 
with steroid dependent disease and some patients who are in the process of reducing 
steroid use after treatment for an exacerbation. Corticosteroid use was present in a 
small portion of patients suggesting that most of the cohort had relatively indolent 
IBD at the time of preoperative therapy. There was no significant association between 
corticosteroid use and grade≥3 acute toxicity in patients treated with preoperative 
CRT (which included almost all cases of grade≥3 toxicity), although the analysis was T
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limited by a low number of patients. This result is in accordance with previous studies 
by Song et al and Willett et al who showed no significant difference in radiation 
induced toxicity in IBD patients with active vs. non-active disease.38,39
After SC-RT overall post-operative complication rates in the literature show substantial 
variation (20.1-54%) with surgical reinterventions in 10-19% of patients.17,20,30,31,40-46 
By comparison, the overall complication rate in the current IBD cohort was at the 
high end of this spectrum (54.8%) with surgical reinterventions in 22.6% for patients. 
The CRT treated IBD patients in this study showed an overall complication rate of 
55.6%, with 22.2% grade≥3 complications and 16.7% surgical reintervention. These 
figures are also in the high range of complication rates reported in the literature, since 
three trials that evaluated sporadic CRT treated rectal cancer patients and employed 
the Clavien-Dindo classification found overall complication rates of 44-54.3%, with 
11-26.1% grade≥3 complications and 2-21.7% surgical reintervention.32,35,47  
In addition, patients treated with surgery only in the current study also showed 
relatively high complication rates, which were comparable with those found in the 
SC-RT and CRT groups. This may be explained by the high number of previous 
abdominal surgery and/or corticosteroid use at the time of operation, which have 
been associated with increased risk of post-operative complications.48,49 
The current nationwide study included patients who underwent surgery in 41 hospitals, 
and for preoperative therapy patients were referred to a total of 10 regional radiation 
oncology centres. The data therefore provides an adequate reflection of daily clinical 
practice regarding treatment of IBD patients with rectal cancer, although the data is 
inevitably influenced by heterogeneity in surgical and radiation therapy procedures. 
The failure to include patients from low volume hospitals may have resulted in an 
underestimation of surgical complication rates for the current study population. 
However, this equally impacts the groups with and without preoperative therapy, and 
conclusions regarding surgical complication rates therefore remain valid. The influence 
of the selection process on acute toxicity was probably limited, since patients in this 
study were treated in a total of 10 radiation oncology centres and there are no more 
than 21 radiation oncology centres in the country, which generally work according to 
the same guidelines. Unfortunately, complete dosimetry data was not available retro-
spectively and therefore it was not possible to reliably analyze the volume of irradiated 
tissue, which may be expected to show variations between patients treated in different 
centres over a long period of time. However, from 2001 onwards guidelines recommended 
to determine the clinical target volume as described in the methods section. The 
introduction of IMRT as an alternative to 3D conformal radiation can be expected to 
have resulted in a substantial decrease of the dose received by the normal tissues of 
patients treated in more recent years in this study.50 Other limitations of this study 
include the relatively small sample sizes in the various preoperative treatment 
categories. In addition, due to the retrospective nature of the study and logistical 
issues related to the large number of centres, such as variable degrees of access 
granted to medical records, variable degrees of completeness of records, and 
patients who move to be treated in different centres, several data items could not be 
adequately evaluated. These included long term follow up, late therapy-induced 
toxicity, IBD disease location and activity at time of treatment, and use of IBD 
medication. Furthermore, we recognize that measuring the toxicity of radiotherapy in 
rectal cancer can be difficult in patients with IBD, since it may be unclear whether 
symptoms are due to the treatment or rather to ongoing bowel inflammation or the 
cancer itself, especially in a retrospective setting. It was not possible to compare the 
results of the IBD patients in this study with an adequate sporadic rectal cancer 
control group, since the study population is very heterogeneous with regard to type 
of therapy, TNM stage, comorbidity status and centre of treatment. 
In summary, the current study found no evidence for excessive levels of therapy- 
induced acute toxicity or Clavien-Dindo graded 30-day post-operative complications 
in this cohort of IBD patients treated with preoperative therapy for rectal cancer. 
Grade≥3 acute toxicity occurred almost exclusively in CRT treated patients. Most patients 
probably had relatively mild disease activity with systemic corticosteroid use in a 
small portion of patients. However, the presence of active bowel inflammation at time 
of treatment could not be adequately determined from the retrospectively searched 
medical charts and the impact of IBD activity on the development of grade≥3 acute 
toxicity therefore remains uncertain. The 30-day post-operative complication rates after 
SC-RT and CRT were at the high end of those reported in the literature for sporadic 
rectal cancer. However, this was also true for IBD patients with surgery only, and may 
be explained by higher levels of previous abdominal surgery and corticosteroid use 
in IBD patients compared with their non-IBD counterparts. 
Therefore, results from this study provide support for the use of standard preoperative 
therapies for rectal cancer (especially SC-RT) in IBD patients with relatively indolent 
disease, whereas caution is still warranted in patients with active bowel inflammation. 
Prospective studies directly evaluating the impact of active IBD on the development 
of preoperative therapy-induced acute and late toxicity in patients receiving pelvic 
irradiation are needed, and may include IBD patients treated for prostate and 
gynecological cancer. 
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General discussion and future perspectives
The introduction of total mesorectal excision (TME) with and without preoperative 
radiation or chemoradiation (CRT) therapy has decreased local recurrence rates and 
improved survival for rectal cancer patients. The role of high quality histopathological 
examination in these developments is profound. Pioneering papers by Quirke and 
others highlighted the importance of lateral tumour spread and mesorectal tumour 
deposits (TDs), as well as the status of the circumferential resection margin (CRM) in 
the development of local recurrences, and thereby provided the pathobiological 
justification for the widespread introduction of TME.1, 2
However, rectal cancer still causes considerable morbidity and mortality. This thesis 
addresses some of the current challenges faced by clinicians and pathologists in the 
management of this disease and focuses on the role of histopathology in improving 
rectal cancer care. These issues include improving the quality of TME surgery in order 
to further decrease local recurrence rates (§1), reducing overtreatment by improving 
the selection of tumours that are suitable for organ preserving therapies such as a 
local excision, or a “wait and see” approach (§2 and §3), and improving staging of 
patients who underwent different preoperative treatment modalities in order to fine- 
tune follow-up and adjuvant strategies (§4). 
§1 Quality of surgery
Plane of surgery
Results from chapter 1 show that the plane of the resection margin is an important 
predictor of local recurrence and survival after TME surgery, independently of CRM 
status. Beside surgeon skill and experience there are other factors which determine 
the quality of surgery. For example, in abdominperineal resection (APR) specimens 
there is a relatively high rate of muscularis propria resection planes and positive 
CRMs, which is related to the progressive thinning of the mesorectum as it reaches 
the level of the levator muscles. Performing an extralevator excision in these patients 
generates a cylindrical specimen, which increases the amount of tissue around the 
tumour and decreases CRM positivity and local recurrence rates, although it is also 
associated with increased perineal wound complications.3-6 This shows that quality 
of surgery is a key factor in the treatment of rectal cancer and optimizing factors that 
influence it may help improve patient care.
Judging and reporting quality of surgery
Although uniform definitions for macroscopic assessment of the mesorectum, as well 
as the sphincter area exist, not all observers interpret them consistently. According to 
a report from the Belgian PROCARE study, the reproducibility of macroscopic plane 
of surgery evaluation can be disappointing. Their data showed that the central Review 
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Committee downgraded the surgical plane from (intra)mesorectal to intramuscular in 
17% of patients, and upgraded it from intramuscular to (intra)mesorectal in 27%.7 
Improving standardization of the macroscopic evaluation of the resection plane by 
pathologists is therefore necessary to meaningfully compare quality data between 
various surgeons and centres.
Increasing the awareness among surgeons and pathologists regarding the association of 
the plane of surgery achieved with patient outcome can help improve quality of surgery. 
One way to achieve this is to include an assessment of the plane of surgery in a 
synoptic reporting protocol, which makes it mandatory for pathologists to report this 
item. Synoptic reporting has been implemented for colorectal cancer in the Netherlands 
and in this way the performance of surgeons and centres can be compared.
In the multidisciplinary setting, surgeons and pathologists should pay adequate 
attention to macroscopic completeness of surgical specimens and openly discuss 
results in a constructive and mutually respectful way in order to improve rectal cancer 
treatment. This opens up opportunities to implement measures that allow surgeons 
to improve their individual performance and that of the centre for the benefits of their 
patients. 
Improving quality of surgery
Training of surgeons in the techniques of TME have had a tremendous impact on 
standardization of surgery and improving quality.8, 9 In addition, the move towards 
higher volume, specialised centres for rectal cancer care also improves quality of 
surgery. Low volume surgeons more often cause a suboptimal plane of surgery and 
an involved CRM, both of which are associated with higher local recurrence rates.10, 11 
In addition, patients treated in high volume centres more often have restorative 
proctectomies, a lower post-operative mortality rate, and, in some studies, even an 
improved 5-year survival.12-14
In addition, colorectal audits have been introduced to collect clinical and pathological 
data from multiple centres. After correcting these data for case mix variables, surgeons 
and centres may compare their own performance with the results from other national 
or international practices which serve as benchmark. This could initiate changes in 
treatment and also enables the identification of “best practices” which may subsequently 
be widely adopted. 
The European Registration of Cancer Care (EURECCA), a promising initiative started 
by the European CanCer Organisation (ECCO), is a collaboration of national auditing 
organizations with the goal to establish a multidisciplinary European registration for 
patient, tumour, and treatment characteristics linked to outcome registration, which 
can serve as the basis of an international audit structure.15
However, this requires registering all the relevant characteristics in the standard 
dataset of these audits. For example, the Dutch Surgical Colorectal Audit registers 
CRM positivity rates but not the rates of suboptimal planes of resection (https://www.
dica.nl/media/219/DICA-Indicatorenset%20verslagjaar%202016.pdf). The CRM positivity 
rate is an important factor in rectal cancer management, however, it is not just an 
indication of surgical quality, but should be regarded as a quality indicator for the 
entire diagnostic and therapeutic process, including the technique and interpretation 
of clinical imaging (MRI), the choice and technique of preoperative therapy, as well as 
the quality of the operation itself. Plane of resection, on the other hand, is primarily 
determined by skill and experience of the surgeon, and is therefore a more precise 
tool. Incorporating this factor in (inter)national audits seems to be an easy way to 
further improve the quality of surgery.
§2 Organ preservation for pT1 colorectal cancer 
The role of histopathology
The introduction of bowel screening programs are expected to generate an increase 
in the number of pT1 colorectal cancers. The majority of pT1 tumours can be cured 
by a local excision, since they do not harbour lymph node metastases (LNM) and 
therefore do not require radical resection of the mesocolorectal fat. The clinical 
 relevance of local excision for pT1 tumours is greatest for rectal cancer, since the 
rectum is more accessible to local treatment, including transanal endoscopic 
microsurgery (TEM), and the potential gain of reducing surgery-induced morbidity is 
greater than in the colon.16-20 Local recurrence can be caused by an incompletely 
removed primary tumour or by tumour involved lymph nodes, or TDs. Our systematic 
meta-analysis in chapter 2 showed that lymphatic channel invasion, high histopatho-
logical grade, budding, and submucosal invasion depth ≥1mm are strong and 
independent histopathological characteristics that predict the presence of LNM. 
Absence of these factors was associated with a very low risk of LNM in several 
Japanese studies.21, 22 However, the prognostic value of this specific combination of 
risk factors to predict locally recurrent disease has not been validated. Previous 
studies reported the risk of local recurrence after TEM for pT1 rectal cancer to vary 
depending on tumour size, submucosal invasion depth, differentiation grade, 
presence of lymphatic or venous invasion, and resection margin status. Tumours with 
favourable characteristics in the TEM specimen showed local failure rates comparable 
with TME surgery.23, 24 However, future studies still have to determine the prognostic 
value of tumour budding in this context.  
Improving quality of pathology reporting
A reproducible and high quality histopathological evaluation of local excision 
specimens is essential for the development of an effective risk stratification which is 
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useful in clinical practice. Currently, routinely reported histopathological characteristics 
such as lymphatic invasion, venous invasion, and differentiation grade suffer from inter- 
observer variation. Uniform definitions for these factors should be used by pathologists 
in various centres in order to improve reproducibility. The use of immunohistochemistry 
and other special stains can substantially improve detection and inter-observer 
agreement for lymphatic and vascular invasion,25, 26 and should be strongly encouraged. 
Tumour budding has been evaluated according to various different methods in 
the literature, 21, 27 which has limited its use in daily practice. Recently, however, 
investigators have worked to standardize the definition of this promising marker.28 
A consensus statement by experts from the International Tumour Budding Consensus 
Conference says the number of buds should be counted on an H&E slide in a hotspot 
with a field area of 0.785mm2 and graded as low (Bd1): 0-4 buds, intermediate (Bd2): 
5-9 buds, or high (Bd3): ≥10 buds.29
Another way in which standardization and quality of histopathological evaluation 
can be increased is to use synoptic reporting.30 The introduction of synoptic reporting 
is an encouraging development within the field of pathology, which mandates 
pathologists to think about and report the presence or absence of certain, sometimes 
subtle, characteristics that may otherwise have been omitted from the report. 
Additional benefits of synoptic reporting are that relevant characteristics are reported 
in a uniform way, which decreases the chance of misinterpretation by clinicians, and 
it greatly enhances the possibility to compare data between centres and to benchmark 
and improve one’s own practice.
§3 Organ preservation after CRT
“Wait and see” 
Non-operative management is an attractive option in patients with a cCR after pre- 
operative therapy, who wish to avoid the morbidity and risk of mortality associated 
with radical surgery. Proof of concept for this approach has been provided by the 
group of Habr-Gama who reported a local recurrence rate as low as 3% in patients 
with a sustained clinical complete response (cCR),31, 32 although other studies found 
much higher local recurrence rates of 23-83%.33-38 In addition, studies investigating 
a “wait and see” approach report variable outcomes and show substantial hetero- 
geneity in patient selection criteria and protocols for follow-up, as well as inconsistent 
definitions for what constitutes a cCR.39 Furthermore, only about 30% of patients with 
a cCR actually have no residual tumour in the histopathological specimen.40
Results from our study in chapter 4 provide an extra word of caution. This study 
investigated histopathological characteristics in resection specimens of CRT treated 
locally advanced rectal cancer (LARC) patients including almost 40% clinical T4 
tumours. The patients with a pathological complete response (pCR) and near-pCR 
showed a remarkably high percentage of residual LNM (29% and 50% respectively), 
and patients with a near-pCR had residual tumour cells in the mesorectum (ypT3 
disease) in 42% of cases. Outcome was excellent in patients with pCR, although 
near-pCR patients had poor disease free and OS, which was comparable with non-
responders. The exact clinical relevance of not removing these residual tumour foci 
as would be the case with “wait and see” is not known. However, currently available 
imaging modalities have difficulty to accurately identify LNM and to detect small 
residual TDs within areas of fibrosis after CRT.41 The results described in chapter 4 
therefore emphasize the considerable risks involved in a “wait and see” approach in 
LARC patients. 
Local excision after CRT: in theory
The use of full thickness local excision in patients with a good clinical response after 
CRT provides additional information on tumour regression while at the same time 
reducing the risk of endoluminal disease recurrence by removing residual tumour 
foci. A possible diagnostic concern when evaluating TEM specimens after CRT is that 
in theory the TEM specimen might be devoid of tumour cells while at the same time 
residual tumour persists in the mesorectum of the patient and this might cause 
disease recurrence. However, a study by Duldulao et al showed that in 98% of ypT3 
and in 100% of ypT4 patients there was tumour tissue in the muscularis propria layer 
and a full thickness TEM biopsy without viable tumour cells therefore adequately 
rules out residual mesorectal disease, as opposed to superficial biopsies of the 
mucosa and submucosa.42 
Another concern is that residual mesorectal LNM may cause disease recurrence. 
Previous studies on LARC report residual LNM in up to 10% of ypT0 and up to 22% of 
ypT1 patients after CRT with TME.43-45 In addition, our study (chapter 3) found a 
17.4% residual LNM rate in resection specimens of LARC patients with ypT0 after 
CRT, which dropped to 10.3% if patient with clinically suspected nodal involvement 
were excluded. These results demonstrate that caution is warranted when treating 
patients with CRT and local excision.
Local excision after CRT: in practice
However, multiple observational studies showed excellent local control in patients 
with ypT0 or ypT1 tumours after preoperative CRT followed by local excision. There 
were only 2 local recurrences in 128 patients (1.5%) described in 7 studies,46-51 
whereas local failure rates of 7-46% have been reported in case of a ypT2 or ypT3.50-52 
Several phase II trials confirmed the low local recurrence rates in patients with ypT0 
or ypT1 after CRT and TEM.53-55 In the CARTS trial patients with early, clinically node 
negative (cT1-3N0), and distal tumours (≤10cm from the anal verge) with a good 
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clinical response after CRT (scar or ulcer, ycT0-2) received TEM. Subsequent local 
recurrences developed in 1 out of 30 patients with a ypT0-1 tumour in the TEM 
specimen (3%). In the ACOSOG Z6041 trial clinical T2 tumours located ≤8cm from the 
anal verge were treated with CRT and TEM resulting in only 2 local recurrences in 79 
patients with ypT0-2 (1.3%). Pucciarelli et al included 63 patients with a clinical T3 or 
distal T2 tumours and major clinical response after CRT. They reported 0 local 
recurrences in 43 patients with ypT0 or ypT1 tumours and a tumour regression grade 
of no more than 2 (TRG≤2). However, these results came at the expense of a 42% 
grade 3-5 CRT-induced toxicity rate (including 2 deaths) and a 10% grade 3-5 
postoperative complications rate in the CARTS trial and a 39% toxicity rate of at least 
grade 3 in the ACOSOG Z6041 trial, mostly rectal pain. 
There were no local recurrences after immediate completion TME surgery in patients 
with unfavourable characteristics in the TEM specimen.53, 55 However, patients with 
unfavourable characteristics that were observed after TEM and developed local 
disease recurrence showed abysmal results with a CRM positivity rate of 87% after 
salvage surgery and 40% re-recurrence.56 These data show that it is of the utmost 
importance to check the post-CRT local excision specimen for histopathological 
unfavourable characteristics, and if they are present, immediate completion surgery 
should follow.
Local excision after CRT: LARC patients
The reported limited number of local recurrences associated with ypT0-1 tumours 
after TEM seems to contrast with the relatively high residual LNM rate in resections of 
CRT treated LARC patients with ypT0-1 disease described in chapter 3. This is 
probably related to the selection of patients in the local excision studies, which 
consist of primarily distally located rectal cancer with a substantial proportion of 
clinical T2 tumours and only a few patients with clinically suspected lymph nodes. 
This results in a low a priori risk of LNM and therefore of residual disease, whereas the 
study population in chapter 3 consists of LARC patients with a high a priori risk. 
Although the evidence for local excision after CRT seems very promising, the rigorous 
selection of patients with distally located, clinical T2 or T3 tumours without suspected 
lymph nodes, imply that these results cannot be generalized to LARC patients.
However, one small study by Perez et al provides some evidence that TEM after CRT 
may be feasible for selected LARC patients. This study included any distal (<7cm 
from anal verge) T3, T4, N+ tumour, or T2 requiring APR. Patients with a cCR were 
followed-up according to “wait and see”, however, patients with  a “near” clinical 
response (residual lesion of ≤3 cm with ycT1-2N0 at clinical and radiological restaging), 
who had an indication for APR or ultralow anterior resection were offered full-thickness 
local excision using TEM. Here the local recurrence rate after CRT and TEM was 23%, 
although all patients who developed a local recurrence had at least one unfavourable 
characteristic (ypT≥2, poor differentiation grade, lymphovascular invasion, or perineural 
invasion) in the TEM specimen. For patients without unfavourable characteristic the 
local recurrence rate was 0% (0 of 17).56
Selection of patients for organ saving therapy  
Although the safety and efficacy of local excision after CRT have not been tested in 
randomized trials, the current evidence supports the use of CRT and local excision in 
selected patients with low tumours and a good clinical response that are unable or 
unwilling to undergo curative radical resection. In case of ypT0 or ypT1 disease in the 
TEM specimen follow-up appears to be oncologically safe. 
However, the view that all ypT2 tumours need additional resection, as advocated in 
the current Dutch colorectal cancer guidelines,57 may be too simplistic. Results from 
chapter 3 show that an algorithm integrating histopathological grade, residual tumour 
size, and presence of clinically detected LNM could predict residual LNM in LARC 
patients treated with CRT. These results were independent of ypT category and 
showed that small (<10mm) ypT2 tumours, without clinically suspected LNM and 
without “high grade” histopathology are associated with a limited probability (7.7%) of 
residual LNM, which is similar as for ypT0 and ypT1 tumours. Although presence of 
residual LNM is not the same as local recurrence, these findings merit further 
investigation.
The high toxicity and complication rates after CRT reported in the CARTS and ACOSOG 
Z6041 trials, as well as considerations about long term functional outcomes58 
emphasize the risk of substantial overtreatment that may caused by CRT with TEM in 
patients with early disease for whom CRT would normally not be indicated. However, 
there is a subpopulation of CRT treated LARC patients with good clinical response 
who may benefit from the judicious use of TEM as they may be spared a debilitating 
APR. In addition, developments in imaging techniques such as diffusion weighed 
MRI and FDG-PET show promise, and may be able to predict a good or complete 
clinical response with much more accuracy in the foreseeable future.59, 60 It appears 
meticulous selection of patients eligible for local excision after CRT with a good 
clinical response could be a key factor in reducing morbidity while preventing potential 
undertreatment in rectal cancer.
§4 Challenges in TNM staging after preoperative therapy
Preoperative therapy may induce changes in rectal cancer specimens which 
influence staging. Replacement of tumour cells by fibrosis is called tumour regression 
and pathologists can assign a tumour regression grade (TRG) based on the 
proportion of residual tumour and fibrotic tissue. Two different patterns of tumour 
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regression have been reported called “shrinkage” and “fragmentation”,61-63 and 
each may have a different impact on staging. Shrinkage goes hand in hand with 
downstaging as tumour tissue disappears from the deeper layers and only remains 
in the more superficial parts. Fragmentation shows general loss of tumour cells, 
which are replaced by fibrosis, although multiple discontinuous small tumour cell 
clusters remain in multiple areas of the tumour, including the deeper layers. Tumour 
remnants associated with the fragmentation pattern may be mistaken for TDs which 
may erroneously lead a pathologist to upgrade the TNM stage. In addition, 
preoperative therapy may reduce the number of lymph nodes found in the specimen.
Prognostic significance of downstaging after CRT
Downstaging after CRT, and especially achieving a pCR, has been associated with 
improved prognosis in rectal cancer patients.64 Since randomized controlled trials 
have not shown a survival advantage in patients treated with preoperative vs. 
postoperative CRT, downstaging may primarily be a reflection of a tumour’s 
susceptibility to treatment as well as a less aggressive biology. Differences in stage 
specific survival between patients treated with preoperative and postoperative 
therapy have been attributed to stage migration.65 
Investigators have attempted to increase the pCR rate by adding therapeutic agents 
to the preoperative schedule, although this resulted in increased toxicity without 
improving tumour response or outcome.66, 67 In addition, an increasing delay between 
preoperative therapy and surgery has been associated with improves pCR rates, 
although an effect on OS was not observed.68-71 Furthermore, an analysis of the 
National Cancer Database showed that achieving a pCR depends on many factors 
including lower tumour grade, lower clinical T category, lower clinical N category, 
more recent diagnosis, female sex, private insurance, increasing interval between 
end of RT and surgery, and treatment at higher volume institutions.72
The study described in chapter 5 included patients from a large national cancer 
registry. This study compared OS in CRT treated patients with patients who underwent 
short-course radiation therapy (SC-RT) with immediate surgery. The interval between 
start of SC-RT and surgery is too short to develop regression and downstaging, and 
for practical purposes these patients may be best classified as pTNM. The study 
showed that CRT treated patients with pathological stage I had an excellent prognosis 
with a comparable outcome as pathological stage I patients in the SC-RT group and 
preoperative treatment with surgery for these patients is therefore adequate. For CRT 
treated patients with stage II and III, on the other hand, the worse prognosis compared 
with the SC-RT group indicates that there is room for improvement and additional 
therapies such as postoperative chemotherapy may be of benefit. This is in line with 
results from a recent trial on postoperative chemotherapy after preoperative CRT that 
showed an increase in 3-year DFS with the addition of oxaliplatin to the postoperative 
chemotherapy regimen compared with 5FU based chemotherapy only, especially in 
ypstageIII patients.73
 
Importance of lymph node yield after CRT
Lymph node yield is considered an important prognosticator and quality indicator. 
A minimum number of lymph nodes need to be evaluated in patients with colorectal 
cancer for reliable nodal staging. ASCO recommends evaluating a minimum of 12 
lymph nodes whereas the Dutch guideline requires at least 10.57, 74 After CRT the 
number of lymph nodes retrieved from resection specimens is reported to decrease 
by as much as 7-53%.75
One study reports a higher rate of LNM associated with an increasing lymph node 
yield regardless of preoperative therapy and therefore recommend a minimum of 12 
nodes should be evaluated in patients treated with preoperative therapy as well.76 
However, another study showed that patients with absence of lymph nodes after CRT 
had an improved survival compared with patients who had LNM (DFS 74% vs. 30% 
for absence of lymph nodes vs. ypN+; p<000.1).77 These data imply that the value of 
number of retrieved lymph nodes after CRT is not clear-cut and the thoughtless use 
of lymph node yield as a quality indicator in this specific group of patients may not be 
justified. Ample attention should be paid to case mix (patients with or without 
preoperative CRT) when judging the performance of a lab or hospital in this regard.
Histopathological tumour regression
Tumour regression in preoperatively treated rectal cancer patients is a widely 
recognized phenomenon and the improved prognosis associated with downstaging 
and especially a pCR has been documented extensively.64 The TRG reflects the 
degree of tumour cell loss and replacement by fibrosis in the histopathological 
specimen. Assessment of TRG is primarily useful as a prognostic factor. It can also 
be used in clinical trials as an alternative endpoint for outcome, since it is an early 
indication of therapy response. In addition, TRG may predict response to adjuvant 
therapies.73
The original TRG system was the 5-tier Mandard system, which was designed for 
esophageal squamous carcinoma and subsequently adapted by Dworak et al for 
rectal adenocarcinoma.78, 79 Multiple alternative grading systems have been 
developed including 5-tier, 4-tier, or 3-tier systems.80-82
Although downstaging to a pCR is well known to be associated with an excellent 
prognosis, the prognostic significance of TRG in patients with various degrees of 
residual disease is not so clear-cut. Only one study reported an independent 
prognostic value for TRG when corrected for downstaging/ypTNM stage,83 whereas 
most studies did not find a significant correlation between TRG and survival on 
univariate62, 84 or multivariable analysis.64, 80, 85
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In addition, substantial interobserver variability has been reported when using these 
methods to assess tumour response with only fair agreement between 17 pathologists 
in one study (kappa 0.28-0.38),86 although another study reported that a simplified 
3-tier system was more reproducible than a 5-tier system with 2 pathologists reaching 
good agreement (kappa 0.64) with a 5-tier and excellent agreement (kappa 0.84) 
with a 3-tier system.82
Interestingly, pathologists who were blinded for treatment characteristics reported 
tumour regression in 33% of patients treated with surgery only in one study.87
Furthermore, TRG assessment depends on the quality of histopathological work-up 
of resection specimens, since more tumour foci are found if more tissue from the 
tumour area is submitted for microscopy.
These difficulties have impeded the use of TRG as a prognostic factor in daily 
practice, although in the recently published 8th edition of TNM staging manual a 
4-tiered TRG system which is a modified version of the classification published by 
Ryan et al has now been embraced. 82, 88
As mentioned before, tumour regression occurs according to either a pattern of 
“shrinkage” or “fragmentation”.61-63 Fragmentation may result in a tumour with near- 
complete response according to the TRG, while at the same time being classified as 
a ypT3. Tumour shrinkage is associated with improved outcome, whereas data on 
the prognostic significance of fragmentation is scarce. Interestingly a study by Kim 
et al reports a near-complete response to be associated with a substantially worse 
outcome than a pCR.89 The study in chapter 4 shows comparable results with poor 
distant metastasis free interval (DMFI), disease free survival (DFS), and overall 
survival (OS) in patients with near-complete response. Many of the tumours with 
near-complete response in both these studies were ypT3 indicating a fragmentation 
pattern. Indeed a subanalysis of patients from chapter 4 suggested that the poor 
survival in the near-complete response group was explained by the outcome in ypT3 
patients (cumulative 3-year OS: 87.5% vs. 50.0% for ypT1/ypT2 vs. ypT3 respectively; 
p for trend = 0.062; unpublished data). 
In short, tumour downstaging or shrinkage, especially the development of a pCR, 
predicts an excellent outcome. TRG lacks prognostic value if adjusted for downstaging 
in most studies and this may well be explained by the fact that it does not distinguish 
between tumour shrinkage and fragmentation. More research is needed to clarify the 
prognostic significance of the fragmentation pattern.
Tumour deposits
TDs are discontinuous foci of tumour cells in the pericolorectal fat and have been 
associated with poor outcome.90, 91 The origin of TDs is diverse and includes 
perineural, perivascular or intravascular invasion in a substantial proportion of cases, 
although they may also represent free discontinuous tumour spread or overgrown 
LNM.92, 93 How pathologists interpret TDs is crucial for staging and changes made to 
TNM in the past 2 decades have resulted in stage migration which may have profound 
clinical consequences.94 In the previous 7th edition of TNM as well as in the recently 
published 8th edition TDs are allocated to the N1c category, which is subsequently 
only assigned in the absence of obvious LNM. This system largely disregards the 
prognostic significance of TDs, even though a recent study provided evidence that 
TDs add prognostic information in patients with LNM.95 
In patients with rectal cancer who are treated with long-course preoperative therapy 
the evaluation of TDs may be very difficult. Tumour regression has been reported to 
result in discontinuous residual tumour (micro)foci in 17-48% of cases, which may be 
present in all the layers of the bowel wall.96 Although these foci are often associated 
with fibrosis, chronic inflammation, and other radiation induced changes,97 they may 
be hard to distinguish from true discontinuous TDs if they are present in the meso- 
rectum. 
If the rules of the most recent edition of TNM are followed, all of these foci would be 
assigned to the N1c category and therefore the node-positive group, although the 
number of foci would be ignored. However, these rules do not apply here, since a 
part of these foci represent remnants of tumour regression, which in theory should be 
associated with improved prognosis, rather than true discontinuous tumour spread, 
which predicts poor outcome. TDs are reported to occur less often after preoperative 
therapy, and small TDs of ≤1mm are reported to be the first to disappear.98
Several studies investigated the prognostic value of TDs after preoperative CRT. 
One study, including 136 CRT treated clinical T3N0 patients of whom 16 (11.8%) had 
TDs, found no difference in DFS or OS between patients with and without TDs, 
although the number of TD positive cases is small.99 In contrast, another small study 
including 76 patients treated with preoperative (C)RT with TDs in 10 (13.2%) found 
TDs in to be associated with DFS with a hazard ratio (HR) of 4.07 (95% CI 1.39–11.95), 
although a multivariable analysis was not performed.61  Gopal et al evaluated 110 
patients treated with preoperative CRT including 23 with TDs (21%) and showed that 
TDs were associated with a higher rate of LNM and a higher proportion of deeply 
invasive tumours. In addition, patients with TDs had a substantially shorter median 
survival (3.1 vs. 11.2 years, P= 0.027), although there was no significant predictive 
value on multivariable analysis.100 Zhang et al included 310 LARC patients treated 
with CRT and 17.4% had TDs. TDs were associated with poor DFS and OS on 
multivariable analysis.101
The study described in chapter 4 found TDs in a relatively high proportion of resection 
specimens of CRT treated LARC patients (26%), which is probably explained by the 
selection of advanced tumours. In this study TDs were associated with worse DMFI, 
DFS, and OS, although significance was not retained if the tests were adjusted for 
ypN-category. The absence of a prognostic value on multivariable analysis in these 
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studies may be explained by the small number of patients with TDs and lack of 
statistical power.
In contrast, an analysis of the SEER database including 4813 patients with TDs in 
10.7% of cases after preoperative radiotherapy found that TDs independently 
predicted cancer specific survival with HR 2.25 (95% CI 1.51–3.35). In addition, TDs 
were associated with aggressive characteristics such as poorer tumour differentiation, 
more advanced ypT category, ypN category and ypTNM stage, presence of distant 
metastasis, elevated carcinoembryonic antigen, increased CRM positivity rates, and 
perineural invasion (all P < = 0.001). However, there was no histopathological review 
of the TDs in this study and the impact of number of TDs on prognosis was not 
investigated.102 
Patients with TDs in the studies described above are probably a mixture of patients 
with true TDs (resistant for preoperative therapy) and discontinuous tumour remnants, 
and it is not surprising that as a group these patients were shown to have worse 
prognosis in the analysis of a large database such as SEER. This seems to justify 
counting TDs in the N-category in this subset of patients. However, the exact 
implications for individual patients remain elusive, since reliable methods to 
discriminate between patients who have either true TDs or discontinuous tumour 
remnants after regression have not been developed. The 8th edition of the AJCC 
staging manual leaves this to the discretion of the pathologist by emphasizing that “it 
is important for the pathologist to assess whether tumour nodules represent tumour 
deposits (…..) or discontinuous eradication of the original tumour so that he or she 
can record the appropriate ypT and ypN categories”.88 In addition, the implications of 
tumour remnants might be more complex than initially thought. Although tumour 
remnants implicate a good response of the tumour to preoperative therapy, the 
remnants themselves are relatively therapy resistant. They indeed reflect heterogeneity 
in the tumour’s susceptibility to therapeutic agents and may identify a tumour clone 
with more aggressive biology. The histopathological correlate of this phenomenon is 
the previously discussed “fragmentation” pattern. Future studies should focus on the 
biology of tumour remnants and should develop methods to distinguish fragmentation 
from true TDs after CRT.
§5 Concluding remarks 
Histopathological examination of rectal resection specimens has contributed to the 
improvement of rectal cancer care in the last 2 decades, which has lead to a reduced 
incidence of local recurrences and an increased survival in rectal cancer patients. 
Assessment of tumour characteristics at both the macroscopic and microscopic 
level is the backbone of staging and is essential for treatment planning and prognosis 
in individual patients. Moreover, it is important for the evaluation of quality of care in 
(inter)national audits, and in determining the efficacy of novel treatment strategies. 
This thesis showed that macroscopic evaluation can play a role in improving quality 
of surgery by providing feedback on surgical performance. In addition, histopathology 
can help reduce morbidity by selecting specific patients with early rectal cancer or 
patients with a good response after CRT (especially for distal tumours requiring APR), 
who are suitable for organ preserving strategies. Furthermore, it was shown that a 
near complete response to CRT does not necessarily translate into a good outcome, 
which could be related to a more aggressive behaviour of tumours that show a 
regression pattern characterized by fragmentation instead of shrinkage, and this is 
relevant for patients who are treated with a “wait and see” approach. Moreover, we 
found stage-specific differences in survival (for patients with stage II or III) between 
patients treated with either SC-RT with immediate surgery (no downstaging) or with 
long course CRT (possible downstaging), and it would be very interesting to learn if 
postoperative chemotherapy or novel adjuvant therapies in CRT treated patients with 
ypTNM stage II or III have the potential to close the survival gap between these 
patients. 
High quality histopathology is expected to remain important in the improvement of 
patient care in the future. A very promising development in the field of pathology is 
the rise of digital pathology systems. Although digital pathology requires costly 
investments in high quality digital infrastructure and storage, it has the potential to 
improve our practice in two important ways. 
First of all, histopathological images can be retrieved from storage for review, double 
reading or consultation almost instantly, avoiding the logistical issues associated with 
physical glass slides. Secondly, digital pathology allows for computer aided diagnosis. 
A computer may perform automatic annotations and measurements and score 
prognostic factors such  as tumour budding and TRG, which can be time- consuming 
and imprecise when performed manually. These applications would improve 
 standardization and objective assessment, thereby  solving various problems that 
currently hamper the widespread implementation of these important histological 
features. Moreover, the development of deep learning techniques may allow 
computers to discover novel histopathological biomarkers.
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Further development and implementation of these methods in daily practice have the 
potential to substantially change the way pathologists work in the coming years. 
In light of the above it is clear that histopathology plays an essential role in modern 
rectal cancer management and high quality histopathological evaluation will continue 
to aid in the development and implementation of novel treatment strategies and help 
improve quality of care. 
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The management of rectal cancer has improved substantially in the last decades. 
The introduction of total mesorectal excision (TME) and the development and 
improvement of preoperative therapy schedules have reduced local recurrence rates 
and improved survival. High quality histopathological examination of rectal resection 
specimens has contributed enormously to these treatment advances. By unravelling 
the role of lateral tumour spread, mesorectal tumour deposits, and the status of the 
circumferential resection margin (CRM) in the development of local recurrences, 
histo pathology provided the pathobiological justification for the widespread introduction 
of TME. 
The field of histopathology continues to develop and it has a key role to play in finding 
solutions for the current challenges in rectal cancer treatment. These include 
improving the quality of TME surgery, expanding the population of patients who can 
be safely treated with organ preserving therapies, and fine-tuning prognosis by 
improving methods for staging. In addition, efforts need to be made to generalize the 
advances made in rectal cancer management to patient populations that are usually 
excluded from preoperative therapy trials, such as patients suffering from inflammatory 
bowel disease (IBD). 
In chapter 1 the prognostic impact of surgical quality as determined by the pathologist 
is systematically reviewed including a pooled meta-analysis of available literature 
data. The standard of care for rectal cancer is surgery according to the principles of 
TME in which the rectum and the mesorectal fat containing possible discontinuous 
tumour foci or lymph node metastases (LNM) are removed. This substantially reduces 
local recurrence rates compared with a blunt dissection. However, even if the CRM is 
free of tumour, local recurrences may develop. This may in part be explained by 
incomplete removal of the mesorectal fat envelope and the presence of discontinuous 
tumour foci and/or lymph node metastases which remain in the patient. The quality 
of surgery can be documented by describing the anatomical plane of the resection. 
The highest quality specimen has a surgical plane on the mesorectal fascia 
(mesorectal plane), whereas defects up to 5mm in the fat envelope are intermediate 
quality (intramesorectal plane), and defects onto or in the muscularis propria 
constitute the worst quality (muscularis propria plane). Surgical quality was found to 
depend on surgeon experience, type of surgery (more often after abdominoperineal 
resection), tumour distance to the anal verge, and body mass index (both very low 
and very high). Preoperative therapy was not reported to influence surgical quality. 
The meta-analysis found plane of resection to predict oncological outcome with an 
increased risk of local recurrence (RR 2.72 [95 % CI 1.36 to 5.44]) and overall 
recurrence (RR 2.00 [95 % CI 1.17 to 3.42]) for a muscularis propria plane compared 
with an (intra)mesorectal plane. In addition, one large study included in this systematic 
review reported 4% vs. 12% local recurrence rates in CRM negative patients with 
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mesorectal vs. muscularis propria plane of surgery respectively, and only 1% of 
patients developed local recurrence if there was a mesorectal plane of surgery after 
preoperative short-course radiation therapy (SC-RT). The results of this systematic 
review show that plane of surgery achieved after TME is an important prognostic 
factor in rectal cancer. It is essential that pathologists document this characteristic in 
order to provide feedback on surgeons’ performance and thereby improve rectal 
cancer treatment.  
In chapter 2 a systematic review with meta-analysis of predictors of lymph node 
metastases (LNM) in early (pT1) colorectal cancer is conducted. In the absence of 
LNM pT1 tumours can be cured with limited local excision, which is associated with 
reduced morbidity and mortality. The introduction of bowel cancer screening 
programs for colorectal cancer is expected to increase the number of diagnosed pT1 
colorectal cancers and this has made the issue of possible overtreatment in these 
patients more pressing. About 8-16% of patients with T1 disease have LNM, and 
several histopathological characteristics, such as poor differentiation grade, lymphatic 
or vascular invasion, and submucosal invasion depth, have been associated with 
presence of nodal disease. The aim of this systematic review was to quantify the 
predictive value of risk factors and determine which characteristics are best suitable 
for the selection of patients who may safely undergo local excision. A total of 17 studies 
were included describing data of 3621 patients with available nodal status. The strongest 
independent predictors of LNM were lymphatic invasion (RR 5.2 [95% CI 4.0-6.8]), 
submucosal invasion ≥1mm (RR 5.2 [95% CI 1.8-15.4]), budding (RR 5.1 [95% CI 
3.6-7.3]), and poor differentiation (RR 4.8 [95% CI 3.3-6.9]). Although a submucosal 
invasion depth of at least 1mm is highly predictive of LNM it seems unpractical to use 
this factor for stratification, since the very low specificity (24%) would result in a high 
false positive rate with many patients undergoing radical surgery unnecessarily. 
Therefore, it is concluded that the absence of lymphatic invasion, budding and poor 
differentiation is associated with low risk of LNM. Risk stratification models integrating 
these factors may help select patients who may be spared radical surgery and need 
to be validated prospectively. In addition, the detection of these risk factors needs to 
be standardized, preferably using immunohistochemistry. 
In chapter 3 clinical and histopathological characteristics were investigated which 
may predict residual LNM in locally advanced rectal cancer (LARC) patients treated 
with preoperative chemoradiation therapy (CRT) who have residual tumour limited to 
the bowel wall (ypT0-2). There is increasing emphasis on organ preserving therapy in 
rectal cancer treatment, particularly for patients who had a good clinical response to 
preoperative therapy. However, residual LNM in the mesorectum may cause local 
recurrences in these patients. Some clinicians employ a “wait and see” approach, 
where patients with a good clinical response are closely followed without additional 
therapy. However, this method is criticized, since the evidence is based on highly 
selected patients and criteria used to determine a good clinical response are not 
consistent in the literature. An alternative approach is to perform a local excision after 
CRT, which is associated with reduced morbidity and mortality compared to TME 
surgery. This method removes tumour remnants in the bowel wall and provides 
additional histopathological information on tumour response. The study found 
residual nodal disease in 44 patients with ypT0-2 disease (21%). Independent 
predictors of LNM were clinical nodal involvement (cN+) (OR 2.79 [95% CI 1.04-7.48], 
p=0.042), “high grade” histopathology assessed in the post-CRT resection specimen 
(OR 6.46 [95% CI 1.23-34.02], p=0.028), and residual tumour diameter ≥10mm (OR 
2.54 [95% CI 1.06-6.09], p=0.036). An algorithm combining these factors was 
developed and was shown to adequately stratify patients according to LNM risk with 
a low risk (7.7%), intermediate risk (17%), and a high risk (51%) group. The predictive 
value of the algorithm was independent of ypT category, which is an important finding, 
especially for patients with ypT2 disease. Recent studies on local excision after CRT 
usually exclude ypT2 patients for fear of high local recurrence rates. However, this 
study shows that in the absence of high grade histopathological differentiation and 
clinically suspected nodal disease on imaging, a patient with a small tumour residue 
in the muscularis propria layer (<10mm in diameter) has the same risk of residual 
LNM as ypT0-1 tumours. Risk stratification based on these factors may help identify 
patients suitable for organ preserving therapy and should be validated in appropriately 
selected populations.
Chapter 4 reports the prognostic value of histopathological characteristics after 
treatment with CRT in a population of 107 uniformly treated and strictly defined LARC 
patients, including 40% with a cT4 tumour. The study focuses primarily on the 
association between tumour regression grade (TRG) and oncological outcomes. 
After preoperative CRT some tumours undergo a pathological complete response 
(pCR) with no residual tumour cells in the resection specimen, whereas in other 
cases clinically undetectable residual tumour deposits or pathologic lymph nodes 
may remain in the mesorectum. In light of the rising attention for organ preserving 
strategies, including a “wait and see” approach, as well as local excision after CRT 
(as described in chapter 3), these tumour remnants may pose a threat to the patients 
if they are not removed. In this study TRG was scored according to a 4-tier grading 
scale adjusted from the Dworak scale, and consisted of 20% pCR, 11% near-pCR, 
55% response and 14% no response. Of 21 pCR patients there were 6 who harboured 
nodal metastases. Out of 12 near-pCR patients 5 had ypT3 disease, while 6 harboured 
nodal metastases. A pCR was associated with an excellent prognosis with only one 
patient developing distant metastases, and no local recurrences. On the other hand, 
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in the near-pCR group distant metastases developed in 5 of 12 patients and a local 
recurrence in 1 patient, corresponding to a 3-year distant metastases free interval, 
disease free survival, and overall survival rate of 65%, 50%, and 67% respectively, 
which is comparable with patients who had no substantial tumour regression. 
The exact impact of not removing residual LNM or small, isolated mesorectal tumour 
deposits in CRT treated LARC patients with a complete or near-complete response 
of the primary tumour remains unknown. Considering that current imaging modalities 
have a low accuracy to detect residual LNM and to distinguish fibrosis from 
microscopic tumour remnants, a “wait-and-see” policy in LARC patients is associated 
with substantial risks.  
In chapter 5 data from a nationwide rectal cancer database is analyzed in order to 
determine stage specific survival in patients who did or did not undergo tumour re-
gression-inducing preoperative treatment. Preoperative CRT is known to induce 
tumour downstaging in a significant proportion of patients with a pCR in 8-24% of 
cases. In contrast, patients treated with preoperative SC-RT followed by surgery 
within 10 days, or patients treated with surgery only are not expected to show 
downstaging. The aim of this study was to determine if TNM stage-specific survival is 
comparable in patients who did or did not undergo tumour downstaging. However, 
patients who underwent surgery without preoperative treatment in this study formed 
a biased selection of older patients with substantially more comorbidities than those 
treated with SC-RT and CRT. These patients were not treated according to the 
prevailing guideline and are not considered to be an adequate control group. The 
most important results of this study therefore arise from the comparison of CRT and 
SC-RT treated patients. Results from the multivariate analysis emphasized that 
downstaging to pathological stage I after CRT is associated with an excellent 
prognosis with cumulative 5-year survival similar to same stage SC-RT treated 
patients without tumour regression (85% vs. 85%; p=0.167). In addition, cumulative 
5-year survival was comparable between CRT treated patients with pathological 
stage I and those reaching a pCR (85% vs. 89%; p=0.113). On the other hand, CRT 
treated patients had a worse stage-specific overall survival compared with SC-RT for 
pathological stage II (HR 1.57 [95%CI 1.27-1.95]; p<0.001) and stage III (HR 1.43 
[95%CI 1.23-1.70]; p<0.001). These results show that TNM stage-specific survival 
depends on type of preoperative therapy, and clinicians should take these differences 
into account. In addition, there were large discrepancies between clinical stage 
(cTNM) and pathological stage (pTNM) in patient treated with surgery only (no 
downstaging by definition), which highlights the inaccuracy of current imaging 
techniques to predict the spread and extent of disease. 
In chapter 6 an analysis is conducted of therapy induced toxicity and postoperative 
complications in rectal cancer patients with IBD. Preoperative CRT is often withheld 
in patients with IBD, due to the perceived risk of excessive side-effects reported in the 
literature. However, the evidence for this is limited. Patients with IBD who develop 
rectal cancer are scarce and no adequately large cohorts are available in single 
centres. Therefore, the Dutch pathology registry (PALGA) was searched for all IBD 
patients diagnosed with rectal cancer in the Netherlands between January 1991 and 
May 2010. After manually scrutinizing the records yielded by the automated search 
and performing medical chart review a 161 patients were included in the study. The 
study included 161 patients with this relatively rare combination of diseases and 66 
had received preoperative therapy (41%).The study focused on the incidence of 
severe (grade ≥3) acute toxicity and post-operative complications in patients. 
Grade≥3 acute toxicity developed in 6 out of 21 CRT treated patients (28%), which is 
at the high end of the range normally reported for sporadic rectal cancer in the 
literature. However, there was no severe toxicity in the SC-RT group (0/32; 0%). The 
grade≥3 post-operative 30-day complication rate (28% overall) was also relatively 
high in this population with IBD compared with sporadic rectal cancer. However, 
there was no difference between patients treated with preoperative therapy and those 
with surgery only, and this complication rate is therefore probably best explained by 
the presence of higher levels of previous abdominal surgery and/or use of corticoste-
roids in IBD patients, which are both associated with increased complication rates. 
Systemic corticosteroids were used by 10.5% of patients at time of preoperative 
treatment, which suggests most of the patients had relatively indolent IBD. Overall, 
the results did not show excessive rates of toxicity or post-operative complications 
and support the use of standard preoperative therapies for rectal cancer (especially 
SC-RT) in IBD patients with relatively indolent disease. Unfortunately, the exact 
impact of active bowel inflammation could not be determined retrospectively and 
caution is therefore still warranted in patients with active IBD. There is a need for 
prospective studies which investigate the influence of active IBD on acute and late 
toxicity in patients receiving pelvic irradiation.
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De behandeling van endeldarmkanker (rectumcarcinoom) heeft in de laatste 20 jaar 
een grote ontwikkeling doorgemaakt. De introductie van totale mesorectale excisie 
(TME) en de opmars van preoperatieve therapie heeft er voor gezorgd dat de kans 
op het ontstaan van lokale recidieven is afgenomen en dat de overleving is verbeterd. 
Histopathologisch onderzoek van operatiepreparaten van het rectum heeft een 
belangrijke bijdrage geleverd aan de ontwikkeling van deze behandelingen. Door 
systematisch histopathologisch onderzoek is aan het licht gekomen wat de invloed is 
van laterale tumoruitbreiding, de aanwezigheid van tumordeposities in het meso- 
rectale vetweefsel en de aanwezigheid van tumorcellen in de circumferentiële resectie- 
marge (CRM) op het veroorzaken van lokale recidieven. Dit heeft de pathologische 
en biologische basis gevormd voor de introductie van de TME als standaardtherapie 
voor rectumcarcinomen.
Het veld blijft zich ontwikkelen en histopathologie speelt ook vandaag de dag een 
belangrijke rol bij het vinden van oplossingen voor de uitdagingen waar behandelaars 
van patiënten met een rectumcarcinoom voor staan. Die uitdagingen zijn onder 
andere het verbeteren van de kwaliteit van de chirurgische resectie, het vergroten van 
de groep van patiënten die veilig behandeld kan worden met rectumsparende therapie 
(zoals een beperkte locale excisie) en daarnaast het verbeteren van methodes voor 
stadiëring van de ziekte zodat er een nog nauwkeurigere prognose kan worden 
gegeven. Tot slot moet er gestreefd worden naar verbetering van de behandeling van 
specifieke patiëntenpopulaties met een rectumcarcinoom die doorgaans worden 
uitgesloten van klinische studies, zoals patiënten met inflammatoire darmziekte 
(inflammatory bowel disease; IBD).
In hoofdstuk 1 van dit proefschrift wordt de prognostische waarde bepaald van de 
kwaliteit van het operatiepreparaat, zoals beoordeeld door een patholoog. Hiervoor 
werd een systematische literatuurstudie verricht waarbij de gepubliceerde medische 
literatuur over dit onderwerp werd samengenomen in een meta-analyse. De standaard-
behandeling voor rectumcarcinoom is een operatie volgens de principes van de 
TME waarbij het rectum en het omgevende mesorectale vet, met daarin eventuele 
discontinue tumordeposities en/of lymfekliermetastasen (LKM), worden verwijderd. 
Dit zorgt voor een aanzienlijke vermindering van het risico op een lokaal recidief in 
vergelijking met de klassieke stompe dissectie zoals dit 20 jaar geleden nog werd 
uitgevoerd. Echter, zelfs als het circumferentiële resectievlak na een TME vrij is van 
tumor, kunnen er lokale recidieven ontstaan. Dit kan deels worden verklaard door 
een matige kwaliteit van de resectie waarbij het omgevende mesorectale vet niet 
volledig is verwijderd. Hierdoor kunnen er mogelijk tumorfoci en/of lymfeklier-
metastasen in de patiënt achter blijven. De kwaliteit van het resectiepreparaat kan 
worden gedocumenteerd door het anatomische vlak van de resectie te benoemen. 
Een hoogwaardig preparaat heeft een chirurgisch vlak op de mesorectale fascie 
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(mesorectale vlak), terwijl defecten dieper dan 5 mm in het vet inhouden dat de 
kwaliteit matig is (intramesorectale vlak). Defecten op of in de muscularis propria 
vormen de slechtste kwaliteit (muscularis propriavlak). In deze studie bleek de 
chirurgische kwaliteit onder andere bepaald te worden door de ervaring van de 
chirurg, het type operatie (vaker na abdominoperineale resectie dan na low anterior 
resectie), de afstand tussen de tumor en de anus en ten slotte de body mass index 
van de patiënt (BMI). Hierbij geldt dat zowel een zeer lage als een zeer hoge BMI 
geassocieerd was met een slechtere kwaliteit van het operatiepreparaat. Het geven 
van preoperatieve radiotherapie had geen invloed op de chirurgische kwaliteit. De 
resultaten van de meta-analyse toonden aan dat een resectievlak in het niveau van 
de muscularis propria geassocieerd was met een slechter oncologisch resultaat. Dit 
uitte zich in een verhoogd risico op lokale recidieven (RR 2,72 [95% CI 1,36-5,44]) en 
totale recidieven (RR 2.00 [95% CI 1,17-3,42]) vergeleken met een (intra) mesorectaal 
resectievlak. Verder bleek dat patiënten met een tumorvrije CRM die respectievelijk 
het snijvlak op de mesorectale fascie versus een muscularis propria resectievlak hadden, 
een locaal recidief percentage hadden van 4% versus 12%. Voorts ontwikkelde slechts 
1% van de patiënten een locaal recidief indien zij waren voorbehandeld met korte 
preoperatieve radiotherapie én indien het operatiepreparaat een mesorectaal resectie - 
vlak toonde. De resultaten van deze systematische meta-analyse tonen aan dat de 
kwaliteit van het resectievlak na TME een belangrijke voorspellende factor is bij 
patiënten met rectumcarcinoom. Om de behandeling van rectumcarcinoom patiënten 
verder te verbeteren is het daarom essentieel dat het anatomische vlak van de resectie 
door pathologen wordt gedocumenteerd. Hierdoor ontstaat belangrijke spiegel-
informatie voor chirurgen die als basis kan dienen om de prestaties van de eigen 
praktijk te verbeteren.
Hoofdstuk 2 bestaat uit een systematische meta-analyse van voorspellers van 
lymfe kliermetastasen (LKM) bij vroege (pT1) carcinomen van het colon en rectum. 
In de afwezigheid van LKM kunnen pT1-tumoren worden genezen met een beperkte 
lokale excisie, wat leidt tot minder morbiditeit en mortaliteit. De introductie van 
screenings programma’s zoals het bevolkingsonderzoek voor darmkanker zal er 
naar verwachting aan bijdragen dat het aantal gediagnosticeerde pT1-colorectale 
carcinomen zal toenemen. Dit maakt het probleem van mogelijke overbehandeling 
bij deze patiënten meer urgent. Ongeveer 8-16% van de patiënten met pT1-ziekte 
hebben LKM. Voorts zijn er diverse histopathologische kenmerken, zoals slechte 
histologische graad van differentiatie van de tumor, invasie van lymfevaten of bloed- 
vaten en de exacte invasiediepte in de submucosa, die zijn geassocieerd met de 
aanwezigheid van tumoruitzaaiingen in de lymfeklieren. Het doel van dit onderzoek 
was om de voorspellende waarde van risicofactoren voor lymfekliermetastasen te 
kwantificeren. Op basis hiervan kan bepaald worden welke kenmerken het best geschikt 
zijn voor het selecteren van patiënten die in aanmerking kunnen komen voor een 
beperkte lokale excisie. Er werden in totaal 17 studies met opgeteld 3621 patiënten 
opgenomen in de analyse. De sterkste onafhankelijke voorspellers van LKM waren 
lymfevatinvasie (RR 5,2 [95% CI 4,0-6,8]), submucosale invasie ≥1mm (RR 5,2 [95% 
CI 1,8-15,4]), tumorcel “budding” (RR 5,1 [95% CI 3,6-7,3]) en slechte histologische 
differentiatiegraad (RR 4,8 [95% CI 3,3-6,9]). Hoewel een submucosale invasiediepte 
van ten minste 1 mm sterk voorspellend is voor LKM, lijkt het niet werkbaar om dit 
kenmerk te gebruiken voor risicostratificatie. De zeer lage specificiteit (24%) zou 
namelijk leiden tot een hoog percentage patiënten dat ten onrechte een radicale 
operatie zou ondergaan (vals positief). De conclusie van het onderzoek luidt 
daarom dat de afwezigheid van lymfevatinvasie, “budding” en slechte histologische 
differentiatie graad zijn geassocieerd met een laag risico op LKM. Modellen voor 
risico stratificatie die deze factoren integreren kunnen helpen bij het selecteren van 
patiënten bij wie een radicale operatie achterwege kan blijven. Deze modellen 
moeten prospectief worden gevalideerd in toekomstige studies. Daarnaast moet de 
detectie van deze risicofactoren door pathologen gestandaardiseerd worden; bij 
voorkeur met behulp van immuunhistochemie.
In hoofdstuk 3 wordt een studie beschreven waarbij klinische en histopathologische 
karakteristieken worden onderzocht die kunnen voorspellen of er resterende LKM 
aanwezig zijn in patiënten die chemoradiatie therapie (CRT) hebben ondergaan 
vanwege een lokaal vergevorderd rectumcarcinoom (locally advanced rectal cancer; 
LARC). De patiënten in deze studie hadden allen een resttumor die beperkt was tot 
de darmwand (ypT0-2). Er wordt steeds meer nadruk gelegd op orgaansparende 
therapie bij de behandeling van rectumcarcinomen, met name voor patiënten die een 
goede klinische respons op preoperatieve therapie hebben gehad. Resten van 
metastasen in de lymfeklieren van het mesorectale vet kunnen bij deze patiënten 
echter lokale recidieven veroorzaken. Sommige clinici gebruiken een “wait and see” 
benadering, waarbij patiënten met een goede klinische respons nauwgezet worden 
gevolgd zonder aanvullende therapie. Deze methode wordt echter ook bekritiseerd, 
aangezien het bewijs gebaseerd is op sterk geselecteerde patiëntengroepen en 
omdat de criteria die zijn gebruikt om een  goede klinische respons vast te stellen, niet 
consistent zijn in de literatuur. Een alternatieve aanpak zou zijn om een lokale excisie 
uit te voeren na preoperatieve CRT. Deze ingreep is geassocieerd met een lagere 
morbiditeit en sterfte dan een TME-operatie. Met een lokale excisie worden tumor- 
resten in de darmwand verwijderd en kan er aanvullende histopathologische informatie 
worden verkregen over de respons van de tumor op de preoperatieve behandeling. 
In deze studie werden resterende LKM gevonden bij 44 patiënten met ypT0-2-ziekte 
(21%). Drie onafhankelijke voorspellers voor de aanwezigheid van LKM waren: 
verdenking op tumor in lymfeklieren bij de preoperatieve beeldvorming (cN +) (OR 
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2,79 [95% CI 1,04-7,48]; p = 0,042), een “hoge histopathologische maligniteitsgraad” 
beoordeeld op basis van het met CRT behandelde resectiepreparaat (OR 6,46 [95% CI 
1,23-34,02]; p = 0,028) en een resterende tumordiameter ≥10mm (OR 2,54 [95% CI 
1,06-6,09]; p = 0,036). Er werd een algoritme ontwikkeld dat deze factoren combineert. 
Dit algoritme deelt patiënten adequaat in op basis van hun risico op LKM. Hierbij 
worden er een groep met een laag risico (7,7%), een intermediair risico (17%) en een 
hoog risico (51%) onderscheiden. De voorspellende waarde van het algoritme was 
onafhankelijk van ypT-categorie. Dit is een belangrijke bevinding, met name voor 
patiënten met ypT2-ziekte. Recente studies die de effectiviteit van lokale excisies na 
CRT onderzoeken, sluiten namelijk de patiënten met ypT2 tumoren meestal uit van 
deelname, uit angst voor hoge lokaal recidiefpercentages bij deze groep. Uit de 
huidige studie blijkt echter dat een patiënt met een klein tumorresidu in de muscularis 
propria (<10 mm in diameter) met afwezigheid van een hoge histopathologische 
maligniteitsgraad en zonder aanwijzingen zijn voor LKM bij radiologische beeld- 
vorming, hetzelfde risico heeft op resterende LKM als patiënten met ypT0-1 tumoren. 
Risicostratificatiemodellen op basis van de beschreven factoren kunnen helpen bij 
het identificeren van patiënten die in aanmerking komen voor orgaansparende therapie. 
Deze modellen dienen daarom te worden gevalideerd in geschikte patiëntenpopulaties.
Hoofdstuk 4 beschrijft de prognostische waarde van histopathologische kenmerken 
in resectiepreparaten van 107 strikt gedefinieerde LARC-patiënten die een uniforme 
behandeling met CRT hebben ondergaan. Van deze patiënten had 40% bij pre- 
operatieve beeldvorming een cT4 tumor. Deze studie richt zich vooral op de associatie 
tussen tumorregressiegraad (TRG) en oncologische uitkomsten. Na preoperatieve 
CRT ondergaan sommige tumoren namelijk een pathologische complete respons 
(pCR) zonder restanten van tumor in het resectiepreparaat. In andere gevallen kunnen 
er tumordeposities of LKM in het mesorectum achterblijven, die niet detecteerbaar 
zijn met lichamelijk onderzoek of beeldvorming. De toenemende interesse voor orgaan- 
sparende behandelingen na preoperatieve CRT met goede respons, waaronder het 
“wait and see” beleid, evenals een lokale excisie van het oorspronkelijke tumor 
gebied na CRT (zoals beschreven in hoofdstuk 3), betekent dat er steeds meer 
patiënten zijn bij wie onverwijderde tumorresten mogelijk een bedreiging kunnen 
vormen. In deze studie werd TRG gescoord volgens een 4-puntsschaal, gebaseerd 
op de TRG schaal van Dworak. De patiënten hadden een pCR in 20%, een bijna-pCR 
in 11%, duidelijke respons in 55% en geen respons in 14% van de gevallen. Van de 
21 patiënten met een pCR waren er 6 die resterende LKM hadden. Van de 12 patiënten 
met een bijna-pCR hadden er 5 ypT3-ziekte, terwijl er in 6 patiënten resterende LKM 
werden gevonden. Patiënten met een pCR hadden een uitstekende prognose 
aangezien er geen lokale recidieven waren en slechts één patiënt die afstandsmeta-
stasen ontwikkelde. 
Aan de andere kant ontstonden er in de bijna-pCR groep metastasen op afstand in 
5 van de 12 patiënten en een lokaal recidief in 1 patiënt. Dit vertaalde zich na 3 jaar in 
een afstandsmetastasenvrije overleving van 65%, ziektevrije overleving van 50% en 
algehele overleving van 67%. Deze resultaten zijn vergelijkbaar met patiënten die 
geen substantiële tumorregressie hadden. Het blijft echter onduidelijk wat de exacte 
waarde is van het verwijderen van resterende LKM en/of kleine resterende geïsoleerde 
mesorectale tumordeposities bij LARC-patiënten met een complete of bijna complete 
respons van de primaire tumor na preoperatieve CRT. Vanwege de beperkte 
nauwkeurigheid van de huidige beeldvormende technieken bij het detecteren van 
resterende LKM en bij het maken van onderscheid tussen fibrose en microscopische 
tumorresten, is een “wait and see” beleid bij LARC-patiënten met een goede klinische 
respons op CRT geassocieerd met aanzienlijke risico’s.
In hoofdstuk 5 worden gegevens uit de landelijke databank van de Nederlandse 
Kanker Registratie geanalyseerd om te bepalen wat de stadiumspecifieke overleving 
is bij patiënten met rectumcarcinoom die wel of niet een preoperatieve behandeling 
hebben ondergaan. Bij een groot deel van de patiënten ontstaat er regressie van de 
primaire tumor na preoperatieve CRT met een complete pathologische respons in 
8-24% van de gevallen. Bij patiënten die worden behandeld met kortdurende pre- 
operatieve radiotherapie gevolgd door een operatie binnen 10 dagen of met chirurgie 
zonder preoperatieve therapie zal er echter naar verwachting geen regressie en geen 
downstaging worden gezien. Het doel van deze studie was om te bepalen of de 
stadium specifieke overleving volgens TNM vergelijkbaar is bij patiënten met en zonder 
tumorregressie. Echter, in de groep die alleen een operatie zonder preoperatieve 
behandeling heeft ondergaan, blijken oudere patiënten met aanzienlijk meer comorbiditeit 
oververtegenwoordigd te zijn. Bij deze kwetsbare patiënten is destijds afgeweken 
van de landelijke richtlijnen die een preoperatieve behandeling met korte radiotherapie 
of CRT voorschreef. Daarom wordt deze groep niet beschouwd als een adequate 
controlepopulatie. De belangrijkste resultaten van deze studie vloeien daarom voort uit de 
vergelijking van patiënten met korte radiotherapie en langdurige CRT. De uitkomsten 
van de multivariate analyse benadrukken dat afname van het stadium van de ziekte 
tot pathologisch stadium I na CRT, gepaard gaat met een uitstekende prognose. Er 
is sprake van een cumulatieve 5-jaarsoverleving die vergelijkbaar is met patiënten die 
hetzelfde stadium hebben na een behandeling met korte radiotherapie gevolgd door 
chirurgie binnen 10 dagen en die daarom geen regressie van de tumor hebben 
gehad (5-jaars overleving 85% versus 85%; p = 0,167). Bovendien was de cumulatieve 
5-jaars overleving vergelijkbaar bij CRT-behandelde patiënten met pathologisch 
stadium I en met een pCR (85% versus 89%; p = 0,113). Voor patiënten met stadium 
II en III bleek er echter wel sprake van een significant slechtere stadiumspecifieke 
algehele overleving na een preoperatieve behandeling met CRT vergeleken met 
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korte radiotherapie (stadium II: HR 1,57 [95% CI 1,27-1,95]; p <0,001); stadium III: HR 
1,43 [95% CI 1,23-1,70]; p <0,001). Deze resultaten tonen aan dat stadiumspecifieke 
overleving afhankelijk is van het type preoperatieve therapie dat een patiënt heeft 
gehad. Clinici dienen daarom bij het inschatten van de prognose van patiënten met 
rectumcarcinoom rekening te houden met deze verschillen. 
Voorts werden er bij de patiënten die behandeld werden met chirurgie zonder pre- 
operatieve behandeling (per definitie geen downstaging) substantiële discrepanties 
gevonden tussen het klinische stadium zoals beoordeeld op basis van beeldvorming 
(cTNM) en het pathologische stadium (pTNM). Deze bevinding benadrukt de on-
nauwkeurigheid van de huidige beeldvormende technieken bij het beoordelen van 
de uitbreiding van de ziekte.
In hoofdstuk 6 wordt onderzocht of preoperatieve therapie bij rectumcarcinoom 
patiënten met IBD wel of niet is geassocieerd met toegenomen toxiciteit en post- 
operatieve complicaties in vergelijking met rectumcarcinoom patiënten zonder IBD. 
Op dit moment wordt preoperatieve CRT bij patiënten met IBD vaak achterwege 
gelaten vanwege het vermeende hoge risico op overmatige bijwerkingen. Het bewijs 
in de medische literatuur is hiervoor echter beperkt. Het totaal aantal patiënten met 
IBD dat een rectumcarcinoom ontwikkelt is laag en het is daarom moeilijk om voldoende 
grote cohorten van patiënten bij elkaar te vinden voor een gedegen onderzoek, zelfs 
als er patiënten uit meerdere centra worden geïncludeerd. Daarom is er voor gekozen 
in de databank van de Nederlandse landelijke pathologie registratie (PALGA) te 
zoeken naar alle IBD-patiënten die zijn gediagnosticeerd met rectumcarcinoom in 
Nederland in de periode van januari 1991 t/m mei 2010. Na het handmatig doorzoeken 
van de resultaten die door de geautomatiseerde zoekopdracht werden gegenereerd 
en het opzoeken en analyseren van de medische dossiers van de patiënten, werden 
er 161 IBD-patiënten met een rectumcarcinoom opgenomen in de studie. Van deze 
161 patiënten hadden er 66 preoperatieve therapie gehad (41%). Er is in deze studie 
met name gekeken naar de incidentie van ernstige (graad ≥3) acute (chemo)radiatie 
geïnduceerde toxiciteit en ernstige (graad ≥3) postoperatieve complicaties. Bij 6 van 
de 21 CRT-behandelde patiënten (28%) ontstond graad ≥3 acute toxiciteit. Vergeleken 
met incidentiecijfers die in de literatuur worden genoemd voor sporadische (niet-IBD 
gerelateerde) rectumcarcinoom patiënten is dit percentage aan de hoge kant. In de 
groep die was behandeld met korte radiotherapie (direct gevolgd door chirurgie) 
werd er geen ernstige toxiciteit gevonden (0/32; 0%). 
Het percentage postoperatieve complicaties binnen 30 dagen van graad ≥3 was 28% 
en daarmee ook relatief hoog in deze populatie van IBD-patiënten in vergelijking met 
rectumcarcinoom patiënten zonder IBD. Er was echter geen verschil tussen de patiënten 
die een preoperatieve behandeling kregen met (chemo)radiatie en de patiënten die 
alleen een operatie ondergingen. Het hoge percentage postoperatieve complicaties 
is daarom waarschijnlijk het beste te verklaren doordat de IBD-patiënten vanwege 
hun ziekte in het verleden vaker buikoperaties hadden ondergaan en/of corticosteroïden 
gebruikten rond de operatie. Dit zijn allebei factoren die zijn geassocieerd met een 
verhoogd risico op complicaties. Op het moment van preoperatieve behandeling werd 
door slecht 10,5% van de patiënten systemische corticosteroïden gebruikt. Dit geeft 
aan dat de meeste patiënten op dat moment een relatief rustige IBD hadden. 
Samenvattend liet deze studie geen onacceptabel hoge percentages van (chemo)
radiatie geïnduceerde toxiciteit of postoperatieve complicaties zien. De resultaten 
ondersteunen hiermee het gebruik van standaard preoperatieve therapieën voor 
rectum carcinoom (en met name korte radiotherapie) bij IBD-patiënten met relatief 
weinig ziekteactiviteit. Helaas kon op basis van de retrospectief verzamelde gegevens 
in deze studie niet worden vastgesteld wat de exacte invloed is van actieve ontsteking 
van de darm ten tijde van preoperatieve therapie op het ontstaan van toxiciteit en 
complicaties. Er is daarom nog steeds voorzichtigheid geboden bij het toepassen 
van (chemo)radiatie op patiënten met actieve IBD op het moment van behandeling. 
Toekomstige studies moeten licht werpen op de invloed die een actieve IBD heeft op 
het ontstaan van acute en late toxiciteit bij patiënten die bestraald worden op het 
kleine bekken.
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